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1ChAPter 1 GeNerAL iNtroduCtioN ANd SCoPe of thiS theSiS
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma (NHL) 
which is confined to the brain, leptomeningines, spinal cord and eyes without manifesta-
tions outside the central nervous system. This tumour was first described by Bailey as ‘sar-
coma of the brain, arising from the leptomeninges’ at the beginning of the 20th century.1 
Later it was recognized as NHL.
The exact pathophysiology is unknown and although it is called a primary CNS lym-
phoma, there is evidence the tumour originates outside the central nervous system. 
Almost all PCNSL contained Bcl-6, an oncogenic protein that is only expressed on B-cells 
in the germinal centre. Since the central nervous system does not contain germ centre 
structures, it suggest an extraneural origin of the tumour that subsequently migrates to 
the central nervous system.2 At histological examination, >90% of PCNSL are diffuse large 
B-cell lymphoma (DLBCL), the remaining 10% are Burkitt, T-cell or low-grade lymphoma.3,4
Epidemiology
Over the last decades the incidence of PCNSL has increased, mainly among elderly (>60-
year old) to 0.44-0.47/ 100,000 per year.5 The reason for this increase is unknown; the 
only known risk factors for this disease are older age and being immunocompromised. 
However, the incidence is increasing among immune competent patients and despite the 
ageing population, the incidence of systemic DLBCL and glioma did not increase with a 
similar rate.6,7 Median age at diagnosis is around 65 years and the incidence in men is 
slightly higher than in women.8
Diagnosis
The most frequent presenting symptoms are focal neurological deficits (70%), signs of 
increased intracranial pressure, such as headache (51%) and cranial nerve palsies, neuro-
psychiatric/cognitive symptoms (26-43%) and seizures (14%).9,10
When a brain tumour, is considered, an MRI of the brain with and without gadolineum 
is the first designated test. On MRI a PCNSL is characterized by solitary (65%) or multiple 
(35%) space occupying lesions, surrounded by vasogenic oedema. Most (90%) lesions 
show homogeneous contrast enhancement, with diffusion restriction (Figure 1). Preferred 
locations are periventricular, the corpus callosum and basal ganglia.11,12 However, more 
rarely non-enhancing space occupying lesions in addition to enhancing lesions may occur. 
These lesions diminished in size or even vanished after treatment, which suggests that 
these lesions should also be considered as tumor.13
Cytological or histological confirmation of the tumour is essential, as treatment is inten-
sive and potentially toxic. In a minority of patients the diagnosis can be made by cytologi-
cal analysis of cerebrospinal fluid (CSF) after a lumbar puncture, or of vitreous fluid in case 
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of eye involvement. Although flow cytometry added tot cytology increases the sensitivity, 
compared to cytological analysis alone14, diagnosis can be made on CSF-analysis alone in 
only 30% of the cases.15 Eye involvement occurs in just circa 4% of the cases.16 As a result, 
in most patients a brain biopsy is remains necessary to obtain a diagnosis. In addition 
to this cytological or histological confirmation a comprehensive screening is necessary 
to determine the extent of the disease and to determine whether the lymphoma is a 
primary CNS lymphoma or a secondary manifestation of a systemic lymphoma. Typically, 
the screening consists of a slit lamp eye examination, a lumbar puncture, a CT of the chest 
and abdomen, a bone marrow analysis and a complete blood analysis.
treatment
The first described treatment for PCNSL was a gross total resection of the tumour, but this 
resulted in median overall survival (OS) of just 1-4 months.17 After the failed effect of sur-
gery, whole brain radiotherapy (WBRT) became the treatment of first choice, but despite 
rapid responses, survival remained more limited than that observed in other lymphoma 
limited to one organ.18 Based on multiple large uncontrolled phase II studies, chemother-
apy based on high-dose intravenous methotrexate (HD-MTX) became subsequently the 





figure 1. T1W (A) and T1W with gadolinium (B) images show multiple homogenous enhancing lesions. A T2W 
(C) shows vasogenic oedema around the lesions and the diffusion weighted image (D) shows diffusion restric-
tion in all enhancing lesions.
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General introduction
1reporting a median overall survival of about 60 months.
19-21 The addition of high-dose 
cytarabine (HD-Ara-C) to HD-MTX was then reported to further improve the progression 
free survival (PFS) and OS.22
The role of WBRT given after chemotherapy remains disputed. The addition of WBRT 
after chemotherapy, may improve the PFS compared to chemotherapy alone (12 versus 
18 months); the overall survival remained similar, however.23 On top, patients treated with 
combined chemotherapy and 45Gy WBRT, had significantly worse scores on neuropsycho-
logical tests, compared to patients treated with chemotherapy only.24
In particular because of these effects on neurocognitive functioning, alternatives for con-
solidation treatment with high-dose WBRT are necessary . An uncontrolled study showed 
a similar effect on survival but without these cognitive consequences with a reduced dose 
of WBRT (23.4Gy).25 Two phase II randomized controlled trials compared autologous stem 
cell transplantation (ASCT) with WBRT as consolidation therapy. No significant differences 
in PFS were found but cognitive performance was reported to be significantly better in the 
ASCT group. Although the OS also seemed similar between both groups and comparable 
to historical treated patients, further follow-up is needed to explore outcome in the long 
run.26,27
Rituximab, a chimeric monoclonal antibody targeting the CD20 cell surface protein, is 
very effective if given in addition to standard chemotherapy in systemic CD20 positive 
B-cell lymphoma.28,29 Since most PCNSL are CD20 positive diffuse large B-cell lymphoma, 
rituximab was assumed to be effective also in PCNSL. A phase II trial randomised 219 
patients between HD-MTX/Ara-C, HD-MTX/Ara-C combined with rituximab of HD-MTX/
Ara-C combined with rituximab and thiotepa. The latter arm, now known as the MATRix-
regime had significantly better PFS and OS.30 Unfortunately there was no arm with thio-
tepa and without rituximab; in addition this study was not powered or designed for a 
comparison between three arms, this made the role of additional rituximab uncertain. 
In a large international phase III randomised controlled trial, the HOVON 105/ ALLG NHL 
24 study, 199 patients were randomized between HD-MTX-based chemotherapy (MBVP: 
methotrexate, tenoposide, BCNU and prednisolone) with or without rituximab and fol-
lowed by HD-cytarabine and, in patients up to 60 years-old with a lower dose of WBRT 
(30Gy). No differences were found between the arms regarding the 1-year event-free 
survival (R-MBVP versus MBVP: 52% (95% confidence interval [CI]: 42-61) versus 49% (95% 
CI: 39-58), p=0.99), PFS and OS.31
Cognitive functioning and health-related quality of life
Cognitive decline and other symptoms, caused by the tumour and/ or the treatment can 
compromise health-related quality of life (HRQoL).32 Up to 43% of PCNSL patients have 
cognitive disturbances to a certain extent at diagnosis.9 In PCNSL symptoms can greatly 
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improve following treatment but reports differ regarding the extent to which this is also 
the case for cognitive symptoms.
Since the prognosis of PCNSL patients has improved over the last decades, (late) ef-
fects on cognitive performance and HRQoL have become more important to measure.5 
Preventing cognitive decline and even better, improving cognitive functioning are major 
challenges in PCNSL patients. Assessment of this important part of patient functioning 
requires the evaluation of cognition at baseline and during follow-up.33,34 In addition, as-
sessing cognitive performance and HRQoL in research is necessary to determine the ‘net 
clinical benefit’ of a (new) treatment. Information on both, survival and neurocognitive 
functioning and HRQoL enables the physicians and patients to make a weighted decision 
regarding patients’ treatment.
Prognosis
Although the prognosis for patients with PCNSL at group level improved over the last 
decades,5 it remains difficult to predict the prognosis for the individual patient. Two prog-
nostic models are currently widely used in PCNSL patients.
- The externally validated Memorial Sloan Kettering Cancer Center (MSKCC) model, 
consist of two factors: age and the Karnofsky performance score (KPS), in which a 
higher age (>50 years-old) and a lower KPS (<70) are unfavourable prognostic factors.35
- The International Extranodal Lymphoma Study Group (IELSG) developed a model of 
5 unfavourable prognostic factors: higher age (>60 years old), higher ECOG/ WHO 
performance score (>1), a high serum LDH, a higher total protein in CSF (>45mg/dL in 
patients ≤60 years-old or >60mg/dL for elderly) and involvement of deep structures 
(i.e. brain stem, cerebellum, periventricular or basal ganglia).36
The latter model is unfortunately limited by missing data, and external validation is still 
needed.
Aims and scope of this thesis
The aims of this thesis are to describe incidence, primary treatment and survival among 
adult PCNSL patients in the Netherlands over the last three decades (Chapter 2) and to 
describe primary treatment and survival among elderly (>70 year-old) in the modern 
era: 2014-2017 (chapter 3). As described above, flow cytometry improves the sensitivity 
over immunohistochemistry alone in CSF. In chapter 4 we aim to define the value of flow 
cytometry on brain biopsies from lesions suspected to be a brain lymphoma. Since PCNSL 
is a rare disease, and choices regarding treatment in clinical studies are generally based 
on local response assessment, we determined the value of a central radiology review and 
the influence of centrally determined response rate on survival (chapter 5). Secondary 
endpoints of the HOVON 105/ALLG NHL 24 study31 were differences between treatment 
13
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1arms regarding health-related quality of life and neurocognitive functioning. PART III 
starts with a comprehensive systematic literature review of neurocognitive functioning 
and HRQoL in PCNSL patients (Chapter 6). In chapter 7 and 8 we describe neurocognitive 
functioning and HRQoL-scores over time and the effect of rituximab on these. Chapter 
7 also describes the association of brain atrophy and white matter abnormalities with 
neurocognitive functioning. Lastly, we aim to determine the prognostic value of the Mini-
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Letter to the editor
Primary central nervous system lymphoma (PCNSL) is a rare, aggressive form of extranodal 
non-Hodgkin lymphoma that exclusively affects the CNS. Although PCNSL has tradition-
ally been associated with a sinister prognosis, recent findings from the few available 
prospective studies demonstrated improved outcome in PCNSL.1-3 However, the results 
from such studies may not reflect the actual clinical practice due to patient selection. 
Population-based studies complement prospective intervention studies by addressing a 
non-selected group of patients within a well-defined geographic area. Currently, compre-
hensive population-based studies that assess long-term patterns of incidence, treatment 
and survival in PCNSL are virtually lacking.
Here we report the outcomes of a comprehensive nationwide population-based study 
on incidence, primary treatment and survival among adult PCNSL patients diagnosed in 
the Netherlands during a 27-year period.
We identified all adult (≥18 years) PCNSL patients diagnosed between 1989-2015, 
with survival follow-up through February 2016, from the nationwide population-based 
Netherlands Cancer Registry (NCR). Established in 1989, the NCR, which is maintained and 
hosted by the Netherlands Comprehensive Cancer Organisation, has an overall coverage 
of >95% of all malignancies in the Netherlands.4 The NCR is based on comprehensive case 
notifications through the Nationwide Network of Histopathology and Cytopathology and 
the National Registry of Hospital Discharges. PCNSL of the diffuse large B-cell type was 
defined using International Classification of Diseases for Oncology morphology and topog-
raphy codes. The selected codes are described in the Supplementary Methods. Informa-
tion on dates of birth and diagnosis, sex, disease topography and morphology, primary 
treatment (that is, no anti-neoplastic therapy, chemotherapy, radiotherapy, combined 
chemoradiotherapy (CT+RT), and other or unknown therapy), and vital statistics (that is, 
alive, emigration or death) is available for individual patients.
Age-standardized incidence rates (ASRs) were calculated per 100,000 person-years, 
using the annual mid-year population size as obtained from Statistics Netherlands. ASRs 
were standardized according to the European standard population. We calculated relative 
survival (RS) for four calendar periods (1989-1995, 1996-2002, 2003-2008 and 2009-2015) 
and three age groups (18-60, 61-70 and >70 years) using the cohort methodology.5 RS is the 
observed patient survival (that is, overall survival, OS) corrected for the expected survival 
of an equivalent group in the general population with respect to age, sex and period. This 
to eliminate the effect of general changes in population survival over time. Expected sur-
vival was calculated using the Ederer-II methodology. RS was calculated from the time of 
diagnosis until death, emigration or end of follow-up, whichever occurred first. We applied 
a generalized linear model that assumed a Poisson distribution for the observed number 
of deaths to assess linear trends in RS over time and to estimate the relative excess risk 
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of mortality during the fi rst 5 years aft er PCNSL diagnosis. For these analyses, a P-value 
<0.05 was considered stati sti cally signifi cant. Pati ents diagnosed without pathologic and/
or cytologic confi rmati on (n=50) and pati ents diagnosed at autopsy were excluded (n=32). 
However, as is customary for incidence esti mati on, these cases were included to calculate 
the ASRs. This study was approved by the Privacy Review Board of the NCR.
A total of 1,673 adult PCNSL pati ents (median age 65 years; 53% males) were included 
in the study. The characteristi cs of these pati ents are presented in Supplemental Table 
S1. In the overall series, 35%, 34% and 31% of pati ents were aged 18-60, 61-70 and >70, 
respecti vely. The overall ASR of PCNSL increased from 0.30/100,000 persons in the period 
1989-1995 to 0.44/100,000 persons in the period 2009-2015. The increase was a result of 
the increasing incidence in the age groups 61-70 and >70 years (Supplemental Figure S1).
Informati on on primary treatment according to age and calendar period of diagnosis 
is shown in Figure 1. There were some notable age-related treatment diff erences over 
ti me. The applicati on of CT+RT increased exclusively among pati ents age 18-60; from 26% 
in the period 1989-1995 to 60% in the period 2009-2015. The use of radiotherapy alone 
among pati ents above age 60 decreased with each calendar period, following the wider 
use of chemotherapy alone over ti me. The use of chemotherapy alone increased most 
prominently for pati ents age 61-70 (64% in the most recent calendar period). Approxi-
mately 40% of pati ents above age 70 did not receive anti -neoplasti c therapy throughout 
the enti re study period.
 
 figure 1. Primary treatment of adult pati ents with PCNSL in the Netherlands according to calendar period of 
diagnosis and age at diagnosis, 1989-2015. The table presents the proporti on of pati ents receiving a parti cular 
treatment within a specifi c calendar period and age group. The absolute number of pati ents within a specifi c 
calendar period and age group is shown in Supplementary Table S1.
25
Improved survival in PCNSL up to age 70 only: a population-based study in the Netherlands, 1989-2015
2
The overall 5-year age-standardized RS (95% confidence interval) among adult patients 
with PCNSL increased from 11% (8%-15%) in 1989-1995 to 30% (27%-34%) in 2009-2015 
(Supplementary Figure S2).
RS according to age and calendar period of diagnosis is shown in Figure 2. Significant 
improvement in 5-year RS was confined to patients age 70 or below. This improvement 
was most pronounced in the most recent calendar period. More specifically, 5-year RS 
(95% confidence interval) for patients age 18-60 improved from 22% (16%-30%) to 56% 
(47%-64%), and for patients age 61-70 from 13% (7%-22%) to 35% (28%-43%) between 
the calendar periods 1989-1995 and 2009-2015. Five-year RS for patients above age 70 
remained poor throughout the calendar periods studied (6% in the calendar period 2009-
2015).
We analyzed the influence of calendar period, age, sex and therapy on the relative 
excess risk of mortality in a multivariable model (Supplementary Table S2). The primary 
multivariable model (that is, without treatment) demonstrated an adverse effect of older 
age and an improvement of survival over time. However, when information on treatment 
was added to the model, the effect of period lost statistical significance. This fits with 
treatment contributing to the improved survival over time. Older age remained a predic-
tor of poor prognosis.
In this comprehensive population-based study, we firstly observed an increasing in-
cidence of PCNSL that was confined to patients above age 60. Similar trends were also 
observed in recent population-based studies from western and eastern countries.6,7 
This increase is most likely driven by immunocompetent patients, which may in part be 
explained by greater diagnostic diligence in elderly patients. This, however, does not com-
pletely explain the increase, as incidence rates of gliomas and non-CNS-related DLBCL in 
the Netherlands did not increase in a similar manner.8,9
Second, we demonstrated a significant improvement in prognosis over the past 2 de-
cades among PCNSL patients aged 18-70, with the major improvement taking place during 
the most recent calendar period (2009-2015). Similarly, Kasenda et al. found improved 
survival in elderly PCNSL patients in the last decades; however, age-related trends over 
time were not analyzed separately.10 The improvements are most likely related to the 
increased application of chemotherapy (18-70 years) and combined chemoradiotherapy 
(18-60 years) over time. Most,6,7,11 although not all,12,13 population-based studies lack 
information on treatment and come from the US. The present comprehensive study thus 
extends on prior studies.
In the most recent study from the United States by Fallah et al.,13 with survival follow-up 
through 2012, 3-year overall survival for the entire PCNSL cohort improved from 36% in 
the period 2004-2006 to 41% in the period 2010-2012. It was suggested that the improve-
ment was related to the increased application of chemotherapy alone, and a concurrent 




figure 2. Relati ve survival rates (RSRs) of adult pati ents with PCNSL in the Netherlands according to calendar 
period of diagnosis and age at diagnosis, 1989-2015. RSRs are shown according to the following age catego-
ries: (a) 18-60 years, (b) 61-70 years and (c) >70 years. The table presents the projected 1-, 3- and 5-year RSRs 
with 95% CIs according to calendar period of diagnosis. *P-value for linear trend from the calendar period 
1989–1995 to the calendar period 2009–2015.
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survival were, however, not assessed in that and most other studies. Similarly, we observed 
that the use of radiotherapy alone decreased substantially, with a concurrent increase in 
the use of chemotherapy alone, especially among patients age 61-70. This suggests that 
physicians and patients age 61-70 more often opt for curative treatment without whole-
brain radiotherapy (WBRT) to prevent late radiotherapy-induced neurotoxicity, which 
constitutes a major concern among patients above age 60.10 In contrast to the study by 
Fallah et al.,13 we demonstrated an increased application of combined chemoradiotherapy 
among patients age 18-60. The disparity in treatment practices between the Netherlands 
and the US may be related to the ongoing debate about the risks and benefits of con-
solidation WBRT after high-dose methotrexate-based chemotherapy among younger (≤60 
years) PCNSL patients.14
Although we demonstrated that the use of chemotherapy increased among patients 
above age 70, their survival was still disappointingly poor. Approximately 40% of these 
patients received no anti-neoplastic therapy throughout the entire study period. A 
population-based study among elderly (≥65 years) PCNSL patients in the United States 
showed that only ~20% of patients received no treatment over the study period (1994-
2002).12 Nevertheless, survival of these patients was poor and remained unchanged over 
time. At present, optimal treatment approaches for elderly PCNSL patients are yet to be 
defined.10,14 Therefore, there is an urgent need to design more international trials in order 
to advance treatment approaches and improve outcomes without increasing (neuro)
toxicity, especially, but not exclusively, for elderly PCNSL patients. Moreover, it has been 
recently shown that prospective studies in elderly patients are feasible, thereby providing 
good grounds for optimism to offer patients the newest therapeutic options.15
The strength of our study includes the use of a nationwide population-based cancer 
registry with comprehensive information available for individual patients. Therefore, un-
like most population-based studies, we could directly link improvements in survival with 
changing treatment practices over time. Limitations of our study mainly pertain to the lack 
of detailed clinical information throughout most of the registry (1989-2013). Despite that 
limitation, cancer registries remain the gold standard for cancer surveillance.
In summary, the incidence of PCNSL continues to increase among patients aged over 60. 
Relative survival increased over the past decades for PCNSL patients aged 18-70. This is 
largely explained by the increased use of intensive therapy over time. Although the use of 
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Primary central nervous system lymphoma (PCNSL) of the diffuse large B-cell type was 
defined using International Classification of Diseases for Oncology morphology (i.e. 9590, 
9591, 9593, 9595, 9675 and 9680-9684) and topography codes (i.e. C69.2, C69.4, C71.0-
C71.9, C72.0 and C72.8). The selected topography codes are consistent with anatomical 
location in the brain (C71.0-C71.9; n=1,552), spinal cord (C72.0; n=54), eyes (C69.2 and 
C69.4; n=50), and leptomeninges or cerebrospinal fluid (C72.8; n=17). Although C72.8 is 
not specific for the latter two localizations, coding rules of the NCR designate C72.8 for 
localizations in the leptopmeninges or cerebrospinal fluid.
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Supplementary Figure S1 
 
 
 Supplementary figure S1. Age-specific incidence rates of adult patients with PCNSL in the Netherlands, 1989-
2015. Age-specific incidence rates are shown according to the following sexes: (a) males and females together, 







Years after diagnosis 
 
 Calender period 
 1989-1995            1996-2002 2003-2008 2009-2015 
 RSR (in%) with 95% CI  
1-year 35 (29-41) 31 (26-36) 44 (40-49) 50 (46-53) 
3-year 19 (14-24) 17 (14-21) 30 (25-34) 38 (34-41) 
5-year 11 (8-15) 14 (10-18) 22 (18-26) 30 (27-34) 
  Numbers at risk  
1-year 119 107 195 283 
3-year 62 60 129 133 




1989-1995 1996-2002 2003-2008 2009-2015
RSR (in%) with 95% CI
1-year 35 (29-41) 31 (26-36) 44 (40-49) 50 (46-53)
3-year 19 (14-24) 17 (14-21) 30 (25-34) 38 (34-41)
5-year 11 (8-15) 14 (10-18) 22 (18-26) 30 (27-34)
Numbers at risk
1-year 19 07 195 283
3-year 62 60 129 133
5-year 37 36 83 81
Supplementary figure S2. Age-standardized relative survival of adult patients with PCNSL in the Netherlands 
according to calendar period of diagnosis, 1989-2015. Relative survival was age-standardized according to the 
standard population as defined by the International Cancer Survival Standard (ICSS).
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1989-1995 1996-2002 2003-2008 2009-2015
No. (%) ASra No. (%) ASra No. (%) ASra No. (%) ASra No. (%) ASra
Total No. of patients 300 0.30 316 0.29 416 0.39 641 0.44 1,673 0.35
Sex
 Male 155 (52) 0.33 177 (56) 0.33 217 (52) 0.42 336 (52) 0.48 885 (53) 0.39
 Female 145 (48) 0.26 139 (44) 0.24 199 (48) 0.35 305 (48) 0.40 788 (47) 0.31
Age, years
 Median (range) 62 (20-87) 65 (19-87) 64 (25-87) 66 (21-87) 65 (19-87)
 18-60 136 (45) 0.23 108 (34) 0.17 153 (37) 0.25 188 (29) 0.27 585 (35) 0.23
 61-70 83 (28) 0.90 112 (35) 1.20 130 (31) 1.44 242 (38) 1.87 567 (34) 1.35
 >70 81 (27) 1.00 96 (30) 1.16 133 (32) 1.72 211 (33) 1.95 521 (31) 1.45
Abbreviation: ASR, age-standardized incidence rate.
aAge-standardized according to the European standard population and present per 100,000 person-years. 
Incidence rates were calculated using the annual mid-year population size as obtained from Statistics 
Netherlands.
Supplementary table S2. Excess mortality ratio (EMR) during the first five years after PCNSL diagnosis
Covariate
model without therapy model with therapy
emra 95% Ci P-valueb emra 95% Ci P-valueb
Period of diagnosis
 1989-1995 1 Reference
 1996-2002 1.10 0.93-1.31 0.269 1.18 0.98-1.41 0.076
 2003-2008 0.73 0.61-0.86 <0.001 1.04 0.87-1.25 0.650
 2009-2015 0.59 0.50-0.70 <0.001 0.86 0.72-1.03 0.100
Sex
 Male 1 Reference 1 Reference
 Female 1.05 0.93-1.18 0.451 0.98 0.87-1.11 0.774
Age at diagnosis, years
 18-60 1 Reference 1 Reference
 61-70 1.67 1.44-1.93 <0.001 1.26 1.08-1.48 <0.001
 >70 3.11 2.70-3.60 <0.001 1.50 1.28-1.76 <0.001
Primary therapy
 No anti-neoplastic therapy 1 Reference
 Chemotherapy and radiotherapy 0.08 0.06-0.09 <0.001
 Chemotherapy 0.14 0.12-0.17 <0.001
 Radiotherapy 0.22 0.19-0.26 <0.001
 Other/unknown therapy 0.28 0.19-0.39 <0.001
Abbreviations: EMR, excess mortality ratio; PCNSL, primary central nervous system lymphoma.
aEach covariate is simultaneously adjusted for all other covariates in the table, along with five years of follow-up.
bP-values are compared with the reference category.
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Letter to the editor
Primary central nervous system lymphoma (PCNSL) is an uncommon, but aggressive 
non-Hodgkin lymphoma confined to the brain, leptomeninges, spinal cord, and eyes. Its 
incidence has increased substantially over the past decades among over 60-year-olds.1 
The median age at diagnosis is around 65 years, and approximately one-third of newly 
diagnosed patients are >70 years.1 Nevertheless, elderly PCNSL patients-especially those 
above age 70-are frequently excluded from or underrepresented in clinical trials due to 
concomitant comorbidities, poor performance status, or concerns regarding treatment-
related sequelae.2,3 Prospective studies specifically designed for elderly PCNSL patients are 
scarce.4-6 Furthermore, the few available, somewhat outdated series mostly included rela-
tively small numbers of patients (range, 10-107). These studies congruently showed that 
the prognosis of elderly patients remained poor and unchanged over the past decades, 
with overall survival (OS) ranging between 14-37 months. Collectively, apart from omitting 
consolidation radiotherapy after chemotherapy, the optimal treatment for elderly PCNSL 
patients is ill-defined.1,6,7
Population-based studies can complement prospective trials, especially in settings 
where data from prospective trials are scarce. At present, contemporary population-based 
studies with detailed data regarding primary therapy specifically among over 70-year-old 
PCNSL patients to inform clinical practice are lacking. Therefore, in this contemporary, 
nationwide, population-based study, we assessed primary therapy and OS among over 
70-year-old PCNSL patients diagnosed in the Netherlands.
Established in 1989, the nationwide Netherlands Cancer Registry (NCR) has an overall 
coverage of >95% of all malignancies in the Netherlands.8 We identified all over 70-year-
old PCNSL patients diagnosed-confirmed with cytology, histology, and/or flow cytometry-
between January 1, 2014 and December 31, 2017 from the NCR. PCNSL of the diffuse large 
B-cell type was defined using the International Classification of Diseases for Oncology 
morphology and topography codes (Supplementary Methods). Two patients diagnosed 
at autopsy were excluded. We included patients diagnosed from 2014 because the NCR 
collected data on the therapeutic regimen from that year onwards. The NCR is based on 
comprehensive case notifications through the Nationwide Network of Histopathology 
and Cytopathology, and the National Registry of Hospital Discharges (i.e. outpatient and 
inpatient discharges). Information on dates of birth and diagnosis, sex, disease stage, 
topography, and morphology, performance score, and primary therapy was available for 
individual patients. This information is collected by trained registrars of the NCR through 
retrospective medical records review. Primary therapy was categorized into chemo-
therapy, radiotherapy only, and supportive care only. Corticosteroids are not standardly 
registered in the NCR and may have been given in all treatment groups. The category of 
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chemotherapy was broken down by the exact therapeutic regimen. The Privacy Review 
Board of the NCR approved the use of anonymous data for this study.
The primary survival endpoint was OS, defined as the time from diagnosis until death. 
Patients were censored at emigration or end of follow-up (February 1, 2019). OS was cal-
culated for three age groups (71-74, 75-79, and ≥80 years) and according to primary treat-
ment (chemotherapy, radiotherapy only, and supportive care only) using the Kaplan-Meier 
method. Survival distributions were compared with the log-rank test. Multivariable Cox 
regression was conducted to assess covariates (sex, age at diagnosis, a prior malignancy 
before PCNSL diagnosis, receipt of rituximab, and type of primary therapy) associated with 
OS. A P<0.05 was considered statistically significant. See Supplemental Data for further 
details about the statistical analyses.
A total of 145 over 70-year-old PCNSL patients (50% males) were included in the study. 
The median age was 75 years (range, 71-87), with 55 (38%), 58 (40%), and 32 (22%) of 
patients aged 71-74, 75-79, and ≥80 years at diagnosis, respectively (Table 1).
table 1. Patient characteristics
Characteristic N (%)
Total no. of patients 145
Sex
 Male 73 (50)
 Female 72 (50)
Age at diagnosis, years
 Median (range) 75 (71-87)
 71-74 55 (38)
 75-79 58 (40)
 ≥80 32 (22)
Performance score
 0-1 24 (17)
 2-4 52 (36)
 Unknown 69 (48)
Prior malignancy
 No 113 (78)
 Yes 32 (22)
Vital status
 Alive 27 (19)
 Death 118 (81)
Median follow-up, months (range)
 Overall 4.1 (0.0-60.0)
 Alive 31.7 (15.2-60.0)
 Death 2.6 (0.0-41.4)
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Overall, 43% of patients received chemotherapy, 20% radiotherapy only, and 37% sup-
portive care only (Table 2). The receipt of chemotherapy decreased with older age (58%, 
40%, and 22% across the three age groups), while radiotherapy only or supportive care 
only increased (P=0.002; Table 2 and Supplemental Table 1). All 62 (43%) chemotherapy-
treated patients except one, were treated with either methotrexate (MTX)-monotherapy 
(n=25) or a variety of MTX-based regimens (n=36; Table 2). MTX with teniposide, car-
mustine, and prednisolone (MBVP) was the most commonly applied MTX-based regimen 
(25/36; 69%). Rituximab was added to chemotherapy in 17/62 (27%) patients (Table 2). 
Of note, six of seven chemotherapy-treated patients aged ≥80 years were treated with 
MTX-monotherapy.
table 2. Detailed information on primary therapy in over 70-year-old patients with PCNSL
Age at diagnosis, years
total
71-74 75-79 ≥80
Primary therapy N (%) N (%) N (%) N (%)
Total no. of patients 55 58 32 145
Supportive care only 17 (31) 22 (38) 15 (47) 54 (37)
radiotherapy alone 6 (11) 13 (22) 10 (31) 29 (20)
Chemotherapy 32 (58) 23 (40) 7 (22) 62 (43)
 MTX-based 20 (36) 15 (26) 1 (3) 36 (25)
 MBVPa,e 15 (27) 10 (17) 0 - 25 (17)
 MPb,f 2 (4) 3 (5) 1 (3) 6 (4)
 MCPMc 1 (2) 1 (2) 0 - 2 (1)
 MCPc 1 (2) 0 - 0 - 1 (1)
 R-CHOP + MTX 0 - 1 (2) 0 - 1 (1)
 MAc 1 (2) 0 - 0 - 1 (1)
 MTX onlyd 12 (22) 7 (12) 6 (19) 25 (17)
 Other 0 - 1 (2) 0 - 1 (1)
 PC 0 - 1 (2) 0 - 1 (1)
Abbreviations: MTX, methotrexate; MBVP, MTX, teniposide, carmustine, and prednisolone; MP, methotrexate 
and procarbazine; MCPM, methotrexate, lomustine, procarbazine, and cytarabine; MCP, methotrexate, lo-
mustine, and procarbazine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; 
MA, MTX and cytarabine; and PC, procarbazine and lomustine.
aCytarabine and rituximab were applied in 15 and 2 patients, respectively.
bRituximab was applied in 5 patients.
cRituximab was applied in 1 patient. 
dRituximab was applied in 6 patients.
eWhole brain radiotherapy was administered after chemotherapy in 3 patients.
fWhole brain radiotherapy was administered after chemotherapy in 1 patient.
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During follow-up, 118 (81%) patients died. The median follow-up of patients still alive 
was 31.7 months (range: 15.2-60.0). Overall, median OS was 4.1 months (95% confidence 
interval [CI], 2.8-6.8) and 2-year OS was 25% (95% CI, 18%-32%; Figure 1A). There were 
no significant differences in OS between the three age groups (P=0.185; Figure 1B). The 
difference in OS between 71-74 year-olds (7.7 months, 95% CI, 2.6-16.3) and those ≥75 
years (3.9 months, 95% CI, 2.4-5.5) was also not statistically significant (P=0.08; Supple-
mental Figure 1). OS according to primary treatment did show significant differences, with 
chemotherapy-treated patients having a superior median OS (16.3 months 95% CI 7.8-
35.2) compared with those who received radiotherapy only (7.7 months, 95% CI 4.6-13.2) 
or supportive care only (1.4 months, 95% CI 1.1-1.7; P<0.001; Figure 1C). Two-year OS was 
45% (95% CI, 32%-57%) in recipients of chemotherapy, whereas it was exceedingly low 
in the other two treatment groups (Figure 1C). The multivariable Cox regression analysis 
revealed that primary treatment was the only factor associated with OS, whereas sex, age, 
a prior malignancy before PCNSL diagnosis, and the receipt of rituximab were not associ-
ated with OS (Supplementary Table 2). Excluding the four patients in the chemotherapy 
group who subsequently received whole-brain radiotherapy did not change survival esti-
mates. Within the chemotherapy group, median OS for recipients of MTX-monotherapy 
was 5 months (95% CI, 2.6-41.4) and for MTX-based regimens 27 months (95% CI, 10.3-not 
reached; Figure 1D). That difference was not statistically significant (P=0.170). Also, and 
more importantly, the number of patients was small for a meaningful comparison. There-
fore, a multivariable analysis of MTX only versus MTX-based regimens was not performed.
In this contemporary, nationwide, population-based study among newly diagnosed 
over 70-year-old patients with PCNSL, we observed that the prognosis of these patients 
remains poor. This finding is congruent with prior population-based studies spanning the 
past decades.1
Age is a strong prognostic factor in adult PCNSL patients.9,10 However, within our study 
population encompassing over 70-year-olds, there was no clear prognostic gradient with 
increasing age, although with greater patient numbers, the association of age on OS might 
show a statistically significant difference. Instead, despite the small patient numbers, 
treatment was a strong prognostic factor. Although only 22% of patients aged ≥80 years 
received chemotherapy—which possibly hints towards selection bias or confounding by 
indication—this finding suggests that treatment, more than age, influences survival in 
elderly patients judged fit enough to receive therapy. Selection bias might also hold for 
MTX-monotherapy versus MTX-based chemotherapy. Performance status and comorbidi-
ty-in particular renal insufficiency-might have influenced the choice of chemotherapeutic 
regimen.
Prior prospective studies provided evidence that high-dose MTX-especially when com-
bined with alkylating chemotherapy-is the most efficacious treatment for elderly PCNSL 
patients.11 Although conflicting data exist on the therapeutic value of chemoradiation over 
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chemotherapy alone in elderly PCNSL patients,11,12 it is unquestionable that consolidation 
with radiotherapy in this population carries a high risk of neurotoxicity and severe cogni-
tive decline.13
Controversy exists regarding the therapeutic value of rituximab in PCNSL. Findings from 
the current study and a recent randomised phase III trial among PCNSL patients aged 
 - -
figure 1. Overall survival (OS) among over 70-year-old patients with primary central nervous system lym-
phoma in the Netherlands, 2014-2017. OS is shown for the total cohort (A), and according to age at diagnosis 
(B), treatment group (C), and the type of therapy with methotrexate (d). The tables below panels B through D 
show the median OS, and the projected 1- and 2-year OS with associated 95% confidence intervals. Abbrevia-
tions: OS, overall survival; CI, confidence interval; and MTX, methotrexate.
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18-70 years showed no added therapeutic value of rituximab on survival outcomes.3 
However, our results should be cautiously interpreted given the low number of rituximab-
treated patients. Similarly, a meta-analysis encompassing 343 patients with PCNSL aged 
50-67 years showed a possible effect of rituximab on PFS but not on OS.14 In contrast, a 
recent population-based study among 164 adult PCNSL patients diagnosed between 2005-
2010 in Austria-of whom 40% were >70 years-suggested that rituximab might augment 
survival, after a short follow-up: median 12 months.15
The strength of the current study is the use of a nationwide population-based cancer 
registry. As such, our study is not plagued by selection and/or referral biases to the extent 
encountered in clinical trials. Therefore, our study represents the general population 
of elderly PCNSL patients. Limitations of our study mainly pertain to the lack of data 
throughout most of the registry on comorbidities, the use of corticosteroids and the dose 
of steroids and chemotherapeutic agents, relapse rates, and salvage treatment. Also, the 
performance score is poorly documented in medical records, thereby hampering its inclu-
sion in the regression analyses due to the high percentage of unknown values (48%; Table 
1). The latter factor limits insight into the decision-making process of physicians based on 
performance status.
In summary, in this nationwide, population-based study, survival among over 70-year-
old PCNSL patients remains poor in contemporary clinical practice. Nevertheless, our data 
demonstrate that MTX-based multi-agent chemotherapy-as compared with radiotherapy 
only and supportive care only-results in the best outcome in elderly patients judged 
eligible to receive such treatment, with a 2-year OS that approximates 50%. The challenge 
remains to balance the benefits and risks of intensive chemotherapy in this patient group. 
Therefore, future prospective intervention studies are needed to assess which elderly 
patients can benefit from intensive chemotherapy or less intensive approaches.
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The Fisher’s exact test for categorical variables was applied to test for differences between 
groups. Univariable and multivariable logistic regression analyses were conducted to in-
vestigate the association of age at diagnosis (71-74, 75-79, and ≥80 years), sex, and a prior 
malignancy before primary central nervous system lymphoma (PCNSL) diagnosis with the 
receipt of chemotherapy. Linear trends in age with chemotherapy receipt were evaluated 
using Wald statistics. Also, univariable and multivariable Cox regression analyses were 
conducted to investigate the prognostic effect of age at diagnosis (71-74, 75-79, and ≥80 
years), sex, a prior malignancy before PCNSL diagnosis, primary therapy (chemotherapy, 
radiotherapy only, and supportive care only), and the application of rituximab on overall 
survival (OS). For both the multivariable logistic and Cox regression analyses, we used a 
reduced model in which variables were included with a forward selection method, after 
adjusting for the influence of the variables already selected according to their level of 
significance. The reduced model was achieved when the P-value for entering an additional 
variable was below 0.05. Also, we developed a full model where all the variables mentioned 
earlier were simultaneously adjusted. The likelihood ratio test (LRT) was used to compare 
the fit of the reduced model to the full model. All statistical analyses were performed with 
STATA Statistical Software Release 14.2 (College Station, TX, United States).
Morphology and topography codes
Primary central nervous system lymphoma (PCNSL) of the diffuse large B-cell type was 
defined using International Classification of Diseases for Oncology morphology (i.e. 
9590, 9591, 9593, 9595, 9675 and 9680-9684) and topography codes (i.e. C69.2, C69.4, 
C71.0-C71.9, C72.0, and C72.8). The selected topography codes are consistent with an 
anatomical location in the brain (C71.0-C71.9), spinal cord (C72.0), eyes (C69.2 and C69.4), 
and leptomeninges or cerebrospinal fluid (C72.8), according to the WHO Classification of 
Tumours of Haematopoietic and Lymphoid Tissues.(1) Although C72.8 is not specific for 
the latter two localizations, coding rules of the NCR designate C72.8 for localizations in the 
leptomeninges or cerebrospinal fluid.
Supplemental results
Chemotherapy receipt
Univariable and multivariable analyses revealed that only age ≥80 years at PCNSL diagno-
sis (ORreduced model, 0.20; 95% CI, 0.07-0.54; P=0.002), as compared with age 71-74 years, was 
the sole variable associated with a lower odds to receive chemotherapy (Supplemental 
Table 1). However, though, there was a linear effect of a lower odds of chemotherapy 
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receipt with increasing age (P for trend = 0.002; Supplemental Table 1). The addition of the 
remaining covariates into the reduced model did not improve the fit of that model (P for 
LRT = 0.199). Also, the linear effect of a lower odds of chemotherapy receipt with increas-
ing age remained significant in the full model (P for trend = 0.003; Supplemental Table 1)
Overall survival
As shown in Supplemental Table 2, the univariable analysis showed that patients who 
received radiotherapy only or supportive care only had a higher risk of mortality, as 
compared with recipients of chemotherapy. In addition, patients who received rituximab 
had a lower risk of mortality, as compared to patients who did not receive rituximab. 
However, multivariable analyses demonstrated that primary therapy (i.e. chemotherapy, 
radiotherapy only or supportive care only) was the sole variable that was associated with 
OS. The addition of the remaining covariates into the reduced model with primary therapy 
only did not improve the fit of the model (P for LRT = 0.930).
Supplemental Figure 1 
 
- -Supplemental figure 1. Overall survival (OS) among over 70-year-old patients with primary central nervous 
system lymphoma in the Netherlands, 2014-2017. OS is shown according to age at diagnosis (that is, 71-74 
versus ≥75 years). The median OS was 7.7 (95% CI, 2.6-16.3) and 3.9 (95% CI, 2.4-5.5) for patients aged 71-74 
and ≥75 years (P for log-rank = 0.08), respectively. The corresponding estimates of 2-year OS were 34% (95% 
CI, 22%-47) and 19% (95% CI, 12%-28%), respectively.
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reduced model full model
Covariate or 95% Ci P or 95% Ci P or 95% Ci P
Sex
 Male 1 (ref) 1 (ref)
 Female 1.28 0.66-2.48 0.458 1.09 0.54-2.21 0.815
Age at diagnosis, years 0.002* 0.002* 0.003*
 71-74 1 (ref) 1 (ref) 1 (ref)
 75-79 0.47 0.22-1.00 0.050 0.47 0.22-1.00 0.050 0.47 0.22-1.01 0.053
 ≥80 0.20 0.07-0.54 0.002 0.20 0.07-0.54 0.002 0.21 0.08-0.59 0.003
Prior malignancy
 No 1 (ref) 1 (ref)
 Yes 0.44 0.19-1.04 0.062 0.45 0.19-1.10 0.081
Abbreviations: OR, odds ratio; and CI, confidence interval.
*, P for trend




reduced model full model
Covariate hr 95% Ci P hr 95% Ci P hr 95% Ci P
Sex
 Male 1 (ref) 1 (ref)
 Female 0.88 0.61-1.26 0.480 0.98 0.68-1.43 0.923
Age at diagnosis, years
 71-74 1 (ref) 1 (ref)
 75-79 1.34 0.89-2.04 0.166 0.99 0.63-1.55 0.958
 ≥80 1.52 0.94-2.47 0.089 0.91 0.53-1.56 0.723
Prior malignancy
 No 1 (ref) 1 (ref)
 Yes 0.92 0.60-1.42 0.709 0.91 0.57-1.45 0.696
Primary therapy
 Chemotherapy 1 (ref) (ref) 1 (ref)
 Radiotherapy alone 1.92 1.15-3.20 0.013 1.92 1.15-3.20 0.013 1.85 1.02-3.36 0.042
 Supportive care only 6.91 4.35-10.97 <0.001 6.91 4.35-10.97 <0.001 6.48 3.80-11.1 <0.001
Application of rituximab
 No 1 (ref) 1 (ref)
 Yes 0.37 0.19-0.74 0.005 0.71 0.33-1.51 0.373
Abbreviations: HR, hazard ratio; and CI, confidence interval.
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Background: To assess the sensitivity, specificity and turnaround time of flow cytometric 
analysis on brain biopsies compared to histology plus immunohistochemistry analysis in 
tumors with clinical suspicion of lymphoma.
methods: All brain biopsies performed between 2010 and 2015 at our institution and 
analyzed by both immunohistochemistry and flow cytometry were included in this retro-
spective study. Immunohistochemistry was considered the gold standard.
results: In a total of 77 biopsies from 71 patients, 49 lymphomas were diagnosed by 
immunohistochemistry, flow cytometry results were concordant in 71 biopsies (92.2%). 
We found a specificity and sensitivity of flow cytometry of 100% and 87.8%, respectively. 
The time between the biopsy and reporting the result (turnaround time) was significantly 
shorter for flow cytometry, compared to immunohistochemistry (median: 1 vs. 5 days).
Conclusions: Flow cytometry has a high specificity and can confirm the diagnosis of a 
lymphoma significantly faster than immunohistochemistry. This allows for rapid initiation 
of treatment in this highly aggressive tumor. However, since its sensitivity is less than 
100%, we recommend to perform histology plus immunohistochemistry in parallel to flow 
cytometry.
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iNtroduCtioN
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma 
confined to the brain, leptomeninges, eyes, or spinal cord.1 Approximately 3% of all brain 
tumors are PCNSL. Secondary central nervous system lymphoma, or CNS localization of 
systemic lymphoma, occurs most frequently in Burkitt lymphoma (up to 43%) or in diffuse 
large B-cell lymphoma (DLBCL) patients (5-14%, depending on its stage or risk factors).2,3 
Common presenting symptoms of a CNS lymphoma are focal neurological deficits, neu-
ropsychiatric symptoms, headache and, less typically, seizures.4 MRI mostly shows single 
or multiple space occupying lesions, with homogeneous contrast enhancement. Before 
starting treatment, cytological, or histologic confirmation of the presence of a lymphoma 
is required. Since clinical deterioration is frequent in both primary and secondary CNS 
lymphoma, a rapid diagnosis is preferable. Sometimes a CNS lymphoma can be diagnosed 
by vitreous or cerebrospinal fluid (CSF) analysis.5 However, a spinal tap may be contraindi-
cated in space occupying lesions and even if safely possible, PCNSL is diagnosed on CSF in 
about 30% of patients only.6 Consequently, a brain biopsy remains necessary in the majority 
of the patients. Similarly, systemic lymphoma may also present with intraparenchymatous 
lesions, and may present with diagnostic uncertainties requiring histological confirmation. 
Histology with immunohistochemistry (IHC) is considered the gold standard in the analysis 
of brain biopsies in diagnosing a lymphoma. Immunophenotyping by flow cytometry is an 
objective and quantitative method ideally suited to identify small populations of cells with 
aberrant phenotypes.7 It is particularly helpful for the detection of small clonal popula-
tions of B-lymphocytes. The technique has proven its value in the analysis of bone marrow, 
fine needle aspiration of lymph nodes and in cerebrospinal fluid.8-12 In cerebrospinal fluid 
the sensitivity increases 2 to 3 times.13-17 However, few data defining the added value and 
diagnostic accuracy of flow cytometry in brain biopsies have been published. In our center 
immunophenotyping using eight-color flow cytometry has been utilized in addition to 
histology with IHC in brain biopsies since 2010 in brain tumor patients in whom a lym-
phoma was suspected, based on clinical and radiological features. The aim of this study 
was to determine the added clinical and diagnostic value of immunophenotyping by flow 
cytometry in brain biopsies. Furthermore, since analysis by flow cytometry is in general 
much faster than by immunohistochemistry, we also sought to investigate the difference 





All brain biopsies performed at the Erasmus University Medical Center in Rotterdam, the 
Netherlands, between January 2010 and December 2015 were retrospectively extracted 
from patient and laboratory registries. See Figure S1 for the flowchart of selecting biop-
sies. Only biopsies which were analyzed by both IHC and flow cytometry were included for 
statistical analysis. Flow cytometric analysis was routinely performed when a lymphoma 
was suspected on radiological grounds. In addition, HIV-status, use of corticosteroids and 
immunomodulating medication, of all patients were collected. Turnaround time (time 
between biopsy and report of the analysis) was extracted from patient files or laboratory 
log. Preliminary results given to the clinician were not included in our statistical analysis. 
The size of the biopsies and the numbers of cells within the flow cytometric analysis were 
registered. As a check for lymphoma patients not included, all patients with CNS lymphoma 
diagnosed in the same period in our center were extracted from the national pathology 
database PALGRA. The study was approved of by the Independent Review Board of our 
institution.
Neurosurgical procedures
Brain tissue was collected by image-guided stereotactic biopsies; when a high grade glioma 
was suspected patients went for open surgery. The stereotactic biopsies were frame-
lessly performed using the Medtronic Stealth TreonTM Vertek® system until 2010 and the 
Brainlab® Varioguide neuronavigation system ever since.18,19 In general, four biopsies were 
obtained at the preoperatively determined target, as well as two to four more biopsies at 
a site proximal to the target on the same biopsy trajectory. Open biopsies were performed 
using image-guided navigation and the operation microscope. After surgery the collected 
biopsies were divided for histopathology and flow cytometry by the neurosurgeon, or by 
the pathologist if all material had initially been sent to the pathology laboratory. Intra-
operative freeze sections were not performed in most patients to maximize available 
tissue for definitive pathology and flow cytometry.
Histology and immunohistochemistry
All tumors were classified according to the World Health Organization (WHO) classifica-
tion of Tumours of Haematopoietic and Lymphoid Tissues version 2008 by conventional 
histological assessment on 2 µm hematoxylin and eosin (H&E) stained sections and on 4 
µm immunohistochemically stained sections. Sections were cut from formalin-fixed brain 
tumor tissues, embedded in paraffin blocks using standard pathology tissue processing 
procedures.20 For immunohistochemistry, the following primary antibodies were used: 
CD3, CD5, CD10, CD19, CD20, CD79a, Bcl-2, Bcl-6, and Mib-1. When appropriate this panel 
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was extended with one or more of the following antibodies: BOB-1, MUM1, CD 15, cyclin 
D1, Smlgkappa, Smlglambda, CD21, CD23, CD68, CD138, CD4, GFAP, CD31, CD43, TIA-1, 
ALK-1, CD8 and PAX-5. All immunohistochemical procedures using primary and second-
ary antibodies and detection systems, were performed according to the manufacturer’s 
recommendations on a Ventana Benchmark Ultra platform (Ventana Medical Systems Inc., 
Tucson, USA), tested and validated according to ISO 15189 standards. See Figure 1 for an 
example of a cerebral NHL, analyzed by histology with immunohistochemistry.
Flow cytometry
Cell suspensions were generated from a single, unfixed brain biopsy by gentle manual 
disaggregation on a 100 µm strainer using a 10 mL syringe plunger rod and wash buffer 
(PBS/BSA 0.5%; not using any enzymes). The released cells were collected by rinsing with 
a total volume of 10 mL wash buffer and washed twice in 10 mL wash buffer; centrifu-
gation steps were for 5 minutes at 540g. After the last wash step, the supernatant was 
discarded and the pellet of cells was suspended in wash buffer. Fifty microliters of the 
cell suspension were stained using the EuroFlow Lymphocytosis Screening Tube (LST), 
according to the EuroFlow protocol.21,22 The LST contains antibodies CD20-Pacific Blue 
(Clone: 2H7; Biolegend), CD4-Pacific Blue (RPA-T4; Biolegend), CD45-Pacific Orange (HI30; 
Invitrogen), CD8-FITC, SmIgλ-FITC, CD56-PE, SmIgκ-PE (SLPC mix; Cytognos), CD5-PerCP-
Cy5.5 (L17F12, BD Biosciences, CD19-PC7 (J3-119; Beckman Coulter), SmCD3-APC (SK7, 
BD Biosciences), and CD38-APCH7 (HB7; BD Biosciences). Subsequently the suspension 
was acquired on a FACSCanto II flowcytometer (BD Biosciences, Erembodegem, BE) using 
EuroFlow settings.23 We aimed to acquire at least 5000 B-cells (with a minimum of 50.000 
figure 1. Histology and immunohistochemistry analysis
HE-staining with diffuse large B-cell lymphoma, activated blast type. Left: HE-staining with diffuse large B-cell 
lymphoma, activated blast type. Brain tissue with infiltration of blastic cells with large vesicular nuclei with 




leukocytes); if this could not be reached we acquired all available cells in the tube. Ap-
propriate instrument set-up and staining protocols were monitored by the EuroFlow QA 
scheme.24 After exclusion of debris, doublets and non-hematopoietic cells (CD45 negative, 
CD19 negative), which all together could add up to over 95% of acquired events in some 
samples, we defined the presence of a B-NHL population as a population with a marked 
shift in the SmIgKappa/SmIgLambda ratio (<0.7 or >2.8) and/or a clearly aberrant immu-
nophenotype (e.g., abnormal expression of Ig, CD19, CD20 and/or CD38, abnormal (high) 
forward scatter). If a B-NHL was detected and sufficient cells were available, EuroFlow 
BCLPD tube 1 to 4 were stained as well. In all cases, the diagnosis of a B-NHL was based on 
the results of the LST tube only, the additional information resulting from the additional 
BCLPD tubes was used to further specify the immunophenotype and to hint to specific 
B-NHL subtypes. Even though pathologists and immunologists who evaluated the analyses 
were not blinded for each other’s conclusion, the flow cytometry results were reported 
independently of histology plus IHC analysis. See Figure 2 for an example of a cerebral 
NHL, analyzed by flow cytometry.
figure 2. Flow cytometry analysis
Flowcytometric analysis on brain biopsy, showing a cerebral NHL with the presence of T-cells (11% of leuko-
cytes) and B-cells (89% of leukocytes). Whereas the T-cells (grey) showed a normal CD4/CD8 ratio (lower row, 
third plot) and a normal immunophenotype (CD3+/CD45+; upper row, second and third), the B-cells (CD19+; 
black) were clearly abnormal, with monotypic Immunoglobulin kappa expression, low expression of CD45, 
and light scatter characteristics (FSC and SSC; upper row, first plot) compatible with large cells. The biopsy was 
stained with the EuroFlow Lymphocytosis Screening Tube according to EuroFlow procedures.
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Statistical analysis
To determine the diagnostic value of flow cytometry, the reports of flow cytometry and 
immunohistochemistry were compared. Morphology plus IHC was considered the gold 
standard. In case the results were suspicious for a lymphoma but not conclusive, it was 
categorized as ‘no lymphoma’. The turnaround time and whether the results were available 
within 24 hours, were compared between the two techniques using the Wilcoxon signed-
ranks and a McNemar test, respectively. Differences with respect to use of dexamethasone 
and sample size, between concordant and discordant groups and between those who had 
multiple biopsies and who did not were analyzed by Mann-Whitney U or a Fisher’s Exact 
test. All analyses were performed by SPSS Statistics 21.
reSuLtS
Between January 2010 and December 2015 77 biopsies which have been analyzed by 
both histology and flow cytometry, were performed in 71 patients (59% male) with a 
median age of 63 (range 15-82). 10% of the patients were immunocompromised, which 
was defined as being HIV-infected (one patient) or using systemic immunomodulating 
treatment (e.g., methotrexate, azathioprine). Of all CNS lymphoma patients diagnosed 
in our hospital between 2010-2015 by histology and IHC, only four were not sent for flow 
cytometric analysis. In two cases all material was immediately preserved in formalin which 
made the tissue no longer suitable for flow cytometry, in two additional cases lymphoma 
was not considered in the pre-operative differential diagnosis.
Forty-nine biopsies were diagnosed as brain lymphoma by histology and immunohis-
tochemistry; 43 of these were also diagnosed as lymphoma by flow cytometry (Table 1). 
By flow cytometry, all identified cases were CD19+/CD20+; Ig light chain restriction was 
observed in most cases (38; 83%) whereas no Ig expression was detected in nine cases 
(17%). None of the 28 tissue samples not diagnosed as lymphoma by histology plus IHC 
were identified as lymphoma by flow cytometry. We thus found a concordance, specific-
ity and sensitivity of immunophenotyping by flow cytometry in brain biopsies of 92.2% 
(71/77), 100% (28/28) and 87.8% (43/49), respectively. The positive predictive value was 
table 1. Diagnostic value of flow cytometry on brain biopsies.
immunohistochemistry
flow cytometry Lymphoma No lymphoma total
Lymphoma 43 0 43
No lymphoma 6 28a 34
49 28 77
a Including 8 cases in which both results were “inconclusive”.
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100% (43/43) and the negative predictive value was 82.4% (28/34). Numbers of leukocytes 
(after exclusion of debris, doublets and non-hematopietic cells) that could be analyzed 
by flow cytometric analysis ranged widely: 9425 (29-207,259), median (range). Although 
statistical analysis to compare biopsies with discordant and concordant results should be 
interpreted with caution due to small numbers, no significant differences were found with 
respect to sample size (P = 0.06), number of cells acquired by flow cytometry (P = 0.62), or 
corticosteroid use prior to biopsy (P = 0.108). All 6 discordant cases were DLBCL, without 
unusual evidence of necrosis. In 6/71 patients a second biopsy and in 2/71 patients even 
a third biopsy was necessary to make a diagnosis, because of an inconclusive diagnosis in 
previous biopsies. Only those biopsies which were investigated by both techniques (6/8) 
were included in the statistical analysis. In the biopsies, analyzed by IHC only, two addi-
tional lymphoma were found. Use of corticosteroids prior to first biopsy (P = 0.06), size of 
the biopsy (P = 0.68 ) and/ or number of cells for flow cytometric analysis (P = 0.19) were 
similar in patients with conclusive and inconclusive diagnoses. The 20 patients without 
a lymphoma were diagnosed with a myriad of diseases: 11 glioblastoma, 1 anaplastic 
astrocytoma, 1 germinoma, 1 stroke, 5 infections and one CLIPPERS syndrome (chronic 
lymphocytic inflammation with pontine perivascular enhancement responsive to steroids), 
a rare auto-immune disorder. We found a significantly shortened time to reporting of the 
results (turnaround time) for flow cytometry, compared to IHC (Table 2). Furthermore, 
in 54% of the biopsies the diagnosis was provided within 24 hours using flow cytometry, 
compared to 9% using histology plus IHC.
diSCuSSioN
In this study, we compared flow cytometry with histology plus IHC on 77 brain biopsies, 
performed in patients clinically suspected of having a lymphoma. We found a high concor-
dance between both techniques (92.2%) and a specificity and sensitivity of flow cytometry 
by immunophenotyping in brain biopsies of 100% and 88%, respectively. In 6 patients 
with histologically proven NHL, the presence of a lymphoma could not be identified by 
flow cytometry. No factors (e.g., sample size, use of corticosteroids prior to the biopsy) 
could be identified which could explain the missing diagnosis in flow cytometry. Unlike 





Turnaround time (days) 5 (0-18) 1 (0-7) p <0.00a
Diagnosis <24 hours (biopsies) 7 (9%) 41 (54%) p< 0.00b
Median time (range) in days between biopsy and diagnosis. Significance was calculated by aWilcoxon signed-
ranks test and bMcNemar Test. In one biopsy the date of reporting was missing for flow cytometry analysis.
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in CSF or bone marrow analysis no additional cases of brain lymphoma were identified 
by flow cytometry that had not been identified by immunohistochemistry. We found a 
significant difference in turnaround time for the two techniques. After biopsy a diagnosis 
was given with a median time of 5 days (range 0-18) for immunohistochemistry, compared 
to median of 1 day (range 0-7) for flow cytometry. In 54% of the biopsies the presence or 
absence of a lymphoma could be confirmed within 24 hours by flow cytometry, compared 
to 9% for immunohistochemistry (P < 0.00), which means that correct treatment could 
be initiated within 24 hours. It should be noted that the preliminary results of the flow 
cytometric analysis were frequently reported to the clinician on the day of biopsy. Given 
the frequently rapid clinical deterioration in CNS lymphoma and the negative impact of 
a lower performance score on survival, according to the two largest validated prognos-
tic models25,26, early diagnosis may improve prognosis.27 Similar findings were reported 
in a much smaller cohort of 18 stereotactic biopsies recently.28 Cordone et al. found a 
significant agreement between flow cytometry and immunohistochemistry diagnosis (P 
= 0.0034). They described a sensitivity and specificity of flow cytometry by immunophe-
notyping of 89% and 100% respectively. In the 2/18 PCNSL biopsies not identified by flow 
cytometry more central necrosis was present, compared to biopsies with concordant 
results and both patients used corticosteroids prior to the biopsy.28 We did not find more 
central necrosis in our discordant biopsies and corticosteroid use did not differ between 
concordant and discordant pairs. One other study analyzed flow cytometry on rinse fluid. 
Even though rinse fluid from the biopsy needle cannot be completely compared to brain 
tissue itself, this study showed similar results.29 In a small sample, a high specificity (100%) 
and sensitivity (75% on rinse fluid and 100% on tissue sample) of flow cytometry in detect-
ing a brain lymphoma were found. The added value was again the time in which the flow 
cytometry could confirm the diagnosis (±3-20 hours, compared to 2-10 days for histo-
pathological diagnosis). Because the diagnosis could be confirmed within 24 hours in 75% 
of the cases, the authors recommend to use both techniques, allowing chemotherapy to 
commence within 24 hours. In contrast with the results of our study and two comparable, 
though much smaller studies on brain biopsies, flow cytometry on bone marrow and 
CSF allowed identification of additional lymphoma cases over cytology. The sensitivity of 
cytological analysis of CSF for lymphoma cells is low (2-32%).30 Several authors found that 
additional flow cytometry on CSF improves the sensitivity, up to 2-3 fold.13-15 In up to 80% 
the lymphoma cells are detected in the first CSF sample, analyzed by flow cytometry.15 It 
is likely that this additional sensitivity of flow cytometry is a result of the low number of 
tumor cells available for diagnosis in CSF and bone marrow. Corticosteroids can induce 
apoptosis in lymphoma cells. This can mask the morphology and can even cause the tumor 
to vanish.31-33 In lymph nodes and CSF samples, flow cytometry can confirm a diagnosis on 
samples with a low cell count. We hypothesized that flow cytometry, being a more sensi-
tive technique, may be able to recognize lymphoma in patients in whom, after steroid use, 
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lympholysis had taken place and histology plus IHC was negative. Unfortunately, this was 
not the case in our series nor in the other two smaller studies available. Five patients who 
went for multiple biopsies and were diagnosed with brain lymphoma after their second or 
third biopsy, used corticosteroids prior to their first (and second) biopsy. In none of these 
patients flow cytometry analysis was able to make the diagnosis when histology plus IHC 
were non-diagnostic. Clearly, immunohistochemistry as well as flow cytometry analysis 
can be compromised in patients using corticosteroids prior to the biopsy.
The strengths of this study are the comprehensive clinical and laboratory data in a 
large, unselected sample, allowing calculation of the diagnostic and clinical value of flow 
cytometry on brain biopsies. To the best of our knowledge, this is the largest cohort ever 
described comparing flow cytometry to immunohistochemistry in brain biopsies. Fur-
thermore, due to our large population, we were able to show that the negative effect of 
corticosteroids on the diagnostic value of flow cytometry was similar to that on IHC. Even 
our series, however, still concerns a relatively small number of cases. The main drawback 
of our study is its retrospective nature: we may have missed some biopsies, even though 
we did a thorough search through all available databases in our hospital (neurosurgery, 
flow cytometry, pathology and neuro-oncology) and the immunologist and pathologist 
were not blinded for each other’s results. Nevertheless the flowcytometric result was 
always reported without knowledge of the pathological evaluation. In addition, we did not 
perform freeze sections, so comparison with intraoperative diagnosis could not be made.
CoNCLuSioN
Flow cytometry analysis in brain biopsy is a feasible technique with 100% specificity to 
confirm the diagnosis of brain lymphoma in patients suspected for lymphoma on clini-
cal grounds. The added clinical value is the speed by which flow cytometry can establish 
or confirm the diagnosis, enabling a faster initiation of treatment, while false positive 
cases were not identified. Flow cytometry is complementary to, but not more sensitive 
than, histopathology with immunohistochemistry analysis. We recommend to perform 
flow cytometry and immunohistochemistry in parallel in brain biopsies, suspected for a 
lymphoma.
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Background. In primary central nervous system lymphoma (PCNSL), small enhancing le-
sions can persist after treatment. It is unknown whether a difference in response category 
(complete response (CR), complete response unconfirmed (CRu) or partial response (PR)) 
reflects survival. We aimed to determine the value of a central radiology review on re-
sponse assessment and whether the extent of response influenced progression-free and/
or overall survival.
methods. All patients in the HOVON 105/ALLG NHL 24 study with at least a baseline MRI 
and one MRI made for response evaluation available for central review were included. 
Tumor measurements were done by two independent central reviewers, disagreements 
were adjudicated by a third reviewer. Crude agreement and interobserver agreement (Co-
hen’s kappa) were calculated. Differences in progression-free and overall survival between 
different categories of response at the end-of-protocol-treatment were assessed by the 
log-rank test in a landmark survival-analysis.
results. Agreement between the central reviewers was 61.7% and between local and 
central response assessment was 63.0%. Cohen’s kappa’s, which corrects for expected 
agreement, were 0.44 and 0.46 (moderate), respectively. Agreement on progression 
or not was 93.3% (kappa 0.87) between local and central response assessment. There 
were no significant differences in progression-free and overall survival between patients 
with CR, CRu or PR at the end-of-protocol-treatment, according to both local and central 
response assessment.
Conclusions. Reliability of response assessment (CR/CRu/PR) is moderate even by central 
radiology review and these response categories do not reliably predict survival. Therefore, 
primary outcome in PCNSL studies should be survival rather than CR or CR/CRu-rate.
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iNtroduCtioN
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma 
confined to the brain, leptomeninges, spinal cord and eyes without manifestations out-
side the central nervous system. For response assessment in PCNSL the criteria from the 
International Primary CNS Lymphoma Collaborative Group (IPCG), are commonly used.1 
These response criteria are based on radiological, ophthalmologic and spinal fluid cytology 
examination, and the use of corticosteroids. The MRI response evaluation defines the fol-
lowing categories: complete response (CR): no signs of abnormal gadolinium-based con-
trast agent enhancement, complete response unconfirmed (CRu): a small but persistent 
contrast enhancement abnormality likely related to biopsy or focal hemorrhage, partial 
response (PR): a reduction of ≥50% of the contrast enhancing lesion, stable disease (SD): 
<50% reduction and ≤25% increase of the contrast enhancing lesion, progressive disease 
(PD): >25% increase in contrast enhancing lesion, relapse: a new contrast enhancing lesion 
after prior CR or CRu.1 These response criteria do not take non-enhancing lesions into 
account. Recent findings and earlier reports suggest that these lesions might, however, be 
considered as tumor as well.2,3
The correlation of radiological response with survival endpoints (progression-free sur-
vival [PFS] and overall survival [OS]) is uncertain: one study showed that patients with a CR 
at the end of induction chemotherapy had a better OS than those who did not reach CR, 
but in this study PR, SD and progression were combined.4 In another study highly variable 
outcomes were found in patients with PR at the end-of-treatment2, and a third study did 
not show a survival difference between those who attained CR compared to those who did 
not reach CR at the end of induction treatment.5 Thus, it is questionable whether in PCNSL 
the extent of radiological response is relevant for predicting OS, the golden endpoint in 
oncology studies. It is also unclear whether interobserver variation exists in assessing 
response in PCNSL, which if present, will affect the reliability of that endpoint.
In the HOVON 105/ ALLG NHL 24 trial, the primary endpoint was event-free survival 
(EFS). Events were defined as ‘not reaching complete response’ or ‘complete response 
unconfirmed at the end-of-treatment’, or ‘progression or death after response’.6 Because 
event-free survival includes a radiological evaluation as endpoint (i.e. achieving CR or 
CRu), based on local assessment, central MRI review is important for the trial analysis. The 
aim of the present study was to review the local assessment by central radiology review 
and to assess whether CR, CRu and PR reflect PFS and OS. In addition, we evaluated the 





The HOVON 105/ALLG NHL 24 study is a phase III randomized controlled trial, in which 
between 2010 and 2016 199 patients were recruited from Dutch, Australian and New Zea-
land hospitals. The treatment protocol and primary outcome results have been published 
before.6 In short, immunocompetent patients with a newly diagnosed, CD20 positive 
B-cell PCNSL aged 18-70 years with WHO/ECOG performance status 0-3 were included. 
Patients were randomized for two courses of high-dose methotrexate (HD-MTX)-based 
chemotherapy: methotrexate, teniposide, BCNU and prednisolone (MBVP) versus MBVP 
with rituximab (R-MBVP). This was followed by HD-cytarabine (Ara-C) chemotherapy. 
Patients ≤60 years-old subsequently received 30Gy whole brain radiotherapy (WBRT). A 
simultaneous focal boost of 10Gy was given to the original enhancing tumor in patients 
who only achieved partial response (PR).
Patients were included for the central MRI review if they gave informed consent for 
central radiology review, and if a baseline MRI as well as at least one follow-up MRI was 
available for central review. Additionally, a measurable brain lesion had to be present at 
baseline in order to be able to assess response. Patients were excluded if only a CT was 
available at baseline and/or if only CTs were used for evaluation at subsequent time points. 
The baseline MRI had to have been made within21 days before initiation of protocol treat-
ment.
Radiological follow-up
According to protocol, MRI evaluations were performed before the initiation of chemo-
therapy (baseline), after the second (R-)MBVP course, after Ara-C and after WBRT, if ap-
plicable. Follow-up MRIs were made every 3 months in the first 2 years after treatment, 
followed by every 6 months up to 5 years after treatment and yearly thereafter.
At least the following MRI sequences were performed: an axial T1 weighted scan before 
and after gadolinium-based contrast agent administration, and an axial T2 weighted and/
or fluid-attenuated inversion recovery (FLAIR) scan. If locally possible additional sagittal or 
coronal T1 weighted scans with gadolinium-based contrast agent administration were also 
performed or reconstructed. All MR images were acquired on a 1.5 or 3.0 Tesla scanner.
Central radiology review
Scans made at baseline and after each treatment component were centrally reviewed to 
evaluate response of the tumor to treatment. In case of relapse or progression, the MRI 
on which this was diagnosed according to the local physician, as well as the last MRI made 
before progression were also centrally reviewed, to verify progression and to make sure 
true progression had not occurred earlier than locally ascertained. Scans made in follow-
69
Extent of radiological response does not reflect survival in PCNSL patients
5
up were not reviewed if response was not changed according to the local evaluation. PD 
was defined as relapse or progression at any site (brain, spinal cord, cerebrospinal fluid 
or eyes). In case progression was located outside the brain parenchyma, the MRI was not 
included in this analysis.
At the end of the study, all MR images were submitted for review on DVD or CD, and 
stored on a secured central server. Except for the baseline scan, locally assessed response 
rates were collected for all MRIs performed for this study. Local physicians were not 
blinded for treatment arm and/or other clinical information.
Central evaluation of response was performed retrospectively, in parallel by two review-
ers (M.M. and A.A.P.). In case of disagreement on the response between these reviewers, 
an adjudicator (M.S.) finalized the central response category. The central reviewers and 
the adjudicator were blinded for study-arm and clinical information.
Single evaluations were excluded if a) both central reviewers considered an MRI not 
assessable, b) no MRI with gadolinium-based contrast agent administration was made or 
c) the MRI was made outside +/- 3 weeks around the planned evaluation moment during 
the treatment period.
MRI Tumor measurement
For all enhancing lesions the largest diameters on the axial post gadolinium-based contrast 
agent T1 weighted images were measured as well as their perpendicular diameter on the 
same slice. The product of these measurements was used to define the size of the tumor. 
In case of multiple lesions, response assessment was based on the sum of all products, up 
to a maximum of four lesions.
Non-enhancing space occupying lesions were measured by one of the central reviewers 
(M.M.) on FLAIR images if possible, and otherwise on the T2 weighted images. In patients 
experiencing recurrent disease the localization of the recurrence was compared to the 
localization of the initial non-enhancing and enhancing lesions.
Landmark analysis
To estimate the survival probability for the different response categories (CR, CRu, or PR) 
in an unbiased way, a landmark analysis was performed.7 Regardless of the type of last 
administered treatment on protocol, the response at the end-of-protocol-treatment was 
related to PFS and OS for those still at risk at that timepoint. PFS was defined as time from 
randomization to progression, relapse, or death from any cause, whichever came first. 
OS was defined as time from randomization to death from any cause. Patients still alive 
at the date of last contact were censored. Follow-up data were available up to October 1, 
2019. In this landmark analysis, all patients alive at the landmark timepoint who had an 
MRI at end-of-protocol-treatment and were classified as CR, CRu or PR on that MRI were 
included. The reference time point (landmark) was set between 4 weeks after last treat-
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ment, but before the first follow-up MRI (i.e. 3 months after end-of-protocol-treatment), 
in such a way that most patients could be included. The landmark analysis was performed 
for both local and central response assessment.
Statistical analysis
Since the HOVON 105/ ALLG NHL 24 study showed no differences in EFS, PFS or OS be-
tween the two treatment arms we analyzed both arms together.6 For the interobserver 
agreement between the central reviewers, and between central and local response evalu-
ations we calculated the crude agreement and Cohen’s kappa8, in which crude agreement 
is corrected for expected agreement (i.e. the agreement that would occur ‘by chance’). 
First, interobserver agreement was assessed for all response categories separately; 
second, agreement was assessed for combined categories CR/CRu and PD/relapse, and 
third for three categories: response (CR/CRu/PR), SD, and progression (PD/relapse). Lastly, 
the crude agreement and kappa’s interobserver agreement for progression versus no 
progression were calculated on the MRI on which progression was diagnosed and on the 
preceding MRI.
In the landmark analysis, the survival curves for PFS and OS were constructed using 
the Kaplan-Meier method for the different categories of response (i.e. CR, CRu and PR) 
according to central and to local response evaluation at the end-of-protocol-treatment. 
Differences by response were assessed with a log-rank test with a 5% significance level. All 
analyses were performed with Stata, version 15.0. The study was approved by the ethics 
committee of all participating centers. All participants signed informed consent for the 
randomized controlled trial and separately for the central radiology review.
reSuLtS
Of the 199 trial patients, 115 were included in this study. Three patients were excluded 
because they did not give informed consent for the radiology review, 12 patients because 
no baseline MRI was present and 3 for whom only CT was available, 61 patients were 
excluded because baseline MRI was made outside the predefined time window, and 5 for 
other reasons (see CONSORT diagram, Figure 1). The median age of patients included in 
this study was 61 years (range: 38-70), 44% were female, and 73% had WHO performance 
score <2, see Table 1. On October 1, 2019 (last follow-up), in the central radiology review 
cohort 45 patients were alive without progression and 15 were alive with progression.
Of these 115 included patients, 396 scans were centrally reviewed: 115 baseline MRIs, 
235 after treatment and 46 PD or last before PD scans. Scans were excluded if they were 
not received for central review (n=154), were made outside the predefined time window 
(n=7), or progression was not located in the brain parenchyma (n=14).
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Central radiology review
For the MRIs made during treatment (n=235) the agreement between central reviewer 1 
and 2 and between local and central response assessment was higher than the expected 
agreement by chance (p<0.001). Between the central reviewers the agreement for all 
response categories was 61.7%, with a kappa of 0.44, see Table 2. After adjudication, if 
necessary, the agreement between local and central response assessment was 63.0% with 
a kappa of 0.46, see Table 3.
199 HOVON 105/ ALLG NHL 24 patients
196 patients
3 no consent for central MRI review
12 no baseline MRI
3 only CT scan available
1 no parenchymal brain involvement
4 no measurable brain lesion
4 baseline scan made after
start protocol treatment 





10 MRIs after first (R-)MBVP cycle
97 MRIs after second (R-)MBVP cycle
85 MRIs after HD-Ara-C
43 MRIs after WBRT
 
figure 1. CONSORT diagram. 235 MRIs from 115 patients were assessed.
(R-)MBVP = (rituximab), methotrexate, teniposide, BCNU and prednisolone, HD-Ara-C = high-dose cytarabine, 
WBRT = whole-brain radiotherapy.
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Sex (n, % males) 64 (56%) 45 (54%) 109 (55%)
Age (median, range) 61 (38-70) 61 (26-70) 61 (26-70)
WHO performance score (n, %)
0 27 (23%) 16 (19%) 43 (22%) 
1 57 (50%) 44 (53%) 101 (51%) 
2 17 (15%) 17 (20%) 34 (17%) 
3 14 (12%) 7 (8%) 21 (10%) 
Comorbidities (n>2, %) 60 (52%) 44 (52%) 104 (52%)








Deep lesion (n, %) 83 (72%) 42 (50%) 125 (63%)
 Periventricular (n, %) 61 (53%) 35 (42%) 96 (48%)
 Basal ganglia (n, %) 8 (7%) 6 (7%) 14 (7%)
 Cerebellar (n, %) 22 (19%) 8 (10%) 30 (15%)
 Brain stem (n, %) 10 (9%) 2 (2%) 12 (6%)
 Spinal (n, %) 2 (2%) - 2 (1%)
 Lobar (n, %) 58 (50%) 37 (44%) 95 (48%)
Study drug exposure
High-dose cytarabine (n, %) 98 (85%) 63 (75%) 161 (81%)
WBRT (n, %) 48 (42%) 22 (26%) 70 (35%)
Radiation boost given (n, %) 24 (21%) 15 (18%) 39 (20%)
Intrathecal treatment given (n, %) 12 (10%) 4 (5%) 16 (8%)
NA = not applicable in case of no brain lesion; WBRT = whole brain radiotherapy.
table 2. Level of agreement between central reviewer 1 and central reviewer 2 in all 235 scans made after 







Cr Cru Pr Sd Pd relapse total
CR 32 34 11 1 0 0 78
CRu 0 38 15 0 0 1 54
PR 0 17 74 4 0 0 95
SD 0 0 2 1 1 0 4
PD 0 0 0 1 0 1 2
relapse 0 0 1 0 1 0 2
Total 32 89 103 7 2 2 235
Agreement 62%, kappa 0.44. CR = complete response; CRu = complete response unconfirmed; PR = partial 
response; SD = stable disease; PD = progressive disease.
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When CR and CRu were combined into one category, and the categories PD and relapse 
were combined, the interobserver agreement and kappa values increased, but the lat-
ter remained in the moderate range. Between reviewer 1 and 2, agreement increased to 
77.0% (kappa 0.57) and between local and central assessment agreement improved to 
74.5% (kappa 0.54), see Supplemental Table 1 and Supplemental Table 2, respectively. 
When response categories were classified into response (CR, CRu or PR), stable disease, or 
progression (PD or relapse) the agreement increased to 95.3% (kappa 0.40) between the 
central reviewers and 94.9% (kappa 0.41) between local and central response assessment. 
The kappa remained relatively low, because of the increased expected agreement.
The response assessment for the MRIs on which progression or relapse was diagnosed, 
and the last MRI made before progression were analyzed separately. Agreement on 
whether there was progression or relapse versus ‘no progression’ was 96.7% between 
central reviewer 1 and 2 (kappa 0.93) and 93.3% between the local and central response 
assessment (kappa 0.87), both were significantly higher than expected agreement 
(p<0.001), Table 4A and 4B.
table 3. Level of agreement between local and central assessment in all 235 scans made after each treatment 






Cr Cru Pr Sd Pd relapse total
CR 42 12 8 0 0 1 63
CRu 15 28 30 0 0 0 73
PR 1 9 74 1 0 1 86
SD 0 0 4 1 1 0 6
PD 0 0 2 0 3 0 5
relapse 0 0 2 0 0 0 2
Total 58 49 120 2 4 2 235
Agreement 63%, kappa 0.46. CR = complete response; CRu = complete response unconfirmed; PR = partial 
response; SD = stable disease; PD = progressive disease.
table 4. Level of agreement A) between both central reviewers: agreement 96.7%, kappa 0.93 and B) be-
tween local and central assessment.











No PD 16 1 17 No PD 14 1 15
PD 0 13 13 PD 1 14 15
16 14 30 15 15 30




Landmark analysis on CR, CRu and PR
In total 91 ‘end-of-protocol-treatment’ MRIs were available and were locally and centrally 
assessed. The landmark, aiming to include as many pati ents as possible aft er the end-of-
protocol-treatment MRI but before fi rst follow-up MRI, was positi oned at 6.9 months aft er 
randomizati on. Only those with a CR, CRu or PR at the end-of-protocol-treatment were 
included in this analysis. Two pati ents who had not had their end-of-protocol-treatment 
scan yet were excluded. For the PFS analysis we also excluded those who had less than PR 
(n=7 according to central response and 8 according to the local response assessment) at 
the end-of-protocol-treatment, had progression before the landmark (n=9 in central and 
n=6 in local response assessment) or died without progression (n=1). For the OS analysis 
we excluded those who had less than PR (see above) or died (n=2) Since we analyzed 
survival according to local as well as to central response assessment, the number of pa-
ti ents the analyses were based on diff ered: survival analysis was performed on 72 (central 
assessment) and 74 (local assessment) pati ents for PFS and 80 (central assessment) and 
79 (local assessment) pati ents for OS.
 
figure 2. Progression free survival (A and B) and overall survival (C and D) for those pati ents who had a parti al 
response (PR), complete response (CR) or complete response unconfi rmed (CRu) at the end of treatment MRI, 
according to central (A and C) and local response (B and D) assessment.
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Regarding PFS (Figure 2A and B) there was no statistically significant difference between 
those judged as CR, CRu or PR, both in central response assessment (p=0.97) and accord-
ing to local judgement (p=0.76). Similar results were found for overall survival (Figure 2C 
and D), for central (p=0.69) and local (p=0.16) response assessment.
Non-enhancing lesions
At baseline seven patients were identified with non-enhancing space occupying lesions. 
Baseline characteristics in these patients were similar to the total trial population, Supple-
mental Table 3. After chemotherapy, in five of the seven patients, the lesions diminished 
with ≥50%.
Four of these patients relapsed, in two patients this was at the same location as the 
original enhancing lesion. None of the patients had a relapse at the location of the non-
enhancing lesions.
diSCuSSioN
We found an excellent crude agreement (96.7%) and kappa score (0.93) between the 
central reviewers and between local and central radiological evaluations (crude agree-
ment 93.3%, kappa 0.86) in differentiating progression from no progression. However, for 
response assessment after treatment, interobserver agreement was moderate at best. 
Furthermore, the crude interobserver agreement and kappa statistics between the two 
central reviewers and between local and central radiology response assessment after each 
treatment component (n=235) were almost identical (local vs central kappa 0.46 and both 
central reviewers 0.44). This suggests that there is little added value of a central radiol-
ogy review in PCNSL patients. Crude interobserver agreement increased when response 
categories were combined, but the kappa statistics remained in the range of moderate 
agreement. This is most likely due to increased expected agreement, since Cohen’s kappa 
statistic is the agreement found, corrected for expected agreement to occur by chance. 
Thus, our data show that although the presence of response is well agreed upon, judge-
ment regarding the extent of response is less reliable. This suggests, together with the 
excellent agreement regarding the moment of progression, that PFS and OS are more 
reliable endpoints than specific and more detailed response categories and which also 
better reflect patient benefit.
To the best of our knowledge, a central radiology review in PCNSL with assessment 
of the interobserver agreement has not been described before. Several studies assessed 
interobserver agreement in glioma patients.9-13 Our excellent agreement on PD vs no PD 
contrasts with the interobserver agreement in standard radiology assessment for progres-
sion in glioma.9,12 This might be explained by the rapid evolution of most PCNSL and its 
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easily recognizable appearance on the MR images: PCNSL, at relapse or progression as well 
as primary presentation, generally appears as a homogenously enhancing, circumscribed 
space-occupying lesion, rather than the ill-defined mass and irregular enhancement in 
high-grade glioma.
In our landmark analyses we found no difference in PFS or OS for the different types of 
response: CR, CRu and PR. The lack of difference in outcome between CR and CRu patients 
is in line with the current response criteria1, which state regarding CRu lesions that if the 
type of abnormality does not change or slowly involutes over time without therapy or cor-
ticosteroids, it is reasonable to categorize these lesions as CR. However, we also found that 
partial response was associated with a similar PFS and even a similar OS, suggesting that 
these response categories do not translate into meaningful differences in outcome and 
are therefore not reliable surrogate endpoints in PCNSL. A few other studies compared 
survival for different response categories.2,4,5,14 Only one of these studies2 used a landmark 
analysis, resulting in selection bias in the other studies (i.e. immortal time bias), since 
response and survival are influenced by the passing time. If survival analysis is done after 
end-of-protocol-treatment, regardless of when the MRI was made, those who have had a 
later MRI would have had more chance to achieve CR. One large, prospective study (n=511) 
showed a significant difference between CR versus no CR (PR, SD and PD combined) for 
OS (39 versus 22 months; p<0.0001) and PFS (36 versus 6 months).4 In that study, CR was 
defined as complete resolution of contrast enhancing lesions on MRI or on CT. The latter 
radiological examination might have missed small contrast enhancing foci. Furthermore, 
combining PR with non-responding and progressive patients does not allow conclusions 
regarding the partially responding (PR) patients. Similarly, in a retrospective analysis of a 
phase II study in 85 patients, differences in survival rates between patients with CR, PR, 
SD or progression after the end of chemotherapy were calculated using a single log-rank 
test. A significant difference was found for OS (p<0.001), and a nearly significant difference 
for PFS (p=0.076).2 Again, due to the comparison of all groups including non-responding 
or progressive patients this analysis does not allow comparison between patients with 
different extents of response. Lastly, a small retrospective single center series, evaluated 
patients after chemotherapy. Those with CR after the completion of chemotherapy (n=10) 
had no better PFS or OS than those with no CR (n=30).5 In that study, however, patients 
without CR subsequently received additional treatment: radiotherapy or autologous stem 
cell transplantation.
Two dimensional measurements are the golden standard in the current PCNSL re-
sponse criteria1, and were therefore also applied in this study. This might, underestimate 
volumetric changes. In glioma, volumetric measurements, either manual or computerized, 
improved agreement regarding radiological response compared to 2D measurements in 
some studies,13,15 and fully automated segmentation was significantly better in predicting 
OS (p<0.0001) than the conventional 2D measurements.13 In contrast, one other smaller 
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study showed no differences in predicting OS between manual 2D and 3D measurement 
or computerized segmentation of the tumor.16 Response in PCNSL is generally easily 
recognizable with reductions > 50% being the rule, so small changes in the volume of 
the enhancing lesion are unlikely to influence response rates. However, small changes in 
residual abnormalities might result in a change in response category, between CRu and PR.
Our study has some limitations: first, the landmark analyses were performed for dif-
ferent categories of response based on the MRI made at the end-of-protocol-treatment. 
This might have led to bias, since patients >60 years-old with a PR at the end-of-protocol-
treatment could have had additional treatment, depending on the discretion of the 
treating physician. Second, analyses were performed on a subgroup from a large clinical 
trial and inadvertent bias may have occurred in the selection of patients for this study, 
even though this selection was based on the availability of scans only. Our results should 
therefore be validated in a larger external cohort.
In conclusion, our results suggest that at the end-of-protocol-treatment, specific radio-
logical response categories (CR, CRu, or PR) do not reliably predict survival in PCNSL pa-
tients, even after central radiology review, but that interobserver agreement in diagnosing 
relapse or progression is high. Therefore, the primary outcome measure in PCNSL studies 
should be PFS or OS; as secondary outcome measure combined response rate (CR, CRu 
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Supplemental table 1. Level of agreement between central reviewer 1 and central reviewer 2 in all 235 scans 







Cr/Cru Pr Sd Pd/relapse total
CR/CRu 104 26 1 1 132
PR 17 74 4 0 95
SD 0 2 1 1 4
PD/relapse 0 1 1 2 4
Total 121 103 7 4 235
CR = complete response; CRu = complete response unconfirmed; PR = partial response; SD = stable disease; 
PD = progressive disease.
Supplemental table 2. Level of agreement between local and central assessment in all 235 scans made after 






Cr/Cru Pr Sd Pd/relapse total
CR/CRu 97 38 0 1 136
PR 10 74 1 1 86
SD 0 4 1 1 6
PD/relapse 0 4 0 3 7
Total 107 120 2 6 235
CR = complete response; CRu = complete response unconfirmed; PR = partial response; SD = stable disease; 
PD = progressive disease.
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Supplemental table 3. Baseline characteristics of the patients with and without non-enhancing lesions at 
baseline, and for the total study population.
n=192 n=7 n=199
Sex (n, % males) 106 (55%) 3 (43%) 109 (55%)
Age (median, range) 61 (26-70) 61 (55-68) 61 (26-70)
WHO performance score (n, %)
0 43 (22%) - 43 (22%)
1 97 (51%) 4 (57%) 101 (51%)
2 32 (17%) 2 (29%) 34 (17%)
3 20 (10%) 1 (14%) 21 (11%)
Unilateral lesions (n, %) 103 (54%) 2 (29%) 105 (53%)
Missing/ NA 19 (10%) 1 (14%) 20 (7%) 
Deep lesion (n, %) 120 (63%) 5 (71%) 125 (63%)
Treatment arm
MBVP (n, %) 96 (50%) 4 (57%) 100 (50%) 
R-MBVP (n, %) 96 (50%) 3 (43%) 99 (50%) 
WHO = World Health Organisation; NA = not applicable, no brain lesion(s); MBVP = methotrexate, tenoposide, 
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Incidence of primary CNS lymphoma (PCNSL) is increasing, while prognosis is improving 
as treatment advance. However, declined cognitive functioning remains a major challenge 
in the treatment of PCNSL. This cognitive decline, in conjunction with other symptoms 
caused by the disease or its treatment, or both, can compromise health-related quality of 
life (HRQOL). The aim of this Review was to give a comprehensive overview on cognitive 
functioning and HRQOL for patients with PCNSL, including an evaluation of patient-related 
and treatment-related factors that can influence cognitive functioning and HRQOL. We re-
viewed the literature for studies on cognitive functioning and HRQOL in newly diagnosed 
adult patients with PCNSL using MEDLINE/Pubmed, Embase, Web of Science, Scopus, 
Cochrane, PsycINFO, CINAHL EBSCO, and Google scholar, up to Jan 4, 2018. Articles were 
selected using predetermined inclusion and exclusion criteria; 42 articles were eligible for 
inclusion. Findings show that the tumour itself has a great effect on cognitive functioning 
and HRQOL. Initially, induction chemotherapy results in improvement of cognition and 
HRQOL in most patients. In the long-term, additional whole brain radiotherapy (WBRT) 
has a negative impact on cognitive functioning, but the magnitude of this impact is not 
always clinically relevant. HRQOL scores were worse compared with controls, and worse 
after combined chemotherapy and radiotherapy when compared with chemotherapy only, 
particularly in the long term. Therefore, combined chemotherapy and radiotherapy seems 
to have a negative effect on HRQOL and cognition in PCNSL patients. Although prolonged 
progression-free survival is achieved with combined therapy, information on its effect on 
cognition and HRQOL should also be included in clinical decision-making.
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iNtroduCtioN
Primary CNS lymphoma (PCNSL) is a rare non-Hodgkin lymphoma confined to the brain, 
leptomeninges, spinal cord and eyes. In previous decades, the incidence rate has increased 
while prognosis has improved.1-3 Improved survival is largely dependent on changes in 
treatment, particularly the addition of high-dose methotrexate-based chemotherapy to 
the previously standard treatment of whole-brain radiotherapy (WBRT). One phase 3 
study has shown that the omission of WBRT decreased progression-free survival (PFS), 
but not overall survival (OS) in patients with PCNSL.4 However, more patients who were 
given chemotherapy and radiotherapy, compared with chemotherapy alone, developed 
neurotoxicity (49% vs 26%), which was defined as progressive neurological or cognitive 
impairment as documented in serial clinical examinations in the absence of recurrent 
lymphoma.4
Although improved survival has been achieved in this population, declined cognitive 
functioning remains a major challenge in the treatment of PCNSL.5 Subsequently, cogni-
tive decline and other symptoms caused by the disease or its treatment, or both, can 
compromise health-related quality of life (HRQOL).6,7 To establish the net clinical benefit 
of a treatment regimen, information on survival has to be combined with information 
from patient-centered outcomes, eg, HRQOL and cognition. Combining both sources of 
information allows informed decision making on the effect of a specific treatment, which 
is useful for all specialists involved in the treatment of patients with PCNSL.
In 2007, a systematic review based on a search in MEDLINE was done to identify studies 
reporting om the effect of different treatment modalities on cognition in PCNSL patients.5 
With the introduction of new treatment modalities, however, and the increased use of 
patient-reported outcomes, an update on the field is warranted. Therefore, the aim of 
this systematic Review was to give a comprehensive overview on the effect of PCNSL 
and different treatment types on cognitive functioning and HRQOL in adult patients with 
newly diagnosed PCNSL. Furthermore, we aimed to identify which patient-related and 
treatment-related factors were associated with cognitive functioning and HRQOL. Possible 
underlying pathophysiological mechanisms, which might explain a decline in cognition or 
HRQOL, or both, are beyond the scope of this Review, and thus will not be discussed.
dAtA CoLLeCtioN
Search strategy and selection criteria
We dis an extensive search for articles published up until Jan 4, 2018, using the electronic 
databases MEDLINE/PubMed, Embase, Web of Science, Scopus, Cochrane, PsycINFO, 
CINAHL EBSCO and Google scholar. Search terms related to “PCNSL” and “cognition” or 
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“HRQOL”, or both, were used, and terms were formulated to exclude case reports and 
studies that only include animals (see appendix for the search strategy in MEDLINE). 
Original peer-reviewed articles published in English, and reported on cognitive functioning 
or HRQOL, or both, in newly diagnosed adult patients with PCNSL (whole population or 
reported separately as a subgroup) were eligible for inclusion. Cognitive functioning had 
to be assessed with a performance outcome instrument8, including formal neurocogni-
tive tests (eg, Neuropsychological Test Battery) or screening tools (Mini-Mental State 
Examination [MMSE]9 or Montreal Cognitive Assessment [MoCA]10), and HRQOL had to be 
measured with a patient-reported outcome (PRO) measure. For both outcomes, the tests 
or scales used for assessment had to be reported, and results clearly described. There 
were no restrictions regarding the study design.
All identified abstracts were screened independently by two reviewers (MvdM and LD), 
and potentially relevant articles were reviewed. The reference lists of these articles were 
screened for additional eligible studies. Disagreements were discussed in a consensus 
meeting between MvdM and LD. The interpretation of the predefined were discussed when 
interpreted differently. If necessary, a third reviewer (JECB) was consulted in instances 
when there was a disagreement. Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis (PRISMA) guidelines were followed to document the search strategy and 
selection process.11
Data extraction
In addition to information on study design, we extracted patient demographics (age, sex, 
and baseline performance status) from each study too. For cognition and HRQOL, the 
assessment schedule, tests or questionnaires used, and the results were extracted. To 
assess whether a change in score in cognitive tests and HRQOL assessments were clinically 
relevant, previously published cut-offs were used. These were MMSE scores less than 27,12 
or Z scores less than -1.513 in cross-sectional analyses, a change or difference of three or 
more points in MMSE score,14 one or more points in Z score15 for cognitive tests, or ten or 
more points for scales oritems of the EORTC QLQ-C30.16
fiNdiNGS
The search resulted in 1634 unique records, of which, 197 were assessed for further eligi-
bility (figure). Of these, 42 articles were eligible according to our inclusion criteria. Most 
articles were excluded because of small sample sizes, because cognition was not formally 
tested or HRQOL was not assessed using a PRO. The study characteristics of the 42 eligible 
articles are described in the appendix. 25 articles (60%) described the effect of treatment 
on cognitive functioning only, two (5%) assessed the effect on HRQOL only, and 15 (36%) 
89
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mentioned the effect of treatment on both outcomes. Tables 1-3 show the rsults for formal 
cognitive tests, screening tools and HRQOL for patients with newly diagnosed PCNSL. Four 
studies were randomised controlled trials (RCTs), and the rest were cohort studies. Sample 
sizes from each study ranged from ten to 318 patients. Only four articles (10%) described 
the effect of treatment on cognition or HRQOL in elderly patients only.17-20 We grouped the 
articles according to treatment modality: immunochemotherapy or chemotherapy alone 
(n=5), with blood-brain barrier disruption (n=5), chemotherapy followed by autologous 
stem cell transplantation (ASCT; n=4), intravenous and intrathecal chemotherapy (n=5), 
and chemotherapy combined with WBRT (n=21). For WBRT the results are separately 
reported for low (<35 Gy) and high dose radiotherapy (≥35 Gy), on the basis of the dose 




Four studies17-19,21 reported on the effect of chemotherapy with or without rituximab, 
on cognitive functioning. Treatment with rituximab, methotrexate, procarbazine, and 
lomustine (R-MPL), a high-dose methotrexate-based chemotherapy with rituximab, in 
elderly patients (66-85 years, n=74)18 resulted in a clinically relevant improvement in 
MMSE18 directly after completion of chemotherapy, which remained stable during further 
treatment.18 Another study observed an improvement immediately after initiation of 
rituximab, methotrexate, procarbazine, and vincristine (R-MPV) on all cognitive tests.22 
Nevertheless, on two tests, in the memory and motor speed domain, Z scores were worse 
compared to the general population (≤-1.5).22 In an RCT in elderly people (≥60 years), most 
patients (48[80%] of 60) had serious cognitive impairments (Mattis Dementia Rating Scale23 
[MDRS], <135) at baseline, but improved to a statistically significant degree in several 
domains (attention and memory) after completion of treatment (high-dose methotrexate 
alone or in combination with temozolomide).17 Similarly, MMSE scores remained stable19,24 
or improved19,21 shortly after chemotherapy in most patients (92%), including the elderly 
population.19 A direct comparison between chemotherapy and immunochemotherapy 
on the long term effects of therapy on cognitive functioning cannot be made, because 
treatment with different additional therapies were used (eg, reduced dose WBRT, full 
dose WBRT, or ASCT). In the short-term in changes in cognition between these treatment 
modalities (chemotherapy and immunochemotherapy) were observed. After an initial 
improvement, scores on the cognitive tests remained stable up to 22 months of follow-up 
in the general21 and in the elderly17,19 population, suggesting that chemotherapy does not 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chemotherapy with blood-brain barrier disruption
A small study (n=23) showed that all patients given chemotherapy with blood-brain bar-
rier disruption had stable or a clinically relevant improvement in their summary cogni-
tion score at the end of treatment and in the short-term, after a mean follow-up of 16.5 
months.25 Three of 23 patients showed declined functioning in motor speed only.25 Up to 7 
years after treatment, most patients (75-83%) had stable or improved cognitive function-
ing. Of those patients who deteriorated cognitive functioning, 31% received WBRT before 
or after chemotherapy.25-28 No details were available on radiotherapy dose. At a median of 
12 years after chemotherapy, 24 patients showed improved mean scores on all cognitive 
test compared to baseline, of which the trail making tests A and B (measuring multiple 
cognitive domains) were statistically significant, but not clinically relevant.29 These results 
suggest no detrimental effect of blood-brain barrier disruption chemotherapy on cognitive 
functioning, even in the long term.
Chemotherapy followed by stem cell transplantation
Three small22,30,31 (n=13-32 patients) and one larger cohort study (n=79)32 described 
the effect of combined treatment with chemotherapy and ASCT on cognitive function-
ing. At 3-6 months after ASCT, additional ASCT resulted in improved cognition in most 
domains (attention, executive function and verbal memory) compared with baseline, 
but these changes were not clinically relevant.22,30,32 Over time, with a median follow-up 
of 45 months, cognition remained largely stable after initial improvement, with slightly 
improved scores on motor speed, although these were still lower than normative values.22 
Similarly, an improvement in MMSE score was seen at 57 months; from 25 at baseline to 
27 during combined treatment, and up to 28 after a median follow-up of 57 months.32 
Lastly, a cross-sectional analysis in ten patients, after a median follow-up of 25 months, 
showed that 90% had a normal MMSE score (≥27) in the long-term, even though four out 
of ten had received WBRT (36-50 Gy).31
Intravenous chemotherapy combined with intrathecal chemotherapy
Five articles33-37 were published describing partially overlapping small populations (n=20-
65), in which patients were given combined intravenous and intrathecal methotrexate-
based chemotherapy. After a median of 4 months, this treatment resulted in clinically 
relevant improvements in verbal episodic memory, word fluency and psychomotor speed 
domains, whereas other domains remained stable.33 After a median follow-up of 32-44 
months, most patients (70%) improved or remained stable.34-37 In a subgroup op 12 pa-
tients, mean standard values slightly improved at 100 months in all domains except for 
non-verbal episodic memory, in which scores diminished (102.3 to 88.5).33
103
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Chemotherapy combined with WBRT
Three articles38-40 described the effect of R-MPV followed by reduced-dose WBRT (23.4 
Gy) in overlapping populations (n=52 in total). In the short-term, improved cognition was 
seen in all domains, but it was only clinically relevant for executive function. Scores in 
motor domain improved the least (n=12).38-40 Up to 4 years after treatment, cognition 
scores remained stable after treatment in these 12 patients, implying that reduced-dose 
radiation did not have a clinically relevant negative effect on cognitive functioning.38,40 Ad-
ditionally, the majority (six of eight) of a small subset had stable or improved intelligence 
approximately 5 years after treatment (20 Gy),41 and MMSE scores improved or remained 
stable directly after treatment and remained stable up to five years after combined 
chemotherapy and radiotherapy (23.4 Gy).42 Studies of high-dose radiotherapy reporting 
MMSE and MoCA10 scores showed improved or stable results43 in 24 of 33 patients (73%)44 
directly after combined chemotherapy and radiotherapy (high-dose methotrexate-based; 
36-45Gy),45,46 lasting up to 1 year.24,42 Even in the elderly a stable MMSE score of 27 
(normal-good) was reported over time.20 One study (n=24) showed an initial improvement 
in cognition after treatment with chemotherapy (high-dose methotrexate, cyclophospha-
mide, doxorubicin, vincristine, and prednisolone) alone or combined with WBRT (36-60 
Gy), at 6 months post-treatment, patients treated without WBRT had stable MMSE scores 
(from baseline to 6 months after treatment, 25 to 24) whereas patients given WBRT 
declined from baseline to 6 months after treatment (28 to 22), representing a clinically 
relevant detoriation.47 For long-term data, results are conflicting. One study reported that 
patients given WBRT (45 Gy) had worse MMSE scores to a clinically relevant degree 2 
years after randomisation compared with those treated without WBRT (26 vs 29).48 By 
contrast, other studies showed that MMSE scores improved (from 25 to 28 for high-dose 
methotrexate and WBRT treated patients, and from 27 to 29 in high-dose methotrexate, 
Ara-C, and WBRT treated patients, radiation dose 36-40 Gy)49 or remained stable for up 
to 3 years,44,46,50 irrespective of radiation dose.46 By contrast, a small retrospective study 
reported that a higher dose (>40Gy) was related to poorer cognitive functioning (three 
of four patients [75%] vs two of 13 patients [15%] with a lower dose of <40 Gy).51 After a 
median of 12 years after combined chemotherapy and radiotherapy, eight of nine patients 
still had an MMSE score of 29 or more.52
Cognition formally measured with a neuropsychological test battery showed slightly 
different results. Two articles, describing partially overlapping populations (total n=50), 
showed that, when measured cross-sectionally, scores in patients given WBRT (36-59 
Gy) were statistically significantly worse than in patients treated without WBRT immedi-
ately after treatment. Clinically relevant differences were found for attention and verbal 
memory.53,54 Moreover, patients with PCNSL treated with chemotherapy and radiotherapy 
were significantly more impaired, compared with normative data 2 years after treatment, 
in all domains except verbal and visuoconstructive ability.55
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HEAlTH-rElATED QuAlITy Of lIfE
Immunochemotherapy or chemotherapy
Three studies17,18,56 reported HRQOL results in patients given immunochemotherapy or 
chemotherapy only. Immediately after completion of chemotherapy, patients showed 
statistically significant and clinically relevant improvements in HRQOL scores, as measured 
with the FACT-Br (improvement from 120 to 134) and the EORTC QLQ-C3057 global health 
status scale (50 to approximately 66).17,22 The global health scores at 24 months did not 
further improve nor decline.17 In 11 patients given high-dose methotrexate, HRQOL was 
measured cross-sectionnally with the FACT-Br (mean 158) after a median follow-up of 22 
months56; similar to FACT-Br scores measured in another study at 24 months follow-up.22 
In elderly patients with PCNSL, global health status improved, though not to a clinically 
relevant degree, straight after treatment with R-MPL (50 vs 58), and remained stable up 
 
figure 1. PRISMA flowchart
PCNSL=primary CNS lymphoma. QOL=quality of life. PRO=patient-reported outcome. NPE=neuropsychological 
evaluation. MMSE-Mini-Mental State Examination.
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to 18 months thereafter.18 Similar results are found, both in the short and long term, for 
chemotherapy17,56 and immunochemotherapy.18,22 Although 83% of patients reported an 
average to good global health status score, and 72% a good to very good score, following 
intravenous and intrathecal chemotherapy after a median follow-up of 4436 and 10033 
months, respectively, patients’ functioning levels (functional scales of the EORTC QLQ-
C30) were worse to a clinically relevant degree compared with that of the general popula-
tion.33,36 Longitudinal measurements up to 100 months in 12 patients showed a significant 
deterioration in social functioning over time.33 Since raw HRQoL scores are absent, it is not 
clear whether this was also a clinically relevant deterioration.
Chemotherapy combined with ASCT
Two studies22,32 showed that 4-6 months after treatment with chemotherapy and ASCT the 
FACT-Br58 score improved significantly (120 to 144)22 and that the global health status im-
proved to a clinically relevant degree (50 to approximately 66).32 After 1 year of follow-up, 
global health status remained relatively stable (66 to 60).32 The FACT-Br score, however, 
showed a further improvement over time, to 149 points at 12 months and 158 points at 
24 months after treatment.22
Chemotherapy combined with whole brain radiotherapy
Two studies of reduced dose WBRT (23.4 Gy) showed that FACT-Br scores improved from 
baseline (122 to 129) at 1 year after reduced dose WBRT (154 to157) and remained stable 
up to 2 years thereafter (154 to 156).38,40 Two articles,53,54 describing partially overlapping 
populations, showed that immediately after treatment, HRQoL scores (FACT-Br) were 
worse in patients given combined chemotherapy and radiotherapy (36-54 Gy) compared 
with those given chemotherapy only (131 vs 142; n=28 in total). However, after 14-16 
months of follow-up (n=50), these scores were 139 versus 127, in favour of patients given 
chemotherapy and radiotherapy.53,54 Also the Spitzer QOL score59 improved from a median 
score of six at baseline to ten (maximum) 3 years after treatment with combined chemo-
therapy and radiotherapy (36 Gy) compared to the chemotherapy alone group.44 Several 
significant differences in HRQOL, among physical, role, emotional and cognitive function-
ing, weakness of the legs, and future uncertainty, were found in favour of no early WBRT 
(45 Gy), compared with upfront WBRT. However, whether these differences were clinically 
relevant or not, remains unknown because crude data were not reported.48 Compared 
with controls (patients treated for systemic haematologic malignancies), HRQOL was 
worse in almost all domains, about 2 years after treatment with combined chemotherapy 
and radiotherapy (39-40 Gy) to a statistically significantly and clinically relevantly degree.55
In one remaining article, the radiation dose was unknown; after a median follow-up of 
3.3 years, younger patients less than 65 years had better scores to a statistically signifi-
cantly and clinically relevant degree on several scales and items of the EORTC QLQ-C30 and 
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QLQ-BN20 questionnaires60 than older patients, indicating that age influences the effects 
of treatment on HRQOL. HRQOL scores in the first 5 years after high-dose methotrexate 
and WBRT (dose unknown) were similar to the scores thereafter (maximum of 14 years), 
underscoring the fact that HRQOL remains stable on extended follow-up.61
Direct comparison of multiple treatment modalities
In two studies62,63, the effect of different treatment modalities on cognition and HRQOL 
were directly compared. One RCT compared ASCT with WBRT (36 Gy), and showed im-
provement in cognition and HRQOL in most patients after consolidation therapy in both 
arms of the study.63 2 years after treatment, a significant impairment in attention and 
executive functions63 was observed in patients given WBRT, although no clinically relevant 
differences62 could be discerned from the results.63 Concerning HRQOL, in all scales or 
items except for emotional functioning62 or global health status63, patients given WBRT 
(45-60 Gy62) had a significantly62,63 and clinically relevant62 lower score compared with 
those who were treated without WBRT.
diSCuSSioN
Most studies included in this systematic Review showed that, compared with baseline, 
cognition and HRQOL were improved to a clinically relevantly degree after induction che-
motherapy in patients with PCNSL, implicating that the tumour itself had negative effects 
on both outcome measures. However, this rapid improvement after initial treatment has 
not been reported in patients with glioma.64-66 As corticosteroids are a part of induction 
chemotherapy, they might have contributed to the improvement observed for both 
outcome measures. Although it might be expected that treatment with chemotherapy 
that disrupts the blood-brain barrier results in a deterioration in cognitive functioning, 
two studies26,29 have shown that patients; cognitive functioning improves directly after 
treatment, and that this improvement is maintained over time, even long term. The effect 
of treatment on cognition is therefore similar to that of convention chemotherapy (ie, 
immunochemotherapy or chemotherapy and intravenous chemotherapy combined with 
intrathecal administrated chemotherapy).17,19,21,33 Likewise, combined chemotherapy with 
ASCT22,30 also resulted in an initial improvement, with stable cognition and HRQOL during 
follow-up. The effect of WBRT on cognitive functioning, however, is ambiguous. Few studies 
have shown clinically relevant differences in scores on several neuropsychological tests53 
and in MMSE scores47,48, both in favour of patients treated without WBRT. By contrast, 
other studies have shown that cognition remained stable up to 4 years after reduced-dose 
WBRT, implying no adverse effects of low-dose radiation on long-term cognitive function-
ing.38,40 As cognitive screening tools, like MMSE and MoCA, lacks sensitivity to detect 
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cognitive impairment67 and results should be interpreted with caution, we combined the 
results of these tests with those from formal neuropsychological evaluation (ie, the gold 
standard) in case they showed a similar trend. It remains important, however, to note that 
MMSE scores - either measured cross-sectionally or longitudinally - are likely to provide 
an underestimation of the incidence of cognitive impairment and changes that may have 
occurred over time in patients with PCNSL. Thus, results from screening instruments, such 
as MMSE or MoCA, are most likely represent an underestimation of the patients’ actual 
level of impairment, limiting the interpretation of the magnitude of the cognitive adverse 
effects of the various treatment regimens used in PCNSL. Moreover, it is important to 
emphasise that future clinical studies use appropriate standard measures in this popula-
tion, as proposed by the International Primary CNS Lymphoma Collaborative Group, to 
better evaluate cognition.5
For HRQOL, most studies showed stable HRQoL directly after WBRT, with a further 
improvement over time in one study44. Only one study showed did a direct comparison 
bewteen patienst given WBRT and those treatedwith other modalities, which showed a 
worse score for a small group (n=11) of patients given WBRT compared with those given 
other modalities (n=60 in total).62 As an example, the global health score was 48 for those 
treated with chemotherapy followed by radiotherapy, and 62-82 for those treated with 
other modalities without radiotherapy.62 Although not always clinically relevant, these 
results do suggest that treatment with radiotherapy results in worse cognitive functioning 
and HRQOL compared with treatment with chemotherapy only, or in combination with 
other therapies. This information should be included in clinical decision making, together 
with information about survival. Although the interpretation of the study is difficult due to 
a large amount of cross-over between study arms, a prolonged progression-free survival 
(18 vs 12 months) was achieved in patients given combined chemotherapy and radiother-
apy, compared with chemotherapy only;4 however, overall survival did not differ between 
groups.4,63 Benefits of extended progression-free survival with WBRT and the associated 
delayed negative effects of recurrent disease on cognition and HRQOL should be weighed 
against the negative effects of full-dose radiotherapy on cognition and HRQOL. It could 
also be argued to preclude the addition of full-dose WBRT from first-line therapy, because 
of its negative impact on cognition and HRQoL without proof of prolonged overall survival. 
As such, reduced-dose WBRT could be an appropriate alternative. Treatment with ASCT 
may also be an alternative to WBRT, as progression-free survival outcomes are similar 
bewteen modalities,63,68 and the effects on cognition are likely to be less detrimental than 
WBRT. The Effect of ASCT on overall survival, however, remains to be seen.
With respect to patient-related factors that are associated with cognition or HRQOL, 
age was only described in a few studies. Most elderly patients (80%) had serious cognitive 
impairment (MDRS, <135) at baseline,17 which improved immediately after treatment and 
at short-term follow-up (up to 1 year),18,19 and remained stable afterwards.17,21 HRQOL 
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was also shown to improve after treatment in the elderly population, although this was 
not clinically relevant.18 Nevertheless, younger patients (<65 years) had statistically signifi-
cantly better scores to a clinically relevant degree on several scales and items of the EORTC 
QLQ-C30 and QLQ-BN20 questionnaires when compared with older patients, indicating 
that age influences the effects of treatment on HRQOL long-term.61
It has been recognized that both cognitive functioning and HRQOL are important outcome 
measures in patients with PCNSL.69 However, both outcomes are measured, evaluated and 
described in many different ways, which make it difficult to perform a meta-analysis and 
draw conclusions on the effect of different treatment modalities in this patient popula-
tion. Moreover, it is difficult to determine the long-term impact of treatments, because 
of the large drop-out rate of participants on cognitive tests or HRQOL questionnaires over 
time. In addition, results from the available cross-sectional studies are often hampered 
by selection bias; those who had neurotoxicity may not have returned for their MMSE 
or neuropsychological testing appointments during follow-up.21 Another limitation is the 
level of reporting of the results described in the included studies. Unfortunately, many 
articles only reported cross-sectional post-treatment results. Without baseline scores it 
is not possible to determine the net change in cognitive functioning that has occurred 
over time. Additionally, sometimes statistically significant differences were described, 
without presenting the actual scores, which meant it was not possible to identify if these 
differences were also clinically relevant. If raw scores were present, significant differences 
should not be automatically interpreted to be clinically relevant too.
CoNCLuSioN
The results of the studies included in this Review showed that both the tumour and 
additional full-dose WBRT can effect cognition and HRQOL in a clinically relevant, and 
negative, way. It is important that this information is included in clinical decision making, 
when discussing the benefits and risks of certain treatments. We advise that research in 
patients with PCNSL address cognition and HRQOL, as recommended by the guideline5 to 
help clinicians to make a reasoned decision, regarding treatment.
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Objective: To analyze the effect of treatment on neurocognitive functioning and the as-
sociation of neurocognition with radiological abnormalities in primary central nervous 
system lymphoma (PCNSL).
methods: 199 patients from a phase III trial (HOVON 105/ALLG NHL 24), randomized to 
standard chemotherapy with or without rituximab, followed in patients ≤60 years-old 
by 30Gy WBRT, were asked to participate in a neuropsychological evaluation before and 
during treatment, and up to 2 years post-treatment. Scores were transformed into a 
standardized z-score; clinically relevant changes were defined as a change in z-score of ≥1 
standard deviation. The effect of WBRT was analyzed in irradiated patients. All MRIs were 
centrally assessed for white matter abnormalities and cerebral atrophy, and their relation 
with neurocognitive scores over time in each domain was calculated.
results: 125/199 patients consented to neurocognitive evaluation. Statistically significant 
improvements in neurocognition were seen in all domains. A clinically relevant improve-
ment was seen only in the motor speed domain, without differences between the arms. In 
the follow-up of irradiated patients (n=43), no change was observed in any domain score, 
compared to after WBRT. Small but significant inverse correlations were found between 
neurocognitive scores over time and changes in white matter abnormalities (regression 
coefficients: -0.048 to -0.347) and cerebral atrophy (-0.212 to -1.774).
Conclusions: Addition of rituximab to standard treatment in PCNSL patients did not impact 
neurocognitive functioning up to two years post-treatment, nor did treatment with 30Gy 
WBRT in patients ≤60 years-old. Increased white matter abnormalities and brain atrophy 
showed weak associations with neurocognition.
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iNtroduCtioN
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma 
confined to the brain, leptomeninges, spinal cord and eyes. Over the last three decades 
the prognosis for patients with PCNSL improved significantly due to improvement of 
treatment, though mainly among patients below the age of 70 years.1,2 Preservation of 
neurocognitive functioning remains a major challenge in the treatment of PCNSL.3 Neu-
rocognitive decline, along with other symptoms caused by the tumor and/ or treatment, 
may subsequently compromise health-related quality of life (HRQoL).4,5
In systemic diffuse large B-cell lymphoma (DLBCL) patients, rituximab, a chimeric anti-
CD20 monoclonal antibody that targets the CD20 cell surface protein, improves survival 
when added to standard chemotherapy.6,7 It has been hypothesized that rituximab added 
to standard high-dose methotrexate (HD-MTX) based chemotherapy could also improve 
survival in PCNSL patients. The HOVON 105/ ALLG NHL 24, a large international multicenter 
phase III randomized controlled trial (RCT), investigated the addition of rituximab to MBVP 
(methotrexate, tenoposide, BCNU and prednisolone) chemotherapy, followed in patients 
≤60 years-old, by whole brain radiotherapy (WBRT). This study showed that rituximab did 
not improve event-free, progression free and overall survival (OS), although OS data were 
still immature.8
For any new treatment regimen, information on the impact of this treatment on both 
the quantity and quality of life should be evaluated to determine the ‘net clinical benefit’. 
Neurocognitive impairment is an important factor that may negatively influence HRQoL 
in brain tumor patients and should therefore be considered in this evaluation. Although 
a direct effect of rituximab on neurocognition was not necessarily expected, improved 
efficacy of treatment resulting in fewer patients needing radiotherapy (boost) could influ-
ence the neurocognitive effect of the treatment. Combined survival and quality of survival 
will allow clinicians and patients to make informed decisions about the best treatment for 
each individual patient.
Radiological features, in particular brain volume and white matter lesions, have been 
found to correlate with worse neurocognitive functioning in patients treated for PCNSL in 
some, but not all, studies.9-13 Most of these studies were limited by a cross sectional design 
and/or small cohorts (n=16-28).11,12
Rituximab was found not to affect HRQoL in patients from the HOVON 105/ ALLG 
NHL24 trial.14 The primary aim of this study was to determine the effect of rituximab, 
when added to standard treatment for PCNSL, on neurocognitive functioning, which was 
a predefined secondary endpoint of the HOVON 105/ALLG NHL 24 trial. In addition, we 
aimed to evaluate the effect of low-dose WBRT on neurocognitive functioning in irradiated 
patients. Lastly, we aimed to identify whether there is a relation between brain volume 




Study design and patient population
In the HOVON 105/ ALLG NHL 24 trial 199 immunocompetent patients, aged 18-70 years, 
with newly diagnosed CD20 positive B-cell PCNSL were included from Dutch, Australian 
and New Zealand hospitals between 2010 and 2016. Only patients who were fluent in Eng-
lish or Dutch and were treated in a center that was equipped for neuropsychological evalu-
ation (NPE) were eligible for participation in this neurocognitive study. The trial design and 
treatment details were published elsewhere.8 In short, patients were randomized for two 
cycles of MBVP without or with rituximab (R-MBVP). Irrespective of treatment arm, this 
induction treatment was followed by consolidative HD-cytarabine chemotherapy. Patients 
≤60 years-old subsequently received 30Gy (20x1.5Gy) WBRT. An integrated boost of 10Gy 
to the tumor-bed was given simultaneously with WBRT to patients who achieved only a 
partial response.15 All participants signed informed consent for the RCT and separately for 
undergoing neurocognitive assessments. The study and the neurocognitive testing part 
were approved by the ethics committees of all participating centers. The HOVON 105/
ALLG NHL 24 trial was registered: EUdraCT number 2009-014722-42 and in the Nether-
lands Trial Register: Trial NL2321.
Neuropsychological evaluation
All patients were tested by a trained research nurse or neuropsychologist using a standard 
test battery, as described in the assessment guidelines in PCNSL.3 For testing attention/
executive functioning, the WAIS III digit span (DS) forward and backward16 and the Trail 
Making Test parts A and B17 were used. The written version of the Letter Digit Substitution 
Test (LDST)18 was used to determine information processing speed. Memory was tested 
with the Rey Auditory Verbal Learning Test (RAVLT)19, and motor speed with the Grooved 
Pegboard Test20 in the dominant and non-dominant hand. To prevent practice effects, 
different versions were used at different visits for the RAVLT, LDST and DS. At baseline, 
premorbid intelligence (IQ) was determined with the national adult reading test (NART) or 
Dutch adult reading test in English and Dutch speaking patients, respectively.21,22
According to protocol, patients underwent NPE before chemotherapy (baseline), after 
completion of chemotherapy, after radiotherapy (if given), and at 3, 6, 12, and 24 months 
post-treatment. NPEs were discontinued if a patient received <2 cycles of (R-)MBVP, when 
a relapse or progression occurred, or when a patient chose to withdraw from the either 
the RCT or NPE side-study.
Radiological assessments
At baseline, after each treatment part (i.e. (R-)MBVP, HD-cytarabine, WBRT (if applicable)), 
and thereafter every three months in the first two years of follow-up, all patients under-
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went cranial MRI. The degree of white matter abnormality (WMA) and brain atrophy were 
assessed centrally. For this evaluation the ‘end of treatment’ MRI, irrespective of the final 
treatment modality, was considered the reference scan. MRI scans at 6, 12 and 24 months 
of follow-up were used to determine changes.
WMA were scored in five brain areas on both sides (frontal, temporal, parieto-occipital, 
basal ganglia and infratentorial) according to Fazekas (range 0-3), with 0 denoting no le-
sions or symmetrical caps or bands, 1 indicating small focal lesions and 2 and 3 indicating 
beginning or diffuse confluent lesions, respectively.23 The lobe or lobes in which the tumor 
lesion or lesions and its surrounding edema were located were not scored to prevent 
overestimation of WMA. The sum score (0-30) of WMA in all scored brain areas at each 
time point was used to calculated individual changes over time. The WMA ratio, defined 
as the sum score divided by the maximum possible sum score for each patient (excluding 
brain areas with tumor), was used to assess the correlation between WMA and neurocog-
nitive functioning at each time point, for each domain. Grey matter (GM), white matter 
(WM) and cerebrospinal fluid (CSF) volume were calculated by automatic segmentation to 
determine brain volume, using a validated method.24 Total brain volume was defined as 
GM+WM volumes, while total intracranial volume was defined as GM+WM+CSF.
StAtiStiCAL ANALySiS
Calculation of neurocognitive scores
For the adult reading test individual test scores were converted to a standardized score, 
corrected for age and sex, and transformed into an IQ-score.25 For all other tests individual 
test scores were transformed into a z-score, corrected for age, sex and/or level of educa-
tion26, using scores from the general population.27
Descriptive analysis
Clinical and sociodemographic characteristics were compared between treatment arms, 
and between patients who did and did not participate in the NPEs to address selection 
bias. Differences were tested using a Chi-Square test for categorical data, and a Mann-
Whitney U or an independent t-test for continuous data, depending on the distribution of 
the tested variable. Compliance with NPE at each time point was calculated, and defined 
as the number of completed NPEs (i.e. all tests in at least one domain should have been 
completed) at a specific time point divided by the number of evaluations expected at that 
time point. A specified time window was defined for each evaluation point (Supplemental 
Methods). Only tests performed within the specified time windows were considered com-
pliant with the assessment protocol and were analyzed. A domain score was calculated 
as the mean of the z-scores of the different tests within that domain. A change in z-score 
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over time or a difference between groups of ≥1 point (1 standard deviation [SD]) was 
considered clinically relevant.
Neurocognitive scores over time
To estimate the impact of the treatment on neurocognitive functioning over time, linear 
mixed models were used, which allow the inclusion of all patients who underwent a NPE 
at least once, with fixed effects for treatment arm, time (as factor), and their interaction. 
Estimated marginal mean scores and their 95% CI were calculated for each domain.
In patients who completed at least two NPEs, one of which was before treatment, we as-
sessed the change from baseline in each domain for each individual patient. Next, patients 
were classified as improved, stable or deteriorated, depending on a change in z-score of 
≥1 SD in each time period.
Impact of WBRT
Using the same methods, we studied neurocognitive functioning after WBRT in irradiated 
patients. For these analyses the scores after WBRT measurement were considered as 
baseline.
Relation of neurocognition with brain volume and white matter abnormalities
Pearson correlation coefficients were calculated between the z-score of each neurocogni-
tive domain and the WMA ratio of the Fazekas score, and the total brain volume at the 
6, 12 and 24 months follow-up visits, cross-sectionally. Next, linear mixed model analyses 
were performed to assess the association between changes in WMA or atrophy up to two 
years post-treatment, and changes in neurocognitive functioning over time. These analy-
ses were corrected for time (i.e. visits), multiple lesions, sex, age, and education, and brain 
volume was also corrected for total intracranial volume. All analyses were conducted with 
Stata, version 15, and a two-tailed p-value <0.05 was considered statistically significant.
dAtA AVAiLABiLity StAtemeNt
Individual de-identified participant data, collected for this study, including the statistical 
analysis plan will be made available for other research to others upon request, after ap-
proval by the HOVON executive board. The data will be available until a maximum of 15 
years after the study has ended.
Please find the trial protocol, a Data Request Form and the criteria for data sharing on 
www.hovon.nl.
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in the HOVON 105/ ALLG NHL 24 trial 199 patients were included, of whom 125 (63%) 
signed informed consent for this side-study. Compliance with NPE was ≥50% at all evalu-
ation points, Figure 1.
In the patients evaluated for neurocognitive functioning, there were no differences 
between treatment arms with respect to baseline clinical and sociodemographic charac-
teristics and drug exposure, including baseline IQ. However, more patients in the R-MBVP-
arm had cognitive impairments (<-1 SD) in at least 1 domain compared to the MBVP-arm 
(68% versus 55%; Table 1). No differences in sociodemographic or clinical characteristics 
were observed between patients who participated in NPEs (n=125) and those who did 
not (n=74). Patients included in this analysis had a median age of 61 years (interquartile 
range 55-66), 72% had a median WHO performance of <2 and 38% received WBRT, which 
is comparable to the total trial population8 (Supplemental Table 1). Mean baseline z-scores 
for each neurocognitive domain are shown in Table 1, and for each test in Supplemental 
Table 2.
Neurocognitive functioning over time
The results of the linear mixed models showed a statistically significant difference over 
time in all neurocognitive domains (all p<0.01), without any significant or clinically rel-
evant difference between treatment arms (Figure 2). The main change in most domains 
was improvement between baseline and after treatment, with a stabilization thereafter. 
Although these difference in all domains were statistically significant, only in the domain 
of motor speed this improvement was also clinically relevant. Nevertheless, the estimated 
marginal mean scores in the motor speed domain still remained below those of the norm 
population (i.e. >-1 SD). For memory, scores did not quite improve to a clinically relevant 
extent, but over time the mean score improved from a clinically relevant impaired level to 
within the range of the norm population (i.e. above -1 SD). Scores in attention/executive 
functioning and information processing speed remained within the range of the norm 
population up to two years post-treatment.
At the individual level, we combined both treatments arms since groups became too 
small and no differences were found between treatment arms. Compared to baseline, 
after 12 months the majority (52-61%) remained stable in all neurocognitive domains, 
except for the domain of motor speed in which the majority improved (58%). After 24 
months, 53% had improved scores in the memory and 68% in motor speed domain. For at-
tention/executive functioning and information processing speed most patients remained 
stable: 59% and 48%, respectively. Only a minority of patients had worse neurocognitive 
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Patient not a native speaker  n= 1 Patient not a native speaker  n= 0
 Hospital does not participate in NPE  side study n= 25  Hospital does not participate in NPE  side study n= 18
 
figure 1. CONSORT diagram showing reasons for not-participating in the neuropsychological evaluations as 
well as the compliance rates at each time point, separately for the treatment arms.
‘After WBRT’ was assessed only in those who had WBRT. FU=follow-up; NPE=Neuropsychological evaluation
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table 1. Baseline clinical and sociodemographic characteristics of the patients included in the neuropsycho-







Sex (n, % male) 35 (58%) 29 (45%) 64 (51%)
Age (median, IQR) 60 (55-66) 61 (55-67) 61 (55-66)
WHO performance score (n, %)
WHO 0 16 (27%) 16 (25%) 32 (26%) 
WHO 1 28 (47%) 33 (51%) 61 (49%) 
WHO 2 11 (18%) 9 (14%) 20 (16%) 
WHO 3 5 (8%) 7 (11%) 12 (10%) 
Comorbidities active at baseline (n, % ≥2) 29 (48%) 33 (51%) 62 (50%)
Baseline IQ (median, IQR) 93 (76-106) 92 (77-106) 93 (77-106)
Level of education (years of education; n,%)
Low (≤6) 10 (17%) 11 (17%) 21 (17%) 
Average (7-9) 30 (50%) 36 (55%) 66 (53%) 
High (10-18+) 12 (20%) 11 (17%) 23 (18%) 
Missing 8 (13%) 7(11%) 15 (12%) 
Solitary lesion (n, %) 35 (58%) 32 (49%) 67 (54%)
Missing/ NA 3 (5%) 3 (5%) 6 (5%) 
Bilateral involvement (n, %) 22 (37%) 27 (42%) 49 (39%)
Missing/ NA 3 (5%) 3 (5%) 6 (5%) 
Deep structures involved (n, %) 39 (65%) 43 (66%) 82 (66%)
Study drug exposure
HD Cytarabine (n, %) 55 (92%) 59 (91%) 114 (91%)
WBRT (n, %) 22 (37%) 26 (40%) 48 (38%)
Radiation boost given (n, %) 10 (17%) 16 (25%) 26 (21%)
Intrathecal treatment given (n, %) 6 (10%) 6 (9%) 12 (10%)
Baseline score for each neurocognitive domain
Neurocognitive domain mBVP r-MbvP total
Attention/ executive functioning (mean, SD) -0.52 (0.95) -0.85 (1.03) -0.70 (1.00)
Information processing speed (mean, SD) -0.99 (1.74) -1.29 (1.72) -1.16 (1.72)
Memory (mean, SD) -1.52 (1.20) -1.70 (1.19) -1.62 (1.19)
Motor speed (mean, SD) -2.78 (3.11) -4.43 (5.57) -3.62 (4.57)
Impaired cognitive functioning (<1 SD) in at least one domain 33 (55%) 44 (68%) 77 (62%)
NA = not applicable in case of no brain lesion(s)
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Neurocognitive functioning in irradiated patients
In the irradiated patients (n=43) we assessed the effect of WBRT on neurocognitive func-
tioning over time, up to 2 years post-radiotherapy. The results of the linear mixed model 
analyses showed no significant and clinically relevant changes over time, neither improve-
ment or deterioration, except for a clinically relevant improvement in motor speed in the 
control-arm at 3 and 6 months post-treatment. There were no other differences between 
treatment arms (Figure 4).
Neurocognitive functioning in relation to radiological features
For brain volumes and Fazekas score at group level at each time point, see Supplemental 





figure 2. Mean z-scores for the different neurocognitive domains over time (A: attention/ executive function-
ing; B: information processing speed; C: memory; D: motor speed), separately for the treatment arms.
Estimated marginal means for each evaluation point separately for each treatment arm, with the vertical bars 
representing the 95% confidence interval of the group mean.
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the amount of WMA or brain volume at baseline on MRI, we observed weak correlations 
between neurocognitive scores and the degree of WMA (between +0.01 and -0.66) or 
brain atrophy (between +0.06 and -0.50; Supplemental Table 5).
In the longitudinal analysis we observed inverse associations between changes in the 
degree of WMA or brain atrophy, and changes in neurocognitive scores, with increasing 
WMA and atrophy correlating with a deterioration in neurocognitive functioning up to 
two years post-treatment (Table 2). Although significant in all domains except for memory, 
the changes in neurocognitive scores were rather small (regression coefficients ranged 
between -0.048 and -0.347), indicating that 1 point increase in the Fazekas sum score 
resulted in only a small, not clinically relevant, deterioration in neurocognitive functioning. 
For brain atrophy, a 10% decrease of brain volume was significantly associated with a 
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figure 3. Percentage of patients at each evaluation point with a clinically relevant change in neurocognitive 




The addition of rituximab to standard MBVP-chemotherapy did not improve the event-
free survival and did not impact HRQoL.8,14 The current analysis shows that this treatment 
regimen resulted in a significant improvement in all neurocognitive domains, compared to 
baseline, although these differences were not clinically relevant except for motor speed. 
There were no significant or clinically relevant differences in neurocognitive functioning 




figure 4. Mean z-scores for each neurocognitive domain over time (A: attention/ executive functioning; B: 
information processing speed; C: memory; D: motor speed), separately for the two treatment arms in the 
irradiated patients only.
Estimated marginal means are shown for each evaluation point separately for each treatment arm, with the 
vertical bars representing the 95% confidence interval of the group mean.
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Impairments in neurocognitive functioning or behavioral problems are reported to be 
presenting symptoms in 32-48% of patients with PCNSL.28 In this study, 62% of the patients 
had impairments in at least one neurocognitive domain before treatment. The slightly bet-
ter scores in all domains at the ‘end of treatment’ compared to baseline, with a stabiliza-
tion thereafter, is a pattern that has been described in multiple PCNSL cohorts.12,29-31 These 
findings suggest that neurocognitive functioning is mostly hampered by the tumor itself, 
and that treating the tumor results in improved neurocognitive functioning. Additionally, 
we found that the extent of improvement between baseline and ‘end of treatment’ was 
not clinically relevant, except for motor speed.
The results at the individual patient level support the finding that neurocognitive scores 
improved over time, although most patients remained stable, and only a minority (0-7%) 
deteriorated. Only in the motor speed domain the majority of the patients improved at 
12 and 24 months, compared to baseline. This supports the results of the longitudinal 
analyses (linear mixed models) suggesting that motor speed improved over time to a 
clinically relevant extent. This finding is, however, in contrast with other studies showing 
less pronounced improvements or even deterioration in this domain, particularly when 
compared to other domains.32,33 An explanation for this may be that patients in our cohort 
had very low scores at baseline, allowing patients to improve. It should be noted though, 
that despite the improvement, the estimated marginal means continued to be lower than 
the norm population (i.e. <-1SD).
In irradiated patients, scores on all neurocognitive domains rather unexpectedly re-
mained stable for up to two years after treatment with 30Gy (20x1.5Gy) WBRT in both arms, 
compared to the scores shortly after WBRT. We used ‘after WBRT’ as baseline because we 
expected maximal reduction of tumor and tumor-related symptoms at that timepoint. 
Stable neurocognitive functioning was also found in a previously reported small cohort of 
PCNSL patients treated with HD-MTX based chemotherapy combined with rituximab and 
followed by reduced dose (rd)WBRT (23.4Gy).12 In that same cohort, a small but significant 
decline in the neurocognitive domains attention and memory was observed between 
three and five years post-treatment.34 This late, non-clinically relevant deterioration, 
however, was also observed in patients who received autologous stem cell transplantation 
(ASCT) instead of WBRT.34 Two randomized trials in adult PCNSL patients compared WBRT 
with ASCT as consolidation therapy.29,31 In the IELSG-32 study, 118 patients who achieved 
at least stable disease after induction chemotherapy were randomized for ASCT or 36Gy 
WBRT as consolidation.29 After two years of follow-up, those who received WBRT had 
significantly worse scores in attention/executive functioning and memory domains.29 In 
the PRECIS study 104 patients aged 18-60 years were randomized between ASCT and 40Gy 
WBRT as consolidation therapy.31 Similarly, significant deterioration was seen in attention/
executive functioning in irradiated patients compared to ‘end of induction chemotherapy’, 
while those treated with ASCT remained stable for up to three years of follow-up.31 Several 
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factors could explain the discrepancy between the above two contemporary studies and 
our study regarding neurocognitive functioning after WBRT. First, the lower total dose and 
fraction dose used in our study could reduce the negative impact of WBRT, as suggested 
by the findings of Morris et al.12 Second, it is possible that in our study longer follow-up 
will show deterioration of neurocognitive function. Such late deterioration has also been 
found to occur in patients with other brain tumors, such as low-grade glioma, in whom 
neurocognitive deterioration after (focal) radiotherapy was found after 12 years but not 
after 6 years.35,36 Lastly, the absence of published individual scores and/or z-scores of the 
neurocognitive tests in the IELSG-3229 and PRECIS31 studies do not allow estimation of the 
magnitude of changes in neurocognition, and consequently the clinical relevance of these 
changes, which may affect the interpretation of results.
Up to two years post-treatment, we observed that the increase in the degree of WMA 
was significantly associated with worsening in all neurocognitive domains except memory, 
while an increase of brain atrophy was associated with worsening in the memory domain 
only. The associations, however, were weak to moderate, indicating that in the first two 
years post-treatment the impact of WMA and brain atrophy on neurocognitive function-
ing seems modest, possibly partially because the extent of decrease in brain volume was 
limited. In a large (n=80) long-term PCNSL survivors cohort (median follow-up of 5·5 years, 
range 2-26 years), the amount of WMA was significantly correlated with worse neurocog-
nitive functioning on the long-term. Moreover, those treated with WBRT (n=15; 45-60Gy) 
in this survivors cohort had twice as much WMA as those treated without WBRT (n=65; 
p<0.001), though this resulted in a clinically relevant difference in the motor speed domain 
only.10 In contrast, although more WMA were observed after rdWBRT (23.4Gy) than after 
ASCT (70% versus 40%, p=0·03), there was no difference in neurocognitive functioning 
between these groups, up to five years post-treatment.34 While assessed in small groups 
and with different durations of follow-up, these results suggest that radiation dose could 
be crucial for neurocognitive functioning in PCNSL patients and this is supported by our 
findings. Longer follow-up is nevertheless needed to determine the effect of 30Gy WBRT 
and of white matter changes and cerebral atrophy on neurocognitive functioning in our 
cohort on the longer term. We were unable to investigate a direct effect of rituximab on 
WMA or cerebral atrophy because the number of patients in these subgroups became too 
small for a meaningful analysis. A recent, small (n=47) retrospective study, however, found 
after a mean follow-up of five years that more patients treated with rituximab plus HD-
MTX developed white matter lesions (68%), compared to rituximab naïve patients (46%).37 
Although this finding does not necessarily support causation, further analysis might help 
to determine the etiology of these lesions.
The strengths of this study are the large, uniformly treated group of patients in which 
radiological assessments were done over time and neurocognitive functioning in multiple 
domains was assessed prospectively, allowing extensive analyses. Limitations of our study 
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are the limited time of follow-up, i.e. two years after end-of-treatment, and our relatively 
crude, visual measurement of the WMA with the Fazekas score as opposed to automatic 
exact measurements of white matter abnormalities, which may have masked an existing 
effect of WMA on neurocognition. Automatic segmentation of WMA was not possible due 
to different scan protocols in different including centers. Although we had some missing 
neurocognitive data over time, our longitudinal analyses were not hampered by this since 
we used linear mixed models, which deal with missing data in a sophisticated way. Lastly, 
we could not compare irradiated with non-irradiated patients with respect to neurocogni-
tive functioning and radiological changes, because these patients differed in age due to 
the study design (i.e. irradiation in younger patients only). For this same reason we could 
not compare younger and older patients.
In conclusion, this analysis showed no effect of the addition of rituximab on neurocogni-
tive functioning, neither positive nor negative. The lack of effect on event-free survival8, 
the primary endpoint, as well as HRQoL14 and this neurocognitive study, as secondary end-
points, do not, however, support the use of rituximab in patients with newly-diagnosed 
PCNSL. Whether specific subgroups of patients benefit from this treatment regimen re-
mains to be investigated. Moreover, in the first two years post-treatment, a lower dose of 
WBRT was not harmful for neurocognitive functioning, compared to just after WBRT. The 
association between white matter abnormalities and brain atrophy and neurocognitive 
functioning was modest and longer follow-up is needed to draw definitive conclusions.
For supplemental Tables and Figures: Neurocognitive functioning and radiologic changes in 
primary CNS lymphoma patients: results from the HOVON 105/ ALLG NHL 24 randomised 






 1. van der Meulen M, Dinmohamed AG, Visser 
O, Doorduijn JK, Bromberg JEC. Improved 
survival in primary central nervous system 
lymphoma up to age 70 only: a population-
based study on incidence, primary treat-
ment and survival in the Netherlands, 
1989-2015. Leukemia 2017;31:1822-1825.
 2. Villano JL, Koshy M, Shaikh H, Dolecek TA, 
McCarthy BJ. Age, gender, and racial differ-
ences in incidence and survival in primary 
CNS lymphoma. Br J Cancer 2011;105:1414-
1418.
 3. Correa DD, Maron L, Harder H, et al. Cogni-
tive functions in primary central nervous 
system lymphoma: literature review 
and assessment guidelines. Ann Oncol 
2007;18:1145-1151.
 4. Boele FW, Zant M, Heine EC, et al. The 
association between cognitive functioning 
and health-related quality of life in low-
grade glioma patients. Neurooncol Pract 
2014;1:40-46.
 5. Aaronson NK, Taphoorn MJ, Heimans JJ, et 
al. Compromised health-related quality of 
life in patients with low-grade glioma. J Clin 
Oncol 2011;29:4430-4435.
 6. Coiffier B, Lepage E, Briere J, et al. CHOP 
chemotherapy plus rituximab compared 
with CHOP alone in elderly patients with 
diffuse large-B-cell lymphoma. N Engl J Med 
2002;346:235-242.
 7. Pfreundschuh M, Schubert J, Ziepert M, 
et al. Six versus eight cycles of bi-weekly 
CHOP-14 with or without rituximab in el-
derly patients with aggressive CD20+ B-cell 
lymphomas: a randomised controlled trial 
(RICOVER-60). Lancet Oncol 2008;9:105-
116.
 8. Bromberg JEC, Issa S, Bakunina K, et al. 
Rituximab in patients with primary CNS 
lymphoma (HOVON 105/ALLG NHL 24): a 
randomised, open-label, phase 3 intergroup 
study. Lancet Oncol 2019;20:216-228.
 9. Harder H, Holtel H, Bromberg JEC, et al. 
Cognitive status and quality of life after 
treatment for primary CNS lymphoma. 
Neurology 2004;62:544-547.
 10. Doolittle ND, Korfel A, Lubow MA, et al. 
Long-term cognitive function, neuroimag-
ing, and quality of life in primary CNS 
lymphoma. Neurology 2013;81:84-92.
 11. Neuwelt EA, Guastadisegni PE, Várallyay P, 
Doolittle ND. Imaging changes and cognitive 
outcome in primary CNS lymphoma after 
enhanced chemotherapy delivery. Am J 
Neuroradiol 2005;26:258-265.
 12. Morris PG, Correa DD, Yahalom J, et al. 
Rituximab, methotrexate, procarbazine, 
and vincristine followed by consolidation 
reduced-dose whole-brain radiotherapy 
and cytarabine in newly diagnosed primary 
CNS lymphoma: Final results and long-term 
outcome. J Clin Oncol 2013;31:3971-3979.
 13. Fliessbach K, Helmstaedter C, Urbach 
H, et al. Neuropsychological outcome 
after chemotherapy for primary CNS 
lymphoma: A prospective study. Neurology 
2005;64:1184-1188.
 14. van der Meulen M, Bakunina K, Nijland M, 
et al. Health-related Quality of Life After 
Chemotherapy With or Without Rituximab 
in Primary Central Nervous System Lympho-
ma Patients: Results From a Randomised 
Phase III Study. 2020;Ann Oncol.
 15. Abrey LE, Batchelor TT, Ferreri AJ, et al. 
Report of an international workshop to 
standardize baseline evaluation and re-
sponse criteria for primary CNS lymphoma. 
J Clin Oncol 2005;23:5034-5043.
 16. Wechsler D. Wechsler Adult Intelligence 
Scale (WAIS-III), 3rd ed. San Antonio: Har-
court Brace & Co, 1997.
 17. R.M. R. Trail making test. Manual for ad-
ministration and scoring. Tuscon, Arizona: 
Reitan Neuropsychological Laboratory, 
1992.
143
Neurocognitive functioning and radiological changes in PCNSL
7
 18. Lezak MD. Neuropsychological assessment. 
: York Oxford University Press, 1976
 19. Lezak MD, Howieson DB, Bigler ED, D. t. 
Neuropsychological Assessment, 5th Re-
vised edition ed. New York Oxford Univerity 
Press, 2012.
 20. Heaton RK, Grant I, Matthews CG. Compre-
hensive Norms for an Expanded Halstead-
Reitan Battery: Demographic Corrections, 
Research Findings and Clinical Applications. 
: Odessa: Psychological Assessment Re-
sources, 1991.
 21. Nelson H. National adult reading test 
(NART): Test manual. Windsor, U.K.: Nfer-
Nelson.1982.
 22. Schmand B, Bakker D, Saan R, Louman 
J. [The Dutch Reading Test for Adults: a 
measure of premorbid intelligence level] De 
Nederlandse Leestest voor Volwassenen: 
een maat voor het premorbide intel-
ligentieniveau. Tijdschr Gerontol Geriatr 
1991;22:15-19.
 23. Wahlund LO, Barkhof F, Fazekas F, et al. 
A new rating scale for age-related white 
matter changes applicable to MRI and CT. 
Stroke 2001;32:1318-1322.
 24. de Boer R, Vrooman HA, van der Lijn F, et al. 
White matter lesion extension to automatic 
brain tissue segmentation on MRI. Neuro-
image 2009;45:1151-1161.
 25. Mulder J, Bouma JM, Schmand B. Neder-
landse leestest voor volwassenen. In: Bou-
ma JM, J. Mulder, J. Lindeboom, Schmand 
B, eds. Handboek neuropsychologische 
diagnostiek Amsterdam: Pearson Assess-
ment and Information B.V., 2012: 127-138.
 26. Verhage F. Intelligentie en leeftijd onder-
zoek bij Nederlanders van twaalf tot 
zevenenzeventig jaar [Intelligence and age: 
Research study in Dutch individuals aged 
twelve to seventy-seven]. . Assen, Neth-
erlands: : Van Gorcum/Prakke & Prakke., 
1964.
 27. van der Elst W, van Boxtel MP, van Breukelen 
GJ, Jolles J. The Letter Digit Substitution 
Test: normative data for 1,858 healthy par-
ticipants aged 24-81 from the Maastricht 
Aging Study (MAAS): influence of age, 
education, and sex. J Clin Exp Neuropsychol 
2006;28:998-1009.
 28. Bataille B, Delwail V, Menet E, et al. Primary 
intracerebral malignant lymphoma: report 
of 248 cases. J Neurosurg 2000;92:261-266.
 29. Ferreri AJM, Cwynarski K, Pulczynski E, et 
al. Whole-brain radiotherapy or autologous 
stem-cell transplantation as consolidation 
strategies after high-dose methotrexate-
based chemoimmunotherapy in patients 
with primary CNS lymphoma: results of the 
second randomisation of the International 
Extranodal Lymphoma Study Group-32 
phase 2 trial. Lancet Haematol 2017;4:e510-
e523.
 30. van der Meulen M, Dirven L, Habets EJJ, van 
den Bent MJ, Taphoorn MJB, Bromberg JEC. 
Cognitive functioning and health-related 
quality of life in patients with newly diag-
nosed primary CNS lymphoma: a systematic 
review. Lancet Oncol 2018;19:e407-e418.
 31. Houillier C, Taillandier L, Dureau S, et al. 
Radiotherapy or Autologous Stem-Cell 
Transplantation for Primary CNS Lymphoma 
in Patients 60 Years of Age and Younger: Re-
sults of the Intergroup ANOCEF-GOELAMS 
Randomized Phase II PRECIS Study. J Clin 
Oncol 2019;37:823-833.
 32. Correa DD, DeAngelis LM, Shi W, Thaler H, 
Glass A, Abrey LE. Cognitive functions in 
survivors of primary central nervous system 
lymphoma. Neurology 2004;62:548-555.
 33. Omuro A, Correa DD, DeAngelis LM, et 
al. R-MPV followed by high-dose chemo-
therapy with TBC and autologous stem-cell 
transplant for newly diagnosed primary CNS 
lymphoma. Blood 2015;125:1403-1410.
 34. Correa DD, Braun E, Kryza-Lacombe M, et 
al. Longitudinal cognitive assessment in pa-
tients with primary CNS lymphoma treated 
with induction chemotherapy followed by 
reduced-dose whole-brain radiotherapy 




 35. Klein M, Heimans JJ, Aaronson NK, et al. 
Effect of radiotherapy and other treatment-
related factors on mid-term to long-term 
cognitive sequelae in low-grade gliomas: a 
comparative study. Lancet 2002;360:1361-
1368.
 36. Douw L, Klein M, Fagel SS, et al. Cognitive 
and radiological effects of radiotherapy in 
patients with low-grade glioma: long-term 
follow-up. Lancet Neurol 2009;8:810-818.
 37. Estephan F, Ye X, Dzaye O, et al. White 
matter changes in primary central nervous 
system lymphoma patients treated with 
high-dose methotrexate with or without 




Health-related quality of life after chemotherapy with 
or without rituximab in primary central nervous system 
lymphoma patients: results from a randomized phase III 
study
Matthijs van der Meulen* MD1, Katerina Bakunina* MSc2, Marcel Nijland MD, PhD3, Monique 
C. Minnema MD, PhD4, Gavin Cull MD5,6, Wendy B.C. Stevens MD7, Joke W. Baars MD8, Kylie D. 
Mason MBBS, PhD9, Aart Beeker MD10, Max Beijert MD11, Martin J.B. Taphoorn MD, PhD12,13, 
Martin J. van den Bent MD, PhD1, Samar Issa MD14, Jeanette K. Doorduijn MD, PhD15, Jacoline 
E.C. Bromberg MD, PhD1, Linda Dirven PhD12,13
*contributed equally
1 Erasmus MC Cancer Institute, Brain Tumor Center, University Medical Center Rotterdam, Netherlands, Department of 
Neuro-Oncology;
2 HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam,
Netherlands;
3 Department of Hematology, University Medical Center Groningen, Groningen, Netherlands;
4 Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands;
5 Haematology Department, Sir Charles Gairdner Hospital and PathWest Laboratory Medicine, Nedlands, WA, Australia;
6 University of Western Australia, Crawley, WA, Australia;
7 Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands;
8 Department of Hemato-Oncology, Antoni van Leeuwenhoek Hospital/Dutch Cancer Institute, Amsterdam, Netherlands;
9 Department of Hematology, Royal Melbourne Hospital, Melbourne, VIC, Australia;
10 Department of Hematology, Spaarne Gasthuis, Haarlem, Netherlands;
11 Department of Radiotherapy, University Medical Center Groningen, Groningen, Netherlands;
12 Leiden University Medical Center, Leiden, Netherlands, Department of Neurology;
13 Haaglanden Medical Center, The Hague, Netherlands, Department of Neurology;
14 Department of Hematology, Middlemore Hospital, Auckland, New Zealand;
15 Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Hematology.




Background: The impact of rituximab on health-related quality of life (HRQoL) in primary 
central nervous system lymphoma patients is not well-known. We determined the impact 
of rituximab added to standard high-dose methotrexate-based treatment on HRQoL from 
patients in a large randomized trial.
Patients and methods: Patients from a large phase III trial (HOVON 105/ALLG NHL 24), 
randomized to standard chemotherapy with or without rituximab and followed by 30Gy 
whole brain radiotherapy (WBRT) in patients ≤60 years, completed the EORTC QLQ-C30 
and QLQ-BN20 questionnaires before and during treatment, and up to 24 months of 
follow-up or progression. Differences between treatment arms over time in global health 
status, role functioning, social functioning, fatigue, and motor dysfunction were assessed. 
Differences ≥10 points were deemed clinically relevant. The effect of WBRT on HRQoL was 
analyzed in irradiated patients.
results: 160/175 patients eligible for the HRQoL study completed at least one question-
naire and were included. Over time, scores improved statistically significant and clinically 
relevant in both arms. Between arms, there were no differences on any scale (range: -3.8 
to +4.0). Scores on all scales were improved to a clinically relevant extent at 12 and 24 
months compared to baseline in both arms, except for fatigue and motor dysfunction at 12 
months (-7.4 and -8.8, respectively). In irradiated patients (N=59), scores in all preselected 
scales except motor dysfunction, remained stable up to 24 months compared to shortly 
after WBRT, overall mean difference ranging between 0.02 and 4.570.
Conclusion: Compared to baseline, treatment resulted in improved HRQoL scores. The 
addition of rituximab to standard chemotherapy did not impact HRQoL over time. WBRT 
did not result in deterioration of HRQoL in the first two years.
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iNtroduCtioN
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma con-
fined to the brain, leptomeninges, spinal cord and eyes. Over the last three decades the 
incidence rate has increased, mainly amongst patients >60 years-old, and prognosis has 
improved significantly.1,2 This prolonged survival has largely been determined by improve-
ments in treatment.1,3
In systemic diffuse large B-cell lymphoma (DLBCL) patients, the addition of rituximab, 
a chimeric monoclonal antibody targeting the CD20 cell surface protein, to standard 
treatment has been shown to improve progression-free (PFS) and overall survival (OS).4,5 
Since most PCNSL are DLBCL, it has been hypothesized that the addition of rituximab to 
standard treatment with HD-MTX-based chemotherapy could also improve survival in 
PCNSL patients. The HOVON 105/ALLG NHL 24, a large international multicentre phase III 
randomized controlled trial (RCT), investigated the addition of rituximab to standard high-
dose methotrexate (HD-MTX)-based chemotherapy, followed by 30Gy whole-brain radio-
therapy (WBRT) in patients aged ≤60 years. The primary endpoint, the 1-year event-free 
survival (EFS), was not improved by rituximab D-MTX, tenoposide,BCNU (carmustine), and 
prednisolone without (MBVP)versus with rituximab (R-MBVP): 49% versus 52%, P=0.99].6
When introducing a new treatment, information on both survival and the patients’ 
functioning and well-being should be taken into account. Combined, these outcomes 
determine the ‘net clinical benefit’ of a treatment strategy. By combining both sources 
of information, clinicians and patients are better able to make well-informed decisions 
concerning which treatment is most suitable for an individual patient.
In this study we describe the HRQoL trajectories in one of the largest RCT’s in PCNSL 
patients and determined whether the addition of rituximab to standard therapy had an 
impact on HRQoL. Second, we aimed to determine the effect of a lower dose WBRT on 
HRQoL in this patient population.
methodS
Study design and patient population
In the HOVON 105/ALLG NHL 24 study, 199 immunocompetent patients aged 18-70 years 
with a newly diagnosed, CD20 positive B-cell PCNSL were included from Dutch, Australian 
and New Zealand hospitals between 2010 and 2016.6 Patients were randomized between 
two courses of HD-MTX, tenoposide, BCNU and prednisolone without (MBVP) or with 
rituximab (R-MBVP). Irrespective of treatment arm, this induction regimen was followed 
by consolidative HD-cytarabine chemotherapy in responding patients, and in patients ≤60 
years-old 30Gy WBRT was subsequently added. An integrated boost to the tumour-bed of 
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10Gy was given to patients who only achieved partial response.7 (Immuno-)chemotherapy 
treatment duration was 2.5-3.5 months and WBRT was administered in one month. Fur-
ther details on the study design and treatment have been published previously.6 The study 
was approved by the ethics committees of all participating centres. All participants who 
signed informed consent for the RCT and for participating in the HRQoL study were eligible 
for inclusion in this analysis.
Health-Related Quality of Life
HRQoL was one of the prespecified secondary outcomes. HRQoL was assessed using the 
European Organisation for Research and Treatment of Cancer (EORTC) core quality of life 
questionnaire (QLQ-C30)8, and the brain cancer module (QLQ-BN20).9,10 The QLQ-C30 com-
prises five functional scales (physical, role, emotional, social and cognitive functioning), 
three symptom scales (fatigue, pain, and nausea and vomiting), a global health status/
quality of life scale, and six single items assessing additional symptoms (dyspnoea, sleep 
disturbance, appetite loss, constipation and diarrhoea) and perceived financial difficul-
ties. The QLQ-BN20 module includes 20 items, comprising four scales (visual disorders, 
motor dysfunction, communication deficit and future uncertainty), and seven disease- or 
toxicity-related symptoms (headache, seizures, drowsiness, hair loss, itchy skin, weakness 
of the legs, and bladder control).
According to protocol, patients had to complete the questionnaires before starting 
chemotherapy, after completion of all chemotherapy, after completion of radiotherapy (if 
given), and 3, 6, 12, and 24 months after completion of protocol treatment. The assessment 
of HRQoL was stopped when a relapse or progression occurred, or when a patient wanted 
to withdraw from participation in either the RCT or HRQoL sub-study. Only questionnaires 
that were completed within a prespecified time window (see Supplemental methods) for 
each evaluation point were included in the statistical analysis.
StAtiStiCAL ANALySiS
Calculation of HRQoL Scores
Following the EORTC procedures, raw item scores were converted to a linear scale rang-
ing from 0 to 100.11 A difference of ≥10 points on each HRQoL scale/item was defined 
as clinically relevant.12 Based on clinical relevance for PCNSL patients, these five scales 
were selected for primary analysis: three functional scales (global health status (GH), 
role functioning (RF) and social functioning (SF), with higher scores representing better 
functioning), and two symptom scales (fatigue and motor dysfunction (MD), with high 
scores representing worse functioning). Results of the primary analysis (i.e. scores over 
time assessed with linear mixed models in the 5 predetermined scales, were corrected for 
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multiple testing. The remaining scales and items were analysed on an exploratory basis. 
All analyses were conducted with Stata, version 15, and a P-value <0·05 was considered to 
be statistically significant.
Descriptive statistics
Patients eligible for the HOVON 105/ ALLG NHL 24 study who received less than two 
courses of (R-)MBVP, or did not give consent for the HRQoL sub-study, were excluded 
from the analysis. We performed a non-response analysis to assess possible imbalances 
between those who gave consent for the HRQoL sub-study and those who did not with 
respect to sociodemographic and clinical characteristics.
Differences were tested using a Chi-Square test for categorical data and Mann-Whitney 
U or independent t-test for continuous data, depending on the distribution of the data. 
Normality was determined with the Kolmogorov-Smirnov test. In addition, for each time 
point the compliance was evaluated, defined as the number of completed questionnaires 
divided by the number of questionnaires expected at that time point. We defined a 
completed questionnaire as a returned form from which at least a score of one of the 
predetermined primary scales could be derived.
HRQoL scores over time
At group level, mean changes from baseline were calculated and plotted for those patients 
who filled in the questionnaire at baseline and at least at one follow-up point. Differences 
between arms at 12 and 24 months of follow-up were assessed with an independent t-test. 
A linear mixed model, which allows inclusion of all patients, with fixed effects for treat-
ment arm, time (i.e. evaluation moments) as a categorical covariate, and their interaction, 
was used to assess whether there is a difference in the HRQoL scores over time between 
the treatment arms. For each scale, the most suitable covariance structure was chosen to 
estimate the impact of the treatment on HRQoL over time.
At the individual patient level, changes in HRQoL between baseline and both 12 and 
24 months of follow-up were calculated for those patients the questionnaires at these 
time points were available. Patients were categorized as deteriorated, stable or improved, 
based on a change of ≥10-points. Differences between treatment arms were assessed with 
the Chi-square statistic.
Deterioration-free survival and time to deterioration
Deterioration-free survival was defined as a deterioration of ≥10 points on a scale/item 
compared to baseline without an improvement of ≥10 points at the subsequent HRQoL 
assessment, or progressive disease (PD), or death in the absence of definite deterioration 
before the next assessment. Time to deterioration was defined similarly as deterioration-
free survival, only excluding PD as an event.13 PD was defined according to the international 
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PCNSL response criteria.7 MRI’s were centrally reviewed; the centrally scored progression 
data were used for these analyses. Questionnaires filled in at the time of or after centrally 
scored PD were excluded. Kaplan-Meier curves were generated for both deterioration-
free survival and time to deterioration and 95% confidence intervals were calculated using 
the Greenwood formula.
Impact of WBRT
In a subgroup, those who received WBRT (N=59), we evaluated the impact of radiation 
on HRQoL. The mean changes from the ‘after WBRT’ time point onwards were calculated 




Of the 199 patients included in the HOVON 105/ALLG NHL 24 trial, 193 (97%) gave in-
formed consent for HRQoL assessment. Eighteen patients were excluded because they did 
not complete two courses of (R-)MBVP, resulting in 175/199 (88%) eligible patients for the 
HRQoL analysis. Of these 175 patients included in the HRQoL analysis, 160 completed at 
least one questionnaire. Compliance of HRQoL evaluation was ≥60% at each time point, 
except ‘after WBRT’ in the MBVP-arm (46%), Figure 1.
In the population participating in the HRQoL analysis, patients in the treatment arms 
were well-balanced with respect to clinical and sociodemographic features and study drug 
exposure. Those included in this HRQoL analysis had a median age of 61 years (interquar-
tile range 55-66 years), and 74% had a WHO performance score <2, which is similar to 
the total trial population6 (Table 1). The non-response analysis showed that there were 
no significant differences with respect to baseline characteristics between those who 
gave consent for the HRQoL sub-study and those who did not (Supplemental Table 1). 
Baseline HRQoL scores for all scales and items for both treatment arms are summarised 
in Supplemental Table 2.
HRQoL scores over time
In all selected primary scales, the mean change from baseline, assessed in those who 
filled in the questionnaires at baseline and at least once thereafter, showed a statistically 
significant (all P<0.002) and clinically relevant improvement in both arms after the end 
of treatment (i.e. ‘after chemotherapy’ or ‘after WBRT’), when compared to baseline, 
except for fatigue. Fatigue improved more slowly: clinically relevant improvement was not 
reached before 3 months post-treatment. The differences in scores between the arms at 
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  Not eligible   n=    1
Included in HRQoL analyses
n=85
Baseline
n=65/85 (76%)  HRQoL stopped n=8
   - death n=  0
   - earlier off protocol n=  5
   - refusal n=  2
   - relapse/progression n=  1 
After chemotherapy
n=52/77 (68%)
 HRQoL stopped n=15
   - death n=  0
   - earlier off protocol n=  4
   - refusal n=  2
   - relapse/progression n=  9 






  Not eligible   n=    0
 HRQoL stopped n=18
   - death n=  2
   - earlier off protocol n=  1
   - refusal n=  5
   - relapse/progression n=  10 
 HRQoL stopped n=17
   - death n=  0
   - earlier off protocol n=  3
   - refusal n=  5
   - relapse/progression n=  9 
200 assessed for 
eligibility and 
randomized
  No consent for HRQoL  n=    3   No consent for HRQoL  n=    3
  Arm R-MBVP   n= 100  Arm: MBVP   n= 100
 Less than two MBVP  n=    7 Less than two R-MBVP  n=  11
After WBRT
n=22/33* (67%)
 HRQoL stopped n=2
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  0
   - relapse/progression n=  2 
After WBRT
n=12/26* (46%)
 HRQoL stopped n=3
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  0
   - relapse/progression n=  3 3m FU
n=37/60 (62%)
 HRQoL stopped n=6
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  1
   - relapse/progression n=  5 
3m FU
n=31/52 (60%)
 HRQoL stopped n=5
   - death n=  1
   - earlier off protocol n=  0
   - refusal n=  0
   - relapse/progression n=  4 
6m FU
n=33/54 (61%)
 HRQoL stopped n=8
   - death n=  1
   - earlier off protocol n=  0
   - refusal n=  1
   - relapse/progression n=  6 
6m FU
n=29/47 (62%)
 HRQoL stopped n=3
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  0
   - relapse/progression n=  3 
12m FU
n=42/46 (91%)
 HRQoL stopped n=4
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  1
   - relapse/progression n=  3 
12m FU
n=32/44 (73%)
 HRQoL stopped n=10
   - death n=  0
   - earlier off protocol n=  0
   - refusal n=  1





figure 1. CONSOrT Diagram representing the compliance with HrQol assessments during follow-up, sepa-
rately for the two treatment arms. FU, months of follow-up after end of treatment; HRQoL, health-related 
quality of life; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab 
with methotrexate, tenoposide, BCNU (carmustine), and prednisolone; WBRT, whole brain radiotherapy. *In 
those who had WBRT only.
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12 and 24 months of follow-up were not statistically significant or clinically relevant for 
any of the scales. Only fatigue at 12 months post-treatment was clinically relevant worse 
in the R-MBVP arm, but this was not statistically significant; R-MBVP versus MBVP: -18.1 
vs -7.4 (P=0·677). For most exploratory scales and items, similar patterns were observed. 
See Supplemental Figure 1 and Supplemental Table 3 for the graphs presenting the mean 
change from baseline over time for all scales/items and the actual mean difference at each 
time point, respectively.
In a next step, HRQoL scores over time were assessed with linear mixed models, allow-
ing inclusion of all patients as these models impute data at all time points (Figure 2). These 
analyses showed that the mean HRQoL score improved significantly in all primary selected 
scales over time in both arms (P<0.001), confirming the previous analyses. We did not find 
any statistically significant nor clinically relevant differences over time between the treat-
ment arms for any of the preselected scales: overall mean difference over time in MBVP 
vs R-MBVP: GH=-0.074 (P=0.981), RF=2.160 (P=0.635), SF=0.531 (P=0.902), FA=-3.350 
(P=0.378), and MD=2.139 points (P=0.511). The results of the linear mixed models show 





Sex (N, % male) 56 (62%) 41 (48%)
Age (median, IQR) 61 (55-66) 61 (55-67)
WHO performance score (N, %)
WHO 0 19 (21%) 23 (27%) 
WHO 1 46 (51%) 42 (49%) 
WHO 2 15 (17%) 12 (14%) 
WHO 3 10 (11%) 8 (9%) 
Comorbidities active at baseline (N, % ≥2) 54 (60%) 51 (60%)
Solitary lesion (N, %) 46 (51%) 44 (52%)
Missing/ NA 10 (11%) 4 (5%) 
Bilateral involvement (N, %) 33 (37%) 33 (39%)
Missing/ NA 10 (11%) 4 (5%) 
Deep structures involved (N, %) 55 (61%) 57 (67%)
Study drug exposure
HD cytarabine (Ara-C) (N, %) 82 (91%) 76 (89%)
WBRT (N, %) 33 (37%) 34 (40%)
Radiation boost given (N, %) 15 (17%) 23 (27%)
Intrathecal treatment given (N, %) 8 (9%) 8 (9%)
MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with methotrex-
ate, tenoposide, BCNU (carmustine), and prednisolone; NA = not applicable in case of no brain lesion(s); IQR 
= interquartile range; HD = high-dose; WBRT = whole brain radiotherapy; WHO = World Health Organisation
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that the largest improvement in scores were between baseline and ‘end of treatment’, 
thereafter the scores gradually improved further, but to a lesser extent. GH remained 
stable from end of treatment until 24 months post-treatment. Exploratory scales and 




rituximab with methotrexate, 
figure 2. HrQol scores over time for the five primary scales (A: global health status; b: role functioning; 
C: social functioning; D: fatigue; E: motor dysfunction), separately for both treatment arms in the total 
study population, based on results of the linear mixed model analyses. BL, baseline; CT, chemotherapy; FU, 
follow-up; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with 
methotrexate, tenoposide, BCNU (carmustine), and prednisolone; RT, radiotherapy.
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Assessing the change from baseline scores at the individual level, in all patients who 
filled in the questionnaires at baseline and at least at one point thereafter, we observed in 
a large proportion of patients in both arms an improvement to a clinically relevant extent 
in HRQoL scores on all primary scales. At 12 months of follow-up, 46-78% of the patients 
had improved scores compared to baseline and these percentages were between 53-82% 
at 24 months of follow-up (Figure 3). There were no significant differences between the 
arms. See Supplemental Table 4 for the exact number of patients who improved, remained 
stable or deteriorated in both the preselected and exploratory HRQoL scales and items.
Deterioration-free survival and time to deterioration
The addition of rituximab to MBVP-chemotherapy did not result in a statistically significant 
longer deterioration-free survival or time to deterioration in any of the preselected scales. 
The median deterioration-free survival in RF was not reached. The median deterioration-
free survival in MBVP versus R-MBVP were for GH: 19.6 vs not reached, SF: 19.6 vs 22.7, 
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24 months of follow-up
deteriorated stable improved
figure 3. Individual changes in HrQol from baseline to 12 months and 24 months of follow-up. FA, fatigue; 
GH, global health status/quality of life; MBVP, methotrexate, tenoposide, BCNU (carmustine), and predniso-
lone; MD, motor dysfunction; R-MBVP, rituximab with methotrexate, tenoposide, BCNU (carmustine), and 
prednisolone; RF, role functioning; SF, social functioning
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reached in GH, RF, and SF. Median ti me to deteriorati on in MBVP versus R-MBVP in FA was 
10.2 vs 7.5 and MD: 4.7 vs 3.8 months. See Figure 4 for the deteriorati on-free survival and 
ti me to deteriorati on for GH and Supplemental Figure 3 and Supplemental Table 5 for the 
remaining primary scales/items.
Impact of WBRT
Seventy pati ents received WBRT, of whom 59 parti cipated in the HRQoL evaluati on. The 
linear mixed model analysis (which allows inclusion of all 59 pati ents) showed no stati sti -
cally signifi cant change over ti me aft er WBRT up to 24 months, except for a deteriorati on 
in MD (P=0.048). There were no signifi cant diff erences between treatment arms: overall 
mean diff erence MBVP vs R-MBVP GH=1.951 (P=0.694), RF=4.570 (P=0.542), SF=3.007 
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Time-to-deterioration: Global health status 
figure 4. Deteriorati on-free survival and ti me-to deteriorati on for global health status (gH), separately 
for the treatment arms. MBVP, methotrexate, tenoposide, BCNU (carmusti ne), and prednisolone; R-MBVP, 
rituximab with methotrexate, tenoposide, BCNU (carmusti ne), and prednisolone.
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The change in HRQoL from WBRT onwards was only determined in those patients who 
were irradiated and who filled in the questionnaires at the evaluation ‘after WBRT’ and 
at least at one of the follow-up evaluations (N=34). This subpopulation was comparable 
to the total irradiated population (data not shown). We observed an improvement (>10 
points) in RF in both arms (P=0.002), from 62.1 after WBRT to 78.8 at 24 months follow-up 
figure 5. HrQol scores from post-WbrT up to 24 months follow-up for the preselected scales (A: global 
health status; b: role functioning; C: social functioning; D: fatigue; E: motor dysfunction), separately for 
the treatment arms, in the irradiated patients only (n=59). Estimated marginal means for each evaluation 
point by treatment arm, where the vertical bars represent 95% confidence interval of the group mean. FU, 
follow-up; MBVP, methotrexate, tenoposide, BCNU (carmustine), and prednisolone; R-MBVP, rituximab with 
methotrexate, tenoposide, BCNU (carmustine), andprednisolone; RT, radiotherapy
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in the R-MBVP arm, and from 65.3 to 77.5 in the MBVP arm. Scores in the other prese-
lected scales remained stable in both treatment arms (see Supplemental Figure 4 for the 
preselected scales).
diSCuSSioN
In the HOVON 105/ALLG NHL 24 trial, the addition of rituximab to standard chemotherapy 
in adult PCNSL patients did not prolong EFS or PFS; in this HRQoL analysis in 160 patients 
(80% of total study population), we showed that the addition of rituximab did not improve 
or deteriorate the patients’ functioning and well-being either. We did, however, observe 
that anti-tumour treatment resulted in improvements in HRQoL, which were statistically 
significant and clinically relevant, but did not differ between patients treated with or with-
out rituximab.
The largest improvements in HRQoL were observed directly after treatment (i.e. after 
induction chemotherapy with or without rituximab and after consolidation with WBRT 
if given). Thereafter, HRQoL scores remained relatively stable or improved more slowly, 
but gradually over time. Other non-randomized studies investigating the effect of chemo-
therapy and/or chemotherapy with rituximab on HRQoL have described a similar pattern: 
an initial improvement after treatment, followed by stabilization of HRQoL scores up to 
three years of follow-up.14-16 Two small studies (in which 12/52 and 16/33 of the patients 
participated in the HRQoL sub-study) even showed an ongoing improvement in HRQoL 
scores (as measured with the FACT-Br) up to 1217 and 24 months of follow-up.18 Clinical 
relevance of this change was, however, not defined. Nevertheless, this pattern suggests 
that HRQoL in PSCNL patients is mainly compromised by the lymphoma itself rather than 
by the treatment, and that treating the tumour improves patient-reported HRQoL.
Mean baseline HRQoL scores in our cohort are much lower (≥20 points) than in the 
general population,19 and also lower (≥10 points) than in patients with brain metastases, 
low-grade glioma and glioblastoma.20-22 HRQoL scores in our population improved signifi-
cantly over time, to levels of the general population for some scales, whereas scores in low 
and high-grade glioma patients typically remain stable up to 24 months of follow-up.21,22 
The non-significant differences between treatment arms in deterioration-free survival and 
time to deterioration for any of the HRQoL scales suggest that treatment itself did not 
cause a major deterioration in HRQoL.
WBRT as consolidation treatment is under debate because of its presumed negative 
effect on neurocognitive functioning and subsequently on HRQoL.23 Surprisingly, we found 
that the HRQoL scores of those patients receiving radiation remained stable for up to two 
years of follow-up after WBRT, suggesting that the WBRT dose (30Gy) used in this study 
does not compromise HRQoL in patients up to 60 years in the period covered by this analy-
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sis, despite the fact that 17% of the patients in the MBVP-arm and 27% in the R-MBVP 
arm also received an integrated boost of 10Gy to the tumor-bed. A possible explanation 
for the stable HRQoL in our cohort after WBRT may be that the 24 month period in our 
study is too short to develop radiation-induced damage detectable with HRQoL instru-
ments, or that the lower radiation dose is less detrimental. Our findings are supported by 
a study by Correa et al. in which patients treated with R-MPV followed by low-dose WBRT 
(23.4Gy) also remained stable in their HRQoL scores, even up to five years of follow-up.24 
Only a small number of patients could be analysed in our sub analysis and results should 
therefore be interpreted with caution. In addition, patients who received WBRT could not 
be compared directly to those who did not receive WBRT because of the age difference 
between the irradiated and non-irradiated patients. Thus, although our results cannot 
be generalized and follow-up is still short, our results do challenge the negative role of a 
relatively low-dose WBRT in this younger subpopulation.
The strengths of our study are the size and standardized treatment of the population 
studied, the use of validated measures for brain cancer patients, the fact that the majority 
of this trial population participated in the HRQoL sub-study and that the compliance at 
every time point was relatively high (>60%). Nevertheless, the actual number of patients 
who filled in the questionnaires was relatively low at 12 and 24 months of follow-up (N=74 
and N=53, respectively) due to progression or death, and patients filling out the question-
naires might have a higher level of functioning and well-being than those not filling-out 
the questionnaires. Also, HRQoL was not systematically assessed at the moment of and 
beyond progression, hampering information on the impact of progression on HRQoL in 
this patient population. Another limitation is possible selection bias, because we analysed 
(subgroups of) a trial population and results may therefore not be generalizable to all 
patients. However, most patients in the trial also participated in the HRQoL sub-study and 
only those who did not tolerate two complete courses of (R-)MBVP were excluded. Lastly, 
the impact of treatment on neurocognition is important in this patient population, and will 
be described in a separate publication.
In conclusion, HRQoL scores improved after treatment but were not impacted by the 
addition of rituximab to standard chemotherapy in adult PCNSL patients. Secondly, treat-
ment with 30Gy WBRT did not reduce HRQOL in the first two years after treatment in 
patients up to 60 years old.
For supplemental Tables and Figures: Health-related quality of life after chemotherapy 
with or without rituximab in primary central nervous system lymphoma patients: results 
from a randomised phase III study - ScienceDirect
https://www.sciencedirect.com/science/article/pii/S0923753420393133
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Objective: To assess the value of the Mini-Mental State Examination (MMSE)-score at 
baseline in predicting survival in adult primary central nervous system lymphoma (PCNSL) 
patients.
methods: In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed 
PCNSL were randomized between high-dose methotrexate-based chemotherapy with or 
without rituximab. Data on potential (MMSE-score), and known baseline prognostic fac-
tors (age, performance status, serum LDH, cerebrospinal fluid (CSF) total protein, involve-
ment of deep brain structures, and multiple cerebral lesions) were collected prospectively. 
Multivariate stepwise Cox regression analyses were used to assess the prognostic value of 
all factors on progression free survival (PFS) and overall survival (OS) among patients with 
available MMSE score at baseline. Age was analysed as continuous variable, the MMSE-
score both as a continuous and as a categorical variable.
results: In univariate analysis, age, MMSE-score and whether the patient received 
rituximab were statistically significantly prognostic factors for PFS. Age and MMSE-score 
were statistically significantly associated with OS. In a multivariate analysis of the univari-
ately significant factors only MMSE-score was independently associated with the survival 
endpoints, as a continuous variable (HR for PFS 1.04, 95% CI 1.01-1.08; OS 1.06 (95% CI 
1.02-1.10) and as categorical variable HR (<27 versus ≥27 for PFS 1.55 (1.02-2.35); OS 1.68 
(1.05-2.70). In our population, performance status, serum LDH, and CSF protein level were 
not of prognostic value.
Conclusion: Neurocognitive disturbances, measured with the MMSE at baseline, are an 
unfavourable prognostic factor for both PFS and OS in adult PCNSL patients up to 70 years-
old.
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iNtroduCtioN
Primary central nervous system lymphoma (PCNSL) is a rare non-Hodgkin lymphoma con-
fined to the brain, leptomeninges, spinal cord and eyes. Over the last decades prognosis 
has improved significantly.1 Although several prognostic factors have been identified and 
prognostic models have been developed, it remains difficult to predict the prognosis of 
individual patients.
Two prognostic models are currently widely used in PCNSL patients: the externally 
validated Memorial Sloan Kettering Cancer Center (MSKCC) prognostic score:2age (>50 
years-old) and Karnofsky Performance score (KPS; <70), and the International Extranodal 
Lymphoma Study Group (IELSG) score: age (>60 years-old), WHO/ECOG Performance Sta-
tus (PS; >1), Lactate dehydrogenase (LDH) serum level, cerebrospinal fluid (CSF) protein 
level and involvement of deep brain structures.3
The Mini-Mental State Examination (MMSE)4 is a crude screening tool for neurocogni-
tive impairment. In high-grade glioma, the MMSE-score was an independent prognostic 
factor for both progression free survival (PFS) and overall survival (OS).5
In PCNSL patients, data regarding the prognostic value of the MMSE are scarce, despite 
the fact that cognitive symptoms occur frequently (up to 43%) in this disease.6 One study 
describes 95 elderly (>60 years-old) PCNSL patients, and found that MMSE-score ≤24 was the 
only independent prognostic factor for OS, while age and PS were not.7 In the present study 
we aimed to assess whether the MMSE-score at baseline was independently prognostic for 
both PFS and OS, in a large trial population with adult PCNSL patients up to 70 years-old.
methodS
Patients in the HOVON 105/ALLG NHL 24 study, a large multicentre phase III randomized 
controlled trial (RCT) for immunocompetent adult patients with newly diagnosed CD20 
positive B-cell PCNSL with WHO/ECOG PS 0-3, were included.8 The treatment regimen 
consisted of two cycles of high-dose methotrexate-based chemotherapy, with or with-
out rituximab, followed by high-dose-cytarabine. Patients <61 years-old subsequently 
received 30Gy whole brain radiotherapy. The study was approved by the ethics committee 
at all participating centres and all participants gave informed consent. Patients underwent 
an MMSE if possible and baseline scores were obtained before chemotherapy was started.
All patients for whom an MMSE-score at baseline was available were included in this 
study. In addition, the following information was collected: sex, age, WHO/ECOG PS, CSF 
protein and serum LDH levels at baseline and whether the patient had multiple cerebral 
lesions, involvement of deep brain structures (periventricular regions, basal ganglia, brain-
stem and/ or cerebellum), and whether they received rituximab.
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First, possible imbalances were assessed with respect to baseline characteristics, treat-
ment details and survival between those who participated in this side-study and those 
who could not due to missing MMSE-scores at baseline.
Subsequently, all the above mentioned prognostic factors were assessed separately for 
association with PFS and OS using univariate Cox regression analysis. PFS was defined as 
time from randomization to progression, relapse or death from any cause, whichever came 
first. OS was defined as time from randomization to death from any cause.8 Patients still 
alive at the date of last contact were censored. MMSE was included both as a continuous 
variable and as categorical variable (<27 or ≥27). Age was included as a continuous variable. 
ECOG status (≤1 versus >1), serum LDH (above versus below local upper limit of normal), and 
CSF protein (above versus below cut-off values according to the IELSG score3) were included 
as categorical variables. Factors that were statistically significant in univariate analysis were 
included in the stepwise multivariate Cox proportional hazards models. A p-value <0.05 
was considered statistically significant. All analyses were performed with Stata version 15.
data availability statement
Individual de-identified participant data, collected for this study, including the statistical 
analysis plan will be made available for other research to others upon request, after ap-
proval by the HOVON executive board. The data will be available until a maximum of 15 
years after the study has ended.
Please find the trial protocol, a Data Request Form and the criteria for data sharing on 
www.hovon.nl.
reSuLtS
MMSE-score at baseline was available for 153 of the 199 (77%) trial patients. Baseline 
characteristics and survival were comparable between those who were included and were 
not, Supplemental Table 1 and Supplemental Figure 1A and B.
In the univariate regression analyses age, receipt of rituximab and baseline MMSE-score 
were associated with PFS. Only age and MMSE were statistically significant predictors of 
OS (Table 1). In multivariate analysis, only MMSE-score at baseline was independently 
associated with both PFS and OS. We found that each unit decrease in MMSE-score was 
associated with a poorer prognosis: for PFS (Hazard Ratio [HR], 95% confidence interval 
[CI] 1.04, 1.01-1.08) and OS (HR, 95% CI: 1.06, 1.02-1.10), Table 2. When including the 
MMSE-score as categorical variable in multivariate analyses, corrected for age and ritux-
imab, a baseline-score <27 (as compared to a score ≥27) was the only factor associated 
with PFS (HR 1.55, 95% CI: 1.02-2.35) and overall survival (HR 1.68, 95% CI: 1.05-2.70), 
Table 2 and Figure 1.
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table 1. Univariate and multivariate Cox regression analysis for all risk factors with MMSE as a continuous 
variable for the progression-free survival and overall survival.
Progression-free survival
univariate Multivariate
n HR (95% CI) p HR (95% CI) p
Female 153 0.85 (0.57-1.28) 0.44
Age (increase; unit = 10 years) 153 1.33 (1.04-1.71) 0.025 1.28 (0.99-1.65) 0.061
WHO/ECOG >1 153 0.92 (0.57-1.50) 0.74
Multiple lesions 138 0.89 (0.58-1.37) 0.59
Deep structures involved 153 1.39 (0.92-2.09) 0.12
Elevated CSF total protein 93 0.78 (0.45-1.37) 0.40
LDH >ULN 153 1.19 (0.77-1.82) 0.44
Rituximab 153 0.66 (0.44-1.00) 0.049 0.69 (0.45-1.04) 0.075
MMSE (decrease unit = 1 point) 153 1.05 (1.01-1.08) 0.0042 1.04 (1.01-1.08) 0.008
overall survival
univariate Multivariate
n HR (95% CI) p HR (95% CI) p
Female 153 1.12 (0.71-1.76) 0.64
Age (increase; unit = 10 years) 153 1.36 (1.02-1.82) 0.036 1.32 (0.97-1.77) 0.069
WHO/ECOG >1 153 1.29 (0.77-2.16) 0.32
Multiple lesions 138 1.01 (0.62-1.63) 0.97
Deep structures involved 153 1.25 (0.79-1.99) 0.34
Elevated CSF total protein 93 0.64 (0.33-1.26) 0.20
LDH >ULN 153 1.15 (0.71-1.88) 0.57
Rituximab 153 0.86 (0.55-1.35) 0.51
MMSE decrease unit = 1 point) 153 1.06 (1.02-1.10) 0.001 1.06 (1.02-1.10) 0.002
Hazard ratio’s (HR) and 95% confidence intervals (CI) are shown with their p-value. WHO = World Health 
Organization, ECOG = Eastern Cooperative Oncology Group, CSF = cerebrospinal fluid, LDH = lactate dehydro-
genase, ULN = upper limit of normal, MMSE = mini-mental state examination.
table 2. Multivariate Cox regression analysis for univariately significant risk factors with MMSE as a categorical 
variable for the progression-free survival and overall survival.
Progression-free survival
Multivariate
HR (95% CI) p
Age (increase; unit = 10 years) 1.24 (0.95-1.60) 0.109
Rituximab 0.70 (0.47-1.05) 0.087
MMSE <27 1.55 (1.02-2.35) 0.040
overall survival
Multivariate
HR (95% CI) p
Age (increase; unit = 10 years) 1.26 (0.94-1.71) 0.127
MMSE <27 1.68 (1.05-2.70) 0.031





In this large, prospectively examined study-population of PCNSL patients, we showed that 
the MMSE-score at baseline, both as a continuous variable and as a categorical variable 
(<27), is an independent prognostic factor for both PFS and OS.. Interestingly, MMSE was 
not evaluated in either of the two most-used prognostic scores in PCNSL but our data 
suggest this factor is the most valuable for predicting outcome.2,3
Our results are consistent with a previously published analysis performed in elderly 
PCNSL patients: those with an MMSE-score ≤24 had a worse OS than those with a score 
>24.7 Moreover, in a recent RCT among over 60 year-olds the Mattis Dementia Rating 
Scale, another screening tool for neurocognitive impairment, was significantly associated 
with OS, though in univariate analysis only. In multivariate analysis, only WHO/ECOG PS 
was associated with both PFS and OS.9
Age and PS are common prognostic factors in oncology patients. In our study, both fac-
tors were not independently prognostic for survival in multivariate analysis, although age 
showed a trend towards significance both for PFS (p=0.061) and OS (p=0.069). For age, 
this might be explained by the small number of patients ≤50 years-old and the exclusion 
of patients >70-years-old in this study. Some other studies also did not find a prognostic 
effect of age, even as categorical variable, although these studies included only younger 
or only elderly patients.7,9,10 Categorizing age has been very useful for stratifying patients 
in clinical trials, but ageing is a continuous process. So, from a biological perspective, it 
is more logical to include age as a continuous variable. In addition, continuous variables 
yields more statistical power. Similarly, in contrast to most other studies2,3,9 we did not find 
an effect of the WHO/ECOG PS on survival. Of note, patients with a WHO/ECOG PS of 4 
were ineligible. Although some other studies7,10 also did not identify a prognostic effect of 




figure 1. A. Progression free survival and B. Overall survival for those with an MMSE-score of <27 and ≥27 at 
baseline.
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The major strength of our study is the prospective data collection within a large clinical 
trial resulting in MMSE-scores for the majority of patients and a uniform treatment and 
evaluation protocol. A limitation is the relatively small number of patients for prognostica-
tion; our sample size is smaller than that in the MSKCC (n=238) and IELSG models (n=378). 
A down-side of all studies based on trial patients is that findings may not be generalizable 
to the whole PCNSL population.
To conclude, the MMSE is an easily assessable and relevant clinical factor which has not 
been included in prior prognostic studies in patients with PCNSL. In this dataset the MMSE-
score at baseline is an independent clinical prognostic factor in adult PCNSL patients up to 
70-years-old. If validated in another large population, patients should be counselled with 
this effect in mind, and other prognostic scores should be re-evaluated.
For supplemental Tables and Figures: MMSE is an independent prognostic factor for sur-
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Primary central nervous system lymphoma is a rare disease and due to stringent inclu-
sion criteria in clinical trials, large population-based studies can complement data from 
prospective intervention studies by addressing an unbiased group of patients within a 
well-defined geographic area. In chapter 2 we described the incidence, primary treatment 
and survival among 1,673 PCNSL patients diagnosed in the Netherlands between 1989 
and 2015 using the comprehensive data of the Netherlands Cancer Registry (NCR). We 
showed that the incidence of primary central nervous system lymphoma increased, but 
only among those over the age of 60. Two major factors have been identified as risk factors 
for PCNSL: being immunocompromised and higher age. However, the incidence increased 
mainly among immunocompetent patients and although the population in the Nether-
lands is ageing, the incidence of systemic lymphoma and of glioma did not increase as 
much as the incidence of PCNSL.1,2 Other population-based studies in Western and Eastern 
countries described similar trends in incidence and survival, also without an explanation 
for the increased incidence.3-5 So it remains undermined which factors contributed to this 
increase.
Survival in PCNSL has improved over the last decades. In this study on 1,673 patients we 
showed that the 5-year relative survival rate, correcting for survival in the general popula-
tion increased from 11% (95% confidence interval [CI] 8-15%) to 30% (95% CI 27-34%) 
over the past 30 years. However, this increased survival was observed only among those 
below the age of 70. In a multivariate regression analysis we demonstrated that age and 
treatment were significantly associated with survival; more chemotherapy was associated 
with better survival. Survival in patients over 70 remained poor, with a 5-year relative 
survival rate of 6% (95% confidence interval [CI] 2-13%) in 2009-2015. This poor survival 
among elderly PCNSL patients is also described in a population-based study on nearly 
26,000 elderly in the United States, based on the Central Brain Tumor Registry of the 
United States (CBTRUS) and Surveillance, Epidemiology, and End Results (SEER) database, 
entitled ‘The elderly left behind’.6
In chapter 3 we described the primary treatment and survival of 145 elderly (>70 year-
old) patients with PCNSL diagnosed in the Netherlands between 2014 and 2017. Overall, 
median overall survival was only 4.1 months (95% CI, 2.8-6.8) After dividing the elderly 
into three groups (71-74, 75-80, >80 years-old) we found no difference in survival between 
these three groups. This might be explained by small numbers (n=58-32) in each group, 
the poor survival even in the youngest of these age groups, or other factors, such as 
performance status or comorbidity. Details on the latter two factors are, unfortunately, 
incomplete. We found that over the last 27 years, the increased use of chemotherapy 
did not result in an improved survival among over 70 year-olds. In the contemporary era 
(2014-2017), however, those elderly patients (>70 years-old) judged fit enough to receive 
chemotherapy had a better overall survival (median: 16.3 months, 95% CI 7.8-35.2) than 
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those who received radiotherapy only (median 7.7 months, 95% CI 4.6-13.2) or supportive 
care only (median 1.4 months, 95% CI 1.1-1.7). Siegal and Bairey, who summarized tri-
als done in elderly PCNSL patients, described the treatment challenges in elderly.7 First, 
elderly are defined differently in the performed trials, which complicates clear treatment 
recommendations for elderly PCNSL patients. Second, although methotrexate causes more 
treatment-related toxicities in elderly patients, a considerable number of elderly patients 
are nevertheless eligible for this important antineoplastic treatment in PCNSL. The key 
here is to identify those who are too much at risk for treatment-related toxicity and those 
who are not. In line with these authors we concluded that new prospective studies are 
needed to define the best treatment for different groups of elderly diagnosed with PCNSL.
Diagnostic evaluation
Before a long, intensive and potentially toxic treatment for PCNSL can be initiated, a 
definitive diagnosis is essential. This diagnosis can be obtained by the examination of 
vitreous fluid in case of eye involvement, of cerebrospinal fluid (CSF) or by a brain biopsy. 
Flow cytometry on CSF, in addition to cytological analysis, is more sensitive than cytology 
alone.8-10 In chapter 4 we showed that flow cytometry analysis on brain biopsies has a 
100%-specificity for the diagnosis of lymphoma, but sensitivity was only 88%. A major 
added value of flow cytometry on brain biopsies was the speed in which a diagnosis could 
be given: median time in days (range) was 1 (0-7) for flow cytometry and 5 (0-18) for 
histology and immunohistochemistry. Because of the highly aggressive nature of PCNSL, 
patients can quickly deteriorate, and a faster diagnostic process is therefore beneficial. 
Our analysis was limited by a retrospective single centre design, but two smaller series, 
one on brain biopsies and one on brain biopsy rinse fluid, gave the same results.11,12 We 
recommend to perform both, histology and immunohistochemistry and flow cytometry, if 
the latter is positive for a lymphoma, treatment steps can be initiated.
After treatment is initiated it is important to measure treatment response, in order to 
be able to adapt treatment in patients not responding sufficiently. According to current 
guidelines, an MRI is made at baseline, after each treatment component, and during fol-
low-up.13,14 After treatment and during follow-up response criteria are used to determine 
whether there is a response, what the extent of response is, or whether there is stable or 
progressive disease (progression or relapse).14 Since PCNSL is a rare disease, most hospi-
tals have limited experience in assessing radiological response in PCNSL. Most treatment 
decisions, however, are based on these response criteria. In chapter 5 we assessed the 
value of a central radiology review based on patients treated in the HOVON 105/ ALLG NHL 
24 study, an international multicentre phase III study on the effect of rituximab in newly 
diagnosed patients with PCNSL.15 In 235 MRIs made after each treatment component, 
the interobserver agreement was rather modest and similar between the two central 




Even between the experienced central reviewers we observed great discrepancies (e.g. 
complete response versus partial response). However, interobserver agreement regarding 
progression or no progression was excellent between the central reviewers (kappa 0.93) 
as well as between local and central radiology assessment (kappa 0.86). Together, these 
data suggest that there is little added value of a central radiology review in PCNSL trial for 
assessing progression and that response categorisation is not straightforward.
Based on the treatment response at the end-of-treatment MRIs we did a landmark 
analysis based on the central response assessment: there were no differences in progres-
sion free survival or overall survival between those categorized as complete response 
(CR), complete response unconfirmed (CRu) or partial response (PR) at 6.9 months after 
randomization (the landmark). Since progression can be clearly recognized and no dif-
ferences in survival was found between different types of response, this suggests that 
survival endpoints are more reliable in clinical trials than the complete response rate. 
Other articles did find a difference between those categorized as CR versus no CR.16,17 
However, in these studies a landmark analysis was not performed and patients who did 
not respond (SD) or even already had progression were included in the ‘no CR’ group. One 
article describes a landmark analysis and found a significant difference between response 
categories, however, all response category: CR, CRu and PR, but also stable disease and 
progression were compared with each other in a single log-rank test.18 Our study concerns 
a modest number of patients and results would need to be validated in a larger cohort. 
However if validated, the response criteria could be simplified into: response, defined as a 
decrease of enhancement of >50%, stable disease or progression.
Cognition and health-related quality of life
In the HOVON 105/ ALLG NHL 24 study, 199 immunocompetent patients with a newly 
diagnosed CD20+ B-cell PCNSL and aged between 18-70 years-old were randomized 1:1 
between high-dose methotrexate based chemotherapy (MBVP) with or without rituximab: 
R-MBVP versus MBVP.15 This induction treatment was followed by consolidative high-dose 
cytarabine (Ara-C), and for patients ≤60 years-old also by reduced dose (30Gy) whole-
brain radiotherapy (WBRT). The primary endpoint of this study, the 1-year event-free 
survival, did not differ between the treatment arms: R-MBVP versus MBVP: 52% (95% CI 
42-61) versus 49% (95% CI 39-58), p=0.99. Moreover, the progression-free survival and 
overall survival, after a median follow-up of 32.9 months, also did not differ. Secondary 
endpoints of this randomized controlled trial were differences in neurocognitive function 
and health-related quality of life (HRQoL). In the search for the best treatment the aim 
is to prolong both the length of survival and the quality of survival. The latter can be 
influenced by neurocognitive functioning and HRQoL. Information about both, survival 
and quality of survival – the net clinical benefit - can help physicians and patients to make 
a well-informed decision regarding individual treatment options.
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In chapter 6 we systematically reviewed the current literature on neurocognitive func-
tioning and HRQoL in PCNSL patients. The main conclusions were that the tumor itself had 
a large impact on both cognitive functioning and HRQoL, and that WBRT in addition to 
chemotherapy had a negative impact on cognitive functioning. However, the magnitude 
of this effectt was mostly not considered clinically relevant (with clinical relevance defined 
as a change in z-score of >1 or >1.5 standard deviation).
In the HOVON 105/ ALLG NHL 24, neurocognitive functioning and HRQoL was assessed 
before, during and up to 2-years after treatment. At group level, we found a significant 
improvement over time in all cognitive domains (chapter 7) and all primary scales of the 
HRQoL analysis (chapter 8), without differences between the treatment arms. In addition 
to a statistically significant improvement, at 12 and 24 months of follow-up, HRQoL-scores 
also improved to a clinically relevant extent (≥10 points), compared to baseline. The larg-
est improvement was seen between baseline and end-of-treatment, thereafter scores 
remained stable, which is a pattern that has been described in other studies.19-24 Again, 
this suggests that neurocognitive functioning and HRQoL is mostly compromised by the 
tumor itself.
At the individual level, we observed that scores at 12 months after treatment in all 
cognitive domains, compared to baseline, improved in 33-58% of the patients. After 24 
months, 53% had improved scores in the memory and 68% in motor speed domain. For at-
tention/executive functioning and information processing speed most patients remained 
stable: 59% and 48%, respectively. Only a minority of patients had worse neurocognitive 
functioning at 12 and 24 months (0-7%).In the HRQoL analysis, at individual level, the 
majority improved at 12 (46-78%) and 24 (53-82%) months post-treatment, compared to 
baseline.
In irradiated patients we observed, surprisingly, that up to 2 years post-treatment, scores 
in all cognitive domains and HRQoL scales remained stable, compared to shortly after 
WBRT. The role of WBRT in the treatment of PCNSL continues to be under debate, mainly 
because of its negative effect on neurocognitive functioning. Since only younger patients 
(≤60 years-old) received WBRT, our results cannot be generalized to the PCNSL patients of 
all ages. The effect of WBRT, both on survival and cognitive functioning has been assessed 
in multiples studies, but in different ways.16,19-21 WBRT prolonged progression free survival 
when WBRT was added to high-dose methotrexate (HD-MTX) chemotherapy, compared 
to chemotherapy only in a large randomised study: 18 versus 12 months, although overall 
survival was similar between both groups.16 However, more neurotoxicity, unfortunately 
only measured with clinical and radiological examinations, was found in those treated 
with 45Gy WBRT compared radiation naïve patients. Formal cognitive testing was not 
performed. A meta-analysis showed that those who received WBRT (45-60Gy; n=65) had 
more white matter lesions and significantly worse scores on multiple cognitive domains, 




however, small and not clinically relevant.25 This comparison was made after a median 
follow-up of 5.5 years, range 2-26 years.
Two recent trials randomized PCNSL patients responding to induction chemotherapy, 
to WBRT or to autologous stem cell transplantation (ASCT).20,21 Both showed significantly 
better neurocognitive functioning in the ASCT-arm, up to two20 and three21 years of follow-
up. Both studies used a higher dose of radiotherapy (36-40 Gy), neither presented indi-
vidual scores or standardised scores of neurocognitive functioning and HRQoL was not 
performed21 or reported on.20 This hampers conclusions about the clinical relevance of the 
changes in neurocognitive functioning and the comparison with our data.
Lastly, a single arm phase II study showed that HD-MTX-based chemotherapy followed 
by 23.4Gy WBRT gave similar survival compared to earlier trials with higher doses of 
radiation, and with neurocognitive functioning remaining stable even up to 5-years post-
treatment.26 These results are in line with our study: patients ≤60 years-old, were treated 
with 30Gy WBRT (20x1.5Gy) and remained stable during the follow-up of 2 years. These 
findings suggest that radiation dose is crucial in the effect of cognitive functioning in 
PCNSL patients. However, longer follow-up is necessary to draw definitive conclusions on 
neurocognitive function after 30Gy WBRT in our population.
In patients for whom a neuropsychological evaluation and MRI images were available at 
end-of-treatment, at 6, 12 and/or 24 months of follow-up we determined the correlation 
between white matter abnormalities (WMA) and brain atrophy on changes (i.e. deteriora-
tion) in each cognitive domain. There was a significant association between an increase 
in WMA and a decrease in z-score in the domains of attention/executive functioning, in-
formation processing speed and motor speed and between brain atrophy and the domain 
of memory. The associations were modest, the regression coefficients ranged between 
-0.048 and -0.921, which is the decrease in z-score after an increase of 1 point in the Faze-
kas27 sumscore for white matter lesions (the Fazekas score in 5 brain areas on both sides 
(0-30)) or after a decrease in brain volume with 10%. One study, which combined data 
on neurocognitive functioning and WMA from multiple studies, also showed a significant 
effect between increased WMA and decreased neurocognitive functioning.25
Prognosis
As discussed in chapter 2, the prognosis of PCNSL patients has improved significantly over 
the past decades. Despite the fact that multiple prognostic models28-30 and prognostic 
factors31-35 have been described, it remains difficult to predict survival for individual pa-
tients. The two most used prognostic models today are the externally validated Memorial 
Sloan Kettering Cancer Center (MSKCC) prognostic model, including only age (>50) and 
Karnofsky Performance Score (PS; >70) and the International Extranodal Lymphoma Study 
Group (IELSG) score, including age (>60), WHO/ECOG PS (>1), the involvement of deep 
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brain structures, increased serum LDH and/ or increased cerebrospinal fluid (CSF) total 
protein.36,37
The Mini-Mental State Examination (MMSE38) score, a simple bedside test originally 
developed for patients with dementia, is a prognostic factor in both low and high-grade 
glioma.39,40 In chapter 9 we showed that, based on HOVON 105/ALLG NHL 24 trial patients, 
the MMSE-score at baseline, i.e. before the start of chemotherapy, is an independent 
prognostic factor associated with progression free and overall survival in PCNSL patients 
up to the age of 70.
Interestingly age and performance status were not independent prognostic factors 
in our multivariate analysis. Several factors could explain the discrepancy between our 
results in this prognostic study, the population-based studies3,41 and the MSKCC and IELSG 
scores.36,37 The small number of patients included below the age of 50 and the exclusion of 
those over 70 years-old in the trial, as well as the relatively small number of patients might 
play a role. The other four studies were larger (n=238-3,100) than ours (n=153), and thus 
had more power to detect correlations. Furthermore, there may be an interaction between 
age, performance status and cognition – all significant in univariate analysis, resulting in 
only one of them remaining significant in multivariate analysis. Lastly, prospective clinical 
trials use stringent inclusion criteria regarding age, performance status and comorbidity.
Future directions
Given the data from recent randomized phase II trials,20,21 which showed a comparable 
efficacy but less cognitive deterioration in patients treated with autologous stem cell 
transplantation (ASCT), probably fewer PCNSL patients, will receive WBRT as consolidative 
therapy in the near future. However, reduced dose WBRT could be a reasonable option 
for some patients, given the above described results, if cognition remains stable even 
with longer-term follow-up. For elderly or frail patients, in whom neither WBRT nor ASCT 
are therapeutic options, maintenance therapy is under investigation.45,46 All considered 
options have advantages and disadvantages, which are influenced by age, comorbidity and 
immune status. Taking all these factors into account, treatment will likely become more 
personalized.
It is becoming more and more clear that not only the length but also the quality of 
survival counts. Combining these can help determine the so called ‘net clinical benefit’ 
of treatments. The challenge here is to measure, calculate and report on neurocognitive 
functioning and HRQoL in a standardized manner so that information from different stud-
ies can be compared. Due to difference in these aspects, as shown above, we could not 
compare results between trials. A consensus paper was published previously about when 
to measure neurocognitive functioning and HRQoL and which tests can be used best.47 
a universal protocol how to measure and to report on these data would facilitate com-




Because survival has increased and neurocognitive functioning remains below the level of 
the norm population (<-1 in z-scores), a more personalized approached, based on toxicity, 
white matter lesions and cognitive functioning would be a helpful in order to counsel 
patients through their follow-up.
Lastly, many PCNSL researchers are currently already collaborating, but in order to 
answer important research questions that a stronger international collaboration is needed. 
Questions such as: what are the reasons for the increased incidence?, which factors main-
tain prognostic value in large, unbiased populations? can perhaps be answered if national 
databases, such as the American SEER and CBTRUS databases, our NCR database, and the 
French Oculo-Cerebral Lymphoma (LOC)-network were combined. This will, however be 
quite a challenge since these databases are organized differently and do not include the 
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SummAry
In this thesis we describe aspects of the epidemiology, diagnostic evaluation, neurocog-
nitive function, health-related quality of life and prognosis in primary central nervous 
system lymphoma (PCNSL) patients. A PCNSL is a rare non-Hodgkin lymphoma limited to 
the brain, leptomeninges, spinal cord and the eyes without systemic localizations.
Epidemiology
In chapter 2 we described the incidence, primary treatment and survival of PCNSL in the 
Netherlands between 1989 and 2015. Using the comprehensive data of the Netherlands 
Cancer Registry (NCR) we identified 1,673 patients diagnosed with PCNSL in this era. After 
dividing patients into three categories: 18-60, 61-70, and >70 years-olds we found that 
the incidence over time increased, but only among those over the age of 60. Although 
our finding is supported by other population-based studies, a clear explanation for this 
increase could not be found.
The primary treatment changed over the last three decades: the use of combined 
chemo- and radiotherapy and the use of chemotherapy only increased among 18-60 year-
olds and a decreasing number of patients were treated with radiotherapy only. Among 
61-70 year-olds and to a lesser extent in those over the age of 70 we found an increase of 
the use of chemotherapy in lieu of radiotherapy only. Lastly we found a clear improvement 
in survival in PCNSL patients, but only in those up to 70-years-old. By multivariate analysis 
we found that the change in treatment contributed significantly to the improved survival.
Despite the increased use of chemotherapy only instead of radiotherapy only, the 
survival of elderly (>70 years-old) did not increase since 1989. In chapter 3 we described 
the primary treatment and survival of all patients (n=145) over the age of 70, diagnosed 
with PCNSL between 2014 and 2017 in the Netherlands. Again, patients were divided into 
three categories: 71-74, 75-80, and >80 years-old. In general, age is a strong prognostic 
factor in PCNSL patients, however, above the age of 70, we found no difference in survival 
between these three groups. Primary treatment was the only significant factor associated 
with overall survival: those judged fit enough to receive chemotherapy had a significantly 
longer median overall survival (OS; 16.3 months 95% CI 7.8-35.2), than those who received 
radiotherapy only (7.7 months, 95% CI 4.6-13.2) or best supportive care only (1.4 months, 
95% CI 1.1-1.7; p<0.001) with a 2-year overall survival of nearly 50%.
Diagnostic evaluation
A quick, but reliable diagnosis is essential before starting anti-tumour therapy targeting 
lymphoma. In most cases a brain biopsy is necessary to obtain a diagnosis. In chapter 4 we 
examined the value of flow cytometry on brain biopsies, in addition to classical histology 
and immunohistochemistry. We found a high specificity of flow cytometry (100%), but 
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lower sensitivity (88%). In other words, if a brain lymphoma was found by flow cytometry 
analysis, the diagnosis was confirmed, but some cases were missed by flow cytometry. 
The additional value of flow cytometry on brain biopsies in lesions suspected for a brain 
lymphoma was the speed in which the diagnosis was obtained. In our retrospective series, 
the median time to diagnosis obtained by flow cytometry was 1 day, compared with 5 days 
by histology plus immunohistochemistry.
After initiation of treatment, treatment response is assessed with MR imaging. In 
chapter 5 we assessed the value of a central radiology review in MRIs made in a large, 
international, phase III study in patients with newly diagnosed PCNSL, the the HOVON 
105/ ALLG NHL 24 study. Each MRI was assessed for response by a local physician in the 
hospital in which the patient was treated. Central radiology review was based on two 
experienced reviewers, and in case of disagreement a third reviewer was asked to adju-
dicate. In 235 MRIs, made after each treatment component, we found a rather modest 
interobserver agreement between local and central radiology review: kappa 0.46. Surpris-
ingly, the interobserver agreement between both central reviewers was similar, suggesting 
that there is no added value of a central radiology review in PCNSL in clinical studies. In 
defining progression versus no progression, the interobserver agreement was excellent, 
both between the central reviewers (kappa 0.93) and between local and central radiology 
review (kappa 0.87).
In addition, we calculated differences in progression free survival (PFS) and overall 
survival for three different levels of response: complete response (CR), complete response 
unconfirmed (CRu), and partial response (PR) at the end-of-treatment MRI, which had to 
have been made before a predetermined timespan after randomization (the landmark). 
In this landmark analysis, in which all ‘end-of-treatment’ MRIs made before 6.9 months 
after randomization were included, we found no differences in PFS or OS for those catego-
rized as complete response, complete response unconfirmed or as partial response, both 
according to central and local radiology review. The latter finding suggests that survival 
endpoints (PFS and OS) or combined response rate are more useful endpoints in clinical 
studies, than the complete response rate.
Neurocognitive function and health-related quality of life
In chapter 6 we describe the results of a systematic review of the literature on neurocogni-
tive functioning and health-related quality of life (HRQoL) in PCNSL patients, published be-
fore January 2018. The main conclusions were that the tumour itself had a large impact on 
both neurocognitive functioning and HRQoL, and that whole-brain radiotherapy (WBRT) in 
addition to chemotherapy had a negative impact on neurocognitive functioning. However, 
the magnitude of this impact was not always clinically relevant, with clinical relevance 
defined as a change in z-score of >1 or >1.5 standard deviation.
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In the HOVON 105/ ALLG NHL 24 study, 199 immunocompetent patients with a newly 
diagnosed CD20+ B-cell PCNSL were randomized 1:1 between high-dose methotrexate 
based chemotherapy (MBVP) with or without rituximab. This was followed by consoli-
dative high-dose cytarabine (Ara-C) and, for patients ≤60 years-old, also by 30Gy WBRT. 
There were no differences between event-free, progression-free and overall survival 
between the treatment arms. In chapter 7 and chapter 8 we described two secondary 
endpoints of this trial: neurocognitive functioning and HRQoL, respectively. Both neuro-
cognitive functioning and HRQoL improved significantly over time, between baseline and 
up to two years post-treatment. The largest improvement was seen between baseline and 
end-of-treatment, implicating that the tumour itself has a large impact on neurocognitive 
functioning and HRQoL. The primary scales we assessed in het HRQoL analysis improved 
to a clinically relevant extent (≥10 points). Scores in all cognitive domains, improved but 
not to a clinically relevant extent, defined as a change in z-score of ≥1 standard devia-
tion. Only motor speed showed a clinically relevant improvement. In those patients who 
received both chemotherapy and WBRT we found that neurocognitive functioning and 
HRQoL-scores maintained stable, up to 2-years of follow-up, compared to scores after 
WBRT. This contrasts with most other studies, which might be explained by the lower 
dose of radiation we used (30Gy), compared to most other trials (36-45Gy). Furthermore, 
our follow-up of two years might be too short to detect deterioration in neurocognitive 
functioning, although this has previously been described to occur as early as 6-12 months 
following treatment.
In chapter 7 we described not only cognitive changes but also the investigation of an 
association between cognitive changes and radiological changes over time in white mat-
ter abnormalities (WMA) and brain atrophy. We found a significant, but rather modest 
relation between increased WMA and brain atrophy and a decrease in neurocognitive 
functioning over time.
Prognosis
Many patients with PCNSL present with cognitive symptoms and in glioma, cognitive 
impairment at diagnosis is associated with a worse prognosis. The Mini-Mental State 
Examination (MMSE) is a screening tool to detect cognitive impairment. In chapter 9 we 
showed in the HOVON 105/ALLG NHL 24 study that the MMSE-score at baseline is an inde-
pendent prognostic factor in predicting progression free survival (PFS) and overall survival 
(OS). We found that each unit decrease in MMSE-score was associated with a decreased 
prognosis for PFS (Hazard Ratio [HR], 95% confidence interval [CI] 1.04, 1.01-1.08) and OS 
(HR, 95% CI: 1.06, 1.02-1.10). When including the MMSE-score as categorical variable, a 
baseline-score <27 (as compared to a score ≥27) was again the only factor associated with 
PFS (HR 1.55, 95% CI: 1.02-2.35) and overall survival (HR 1.68, 95% CI: 1.05-2.70). Age 
and performance status, common prognostic factors in oncology and both included in the 
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most used prognostic models in PCNSL, were not significantly associated with progression 
free survival (PFS) and overall survival (OS) in multivariate analysis of our PCNSL cohort of 
153 patients aged up to 70 years. Of note, age did show a trend towards significance for 
both PFS (p=0.061) and OS (p=0.069).
In chapter 10 we discussed the most relevant results of chapters 2 to 9 described in this 
thesis in the light of recent literature.
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SAmeNVAttiNG iN het NederLANdS
Het primair centraal zenuwstelsel lymfoom (PCZSL) is een zeldzame vorm van een non-
Hodgkin lymfoom dat zich beperkt tot de hersenen, de hersenvliezen (ofwel leptomenin-
gen), het ruggenmerg en de ogen, zonder aanwijzingen voor ziekteactiviteit in de rest van 
het lichaam. De tumor presenteert zich meestal met klachten die binnen enkele weken 
ontstaan, zoals uitval (verlamming of niet kunnen spreken) of cognitieve veranderingen. 
In dit proefschrift beschrijven we aspecten van de epidemiologie, diagnostiek, neurocog-
nitief functioneren, kwaliteit van leven en prognose van het primair centraal zenuwstelsel 
lymfoom.
Epidemiologie
In hoofdstuk 2 beschrijven we onderzoek naar het voorkomen, de primaire behandeling 
en de overleving van patiënten met het PCZSL in Nederland tussen 1989 en 2015 gebruik 
makend van de data van de Nederlandse Kanker Registratie (NKR). In deze periode werden 
1.673 patiënten met PCZSL gediagnosticeerd. De patiënten werden verdeeld in drie groe-
pen: 18-60 jaar, 61-70 jaar en >70 jaar. We zagen dat het voorkomen (de incidentie) van 
de ziekte sterk was toegenomen, maar alleen onder patiënten >60 jaar. Deze bevinding 
komt overeen met bevolkingsonderzoeken in andere landen, maar de oorzaak hiervan is 
niet bekend.
De primaire behandeling van het PCZSL is sterk veranderd in de afgelopen dertig jaar: 
zowel behandeling met chemotherapie in combinatie met radiotherapie als behandeling 
met alleen chemotherapie nam toe in de leeftijdscategorie 18-60, en behandeling met 
alleen radiotherapie nam juist af. In de categorieën 61-70 jaar en in mindere mate in 
patiënten >70 jaar nam behandeling met alleen chemotherapie toe en nam behandeling 
met alleen radiotherapie af. Tenslotte zagen we dat de overleving sterk was toegenomen 
de afgelopen dertig jaar, maar alleen in patiënten tot 70 jaar. Doordat de Nederlandse Kan-
ker Registratie ook behandelgegevens bevat konden we vaststellen dat deze verbeterde 
overleving werd verklaard door veranderingen in de behandeling.
Ondanks het toegenomen gebruik van chemotherapie bij patiënten ouder dan onder 
70 blijft de overleving in deze groep slecht. In hoofdstuk 3 beschrijven we de primaire 
behandeling en overleving van 145 ouderen (>70 jaar) met een PCZSL in Nederland, gedi-
agnosticeerd tussen 2014 en 2016. Deze groep werd verdeeld in leeftijdsgroepen: 71-74, 
75-80 en >80 jaar. In zijn algemeenheid is leeftijd een sterke prognostische factor in PCZSL 
patiënten, echter wij zagen geen verschil meer in overleving tussen de drie groepen die 
allen ouder waren dan 70 jaar. De primaire behandeling was de enige factor die significant 
geassocieerd was met totale overleving: diegene die kennelijk geschikt waren bevonden 
om chemotherapie te krijgen hadden een significant betere overleving (mediane totale 
overleving [mOS] 16,3 maanden, 95% betrouwbaarheidsinterval [BI]: 7,8-35,2) dan die-
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gene die alleen radiotherapie (mOS 7,7 maanden, 95% BI 4,6-13,2) of alleen ‘supportive 
care’ kregen (mOS 1,4 maanden, 95% BI 1,1-1,7; p<0,001).
Diagnostiek
Het vaststellen van een zekere diagnose van een PCZSL is noodzakelijk voordat chemo-
therapie kan worden gestart en doordat deze patiënten vaak snel achteruit gaan is hierbij 
haast geboden. In veel gevallen is er een hersenbiopt nodig om de diagnose te stellen. 
In hoofdstuk 4 onderzochten we de waarde van flowcytometrie op hersenbiopten in 
aanvulling op de gebruikelijke histologie en immuunhistochemie. Flowcytometrie had een 
specificiteit van 100% en een sensitiviteit van 88%. Met andere woorden, indien er een 
lymfoom werd gevonden met flowcytometrie, dan was de diagnose bevestigd. Er werden 
wel enkele gevallen gemist. De toegevoegde waarde van flowcytometrie was de snelheid 
waarmee een diagnose kon worden bevestigd. In onze retrospectieve serie kon de diag-
nose <24uur worden gegeven in 54% van de biopten met behulp van flowcytometrie, ten 
opzichte van 9% met histologie en immuunhistochemie.
Na het starten van de behandeling wordt het effect van die behandeling gemonitord 
middels MRI beelden van de hersenen. In hoofdstuk 5 onderzoeken we de waarde van 
een centrale radiologische beoordeling van MRI’s die gemaakt werden in het kader van de 
behandeling van patiënten in de HOVON105/ ALLG NHL24 trial. Elke MRI werd beoordeeld 
op de mate van respons van de tumor in het ziekenhuis waar de patiënt werd behandeld 
door een lokale arts. De centrale radiologiebeoordeling was gebaseerd op twee ervaren 
beoordelaars en in geval zij van mening verschilde, besliste een derde beoordelaar. In 235 
MRI’s, gemaakt gedurende de behandeling, vonden we een matige overeenstemming tus-
sen de beoordelaars (interobserver agreement) tussen de lokale en centrale beoordeling: 
kappa 0.46. Verrassend genoeg was de interobserver agreement tussen beide centrale 
beoordelaars niet beter. Dit suggereert dat de beoordeling voor de mate van respons 
beperkt is en dat er geen toegevoegde waarde is van een centrale radiologische beoorde-
ling van de respons bij PCZSL in klinische studies. Bij het onderscheid tussen progressie of 
recidief en geen progressie of recidief was de interobserver agreement uitstekend, zowel 
tussen de centrale beoordelaars (kappa 0.93) als tussen de lokale en centrale beoordeling 
(kappa 0.87).
Daarnaast berekenden we verschillen in progressie vrije overleving en totale overleving 
voor erkende categorieën van de mate van respons: complete respons (CR), onbevestigde 
complete respons (CRu) en partiële respons (PR) op de MRI gemaakt aan het einde van 
de behandeling. Deze MRI moest zijn gemaakt binnen een vooraf gedefinieerde periode 
(zogenoemde landmark analyse) vanaf de randomisatie. In deze landmark analyse, wer-
den alle ‘end-of-treatment’-MRI’s meegenomen die vóór 6,9 maanden na randomisatie 
waren gemaakt. Hierin vonden we geen verschillen in progressie vrije overleving en totale 
overleving tussen patiënten met een complete respons (CR), onbevestigde complete res-
199
Summary en samenvatting in het Nederlands
11
pons (CRu) en partiële respons (PR), zowel volgens de centrale als de lokale radiologische 
beoordeling. De laatste bevinding suggereert dat de verschillende response maten geen 
goed surrogaat eindpunt zijn, noch voor progressie vrije noch voor totale overleving.
Neurocognitief functioneren en kwaliteit van leven
In hoofdstuk 6 geven we een uitgebreid, systematisch overzicht van de literatuur over 
neurocognitief functioneren en kwaliteit van leven in PCZSL patiënten, gepubliceerd vóór 
januari 2018. De belangrijkste conclusies waren dat de tumor zelf een grote impact heeft 
op zowel neurocognitief functioneren als kwaliteit van leven, en dat totale schedelbestra-
ling in aanvulling op chemotherapie een negatief effect heeft op neurocognitief functio-
neren. De mate van deze impact was echter niet altijd klinisch relevant, waarbij relevantie 
gedefinieerd was als een verandering in z-score van >1 of >1,5 standaarddeviatie.
In de HOVON 105/ ALLG NHL 24 trial werden 199 immuun competente patiënten met 
een nieuw gediagnosticeerde CD20+ B-cel PCZSL 1:1 gerandomiseerd tussen chemo-
therapie, gebaseerd op hoge dosis methotrexaat (MBVP), met of zonder rituximab. Dit 
werd gevolgd door consolidatie behandeling met hoge dosis cytarabine (Ara-C) en voor 
patiënten ≤60 jaar gevolgd door 30Gy bestraling van de gehele schedelinhoud. Er waren 
geen verschillen tussen de event vrije, progressie vrije en totale overleving tussen de twee 
behandelarmen. In hoofdstuk 7 en hoofdstuk 8 beschrijven we de secundaire eindpunten 
van deze trial: respectievelijk neurocognitief functioneren en kwaliteit van leven. Zowel 
het neurocognitief functioneren als de kwaliteit van leven verbeterden significant in de 
tijd, vanaf baseline tot twee jaar na behandeling. De grootste verbetering trad op tussen 
de start en het einde van de behandeling. Doordat het PCZSL heel goed kan reageren op 
de behandeling impliceert dit dat de tumor zelf een grote invloed heeft op het neurocog-
nitief functioneren en kwaliteit van leven. De verbetering in de primaire schalen die we 
gebruikten in de kwaliteit van leven analyse was ook klinisch relevant (≥10 punten). De 
scores in alle cognitieve domeinen, behalve motorsnelheid, verbeterden niet dusdanig 
dat dit klinisch relevant genoemd mag worden, waarbij dit gedefinieerd was als een 
verandering in z-score van ≥1 standaarddeviatie. Bij die patiënten die chemotherapie en 
totale schedelbestraling kregen, zagen we dat neurocognitief functioneren en kwaliteit 
van leven-scores stabiel bleven tot 2 jaar follow-up, ten opzicht van scores na WBRT. Dit 
is in tegenstelling tot de meeste andere studies, hetgeen mogelijk verklaard kan worden 
door de lagere dosis bestraling die wij hebben gebruikt (30Gy), vergeleken met de meeste 
andere onderzoeken (36-45Gy) en onze follow-up is mogelijk nog te kort om achteruitgang 
in neurocognitief functioneren te detecteren. Echter, het is eerder beschreven dat cogni-
tieve achteruitgang al na 6-12 maanden na de bestraling kan optreden.
In hoofdstuk 7 beschrijven we niet alleen de cognitieve veranderingen, maar ook of 
er een relatie is tussen cognitieve veranderingen en radiologische veranderingen: witte 
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stof afwijkingen en breinatrofie. Er was een significante, maar zwakke relatie tussen een 
toename in WSA en hersenatrofie en een afname van neurocognitief functioneren.
Prognose
Veel patiënten met PCZSL hebben cognitieve stoornissen bij het debuut van de ziekte. De 
Mini-Mental State Examination (MMSE) is een grove screeningstool om neurocognitieve 
stoornissen te detecteren. In hoofdstuk 9 is de prognostische waarde van de MMSE on-
derzocht in patiënten uit de HOVON105/ ALLG NHL24 studie. De MMSE-score, als continue 
variabele bij de start van de behandeling , voor start van de chemotherapie, bleek een 
onafhankelijke prognostische factor is bij het voorspellen van de progressievrije overleving 
en totale overleving. We zagen dat elk punt daling van de MMSE-score geassocieerd was 
met een slechtere prognose: voor progressievrije overleving (Hazard Ratio [HR], 95% be-
trouwbaarheidsinterval [BI] 1,04, 1,01-1,08) en voor totale overleving (HR, 95% BI: 1,06, 
1,02-1,10). Wanneer de MMSE-score als categoriale variabele (afwijkend versus normaal) 
werd gebruikt voor de analyse was een baseline-score <27 (vergeleken met een score 
≥ 27) opnieuw de enige factor die geassocieerd was met progressievrije (HR 1,55, 95% 
BI: 1,02-2,35) en totale overleving (HR 1,68 95% BI: 1,05-2,70). Leeftijd en ‘performance 
status’ zijn belangrijke prognostische factoren bij veel oncologische aandoeningen en 
beide worden gebruikt in de belangrijke prognostische modellen voor PCZSL patiënten. In 
ons cohort van 153 PCZSL patiënten, waarin alleen patiënten tot de leeftijd van 70 werden 
geïncludeerd, waren deze in multivariate analyse niet geassocieerd met progressievrije 
overleving en totale overleving. Echter, leeftijd vertoonde wel een trend naar significantie 
voor progressievrije overleving (p=0,061) en totale overleving (p=0,069).
In hoofdstuk 10 bespreken we de meest relevante resultaten van de hoofdstukken 2 
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Er zijn veel mensen die mij geholpen hebben het proefschrift dat voor u ligt te voltooien. 
Voordat ik diegene hieronder bedank, wil ik allereerst graag alle patiënten die hebben 
meegedaan aan de HOVON 105/ ALLG NHL 24 studie enorm bedanken. In het bijzonder 
voor het ondergaan van meerdere neuropsychologische onderzoeken en het invullen van 
de kwaliteit van leven vragenlijsten. Zonder jullie had ik niet kunnen promoveren.
Prof. dr. m.J. van den Bent, beste Martin, in het begin was je meer op afstand betrokken 
bij mijn promotie, maar ik kon altijd bij je terecht voor vragen over het onderzoek, de plan-
ning, discussies over eindpunten en mijn carrière(plannen). De manuscripten kwamen 
altijd zeer snel met behulpzaam en soms humoristisch commentaar terug. In de laatste 6 
maanden van mijn opleiding heb ik in mijn stage neuro-oncologie veel mogen leren. Veel 
dank voor het vertrouwen, in het bijzonder om mij te steunen in mijn Canada plannen, 
en alles wat ik van je geleerd heb in onderzoek doen en de zorg voor neuro-oncologische 
patiënten.
dr. J.e.C. Bromberg, beste Jacoline, toen ik begon aan deze promotie, begon jij aan 3 
nieuwe projecten tegelijkertijd: opleider worden van ca. 40 A(N)IOS, supervisor binnen 
de algemene neurologie (na 12 jaar Daniël den Hoed) en co-promotor van je eerste pro-
movendus. Hoe je de afgelopen jaren tussen al deze taken tijd wist te maken voor mij, 
mijn stukken en de overleggen met Linda, Katerina, Marion, Esther en Martin zijn mij een 
raadsel. Naast de kans en het vertrouwen dat ik kreeg om met de data van ‘jouw’ HOVON 
105/ ALLG NHL 24 studie aan de slag te gaan, heb je mij ook betrokken in de samenwerking 
met het IKNL en mocht ik ook kijken naar allerhande radiologische aspecten van primair 
centraal zenuwstelsel lymfomen. Je geeft veel vertrouwen, stimuleert en benadrukt wat 
er goed gaat, wat er al wél af is of wat er al wél gedaan is, in plaats van wat nog moet. 
Dit werkt enorm stimulerend en ik hoop, ondanks je volle agenda, dat er na mij nog vele 
promovendi mogen volgen die door jou begeleid gaan worden.
dr. L. dirven, beste Linda, als het gaat om de analyse en interpretatie van data over 
kwaliteit van leven en cognitief functioneren in primair centraal zenuwstelsel lymfoom-
patiënten was jij een beetje mijn tweede co-promotor. Het enthousiasme en de snelheid 
waarmee je mij hebt willen helpen met de analyses en het opschrijven van meerdere 
stukken was enorm behulpzaam. Daarnaast hebben we samen met Marijke, Maarten en 
Jaap Rotterdam en half Limburg op de racefiets verkend en in Stockholm en Lyon een mooi 
feestje gebouwd tijdens de congressen. Veel dank voor de hulp en de gezelligheid. Ik vind 
het leuk dat je ook in mijn promotiecommissie hebt willen plaatsnemen.
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De analyses in dit proefschrift waren niet gelukt zonder katerina Bakunina. Veel vraagstel-
lingen en onderwerpen waren nieuw voor je, maar je bent de vele analyses en figuren 
onverminderd blijven uitvoeren en aanpassen, op ons verzoek of op verzoek van een 
reviewer. Veel dank voor al het werk dat je gedaan hebt, zelfs nadat je al officieel uit dienst 
was van het Erasmus MC.
dr. J.k. doorduijn and dr. issa, beste Jeanette and dear Samar, thank you for your 
confidence and support I received as PhD candidate, but also as resident of neurology 
doing analyses and writing manuscripts about your ‘hematological’ HOVON 105/ ALLG 
NHL 24 trial. I am grateful I had the possibility to write many manuscripts with both of 
you. Jeanette, dank dat je het manuscript kritisch hebt willen beoordelen en hebt willen 
plaatsnemen in mijn promotiecommissie.
Het HOVON data center heeft de afgelopen jaren veel data bijgehouden voor de HOVON 
105/ ALLG NHL 24 studie. Ook data die niet dagelijks in hematologie studies wordt gere-
gistreerd: kwaliteit van leven en in het bijzonder cognitief functioneren. Met veel dank aan 
Martine Abrahamse, voor het achterhalen en bijhouden van al deze gegevens.
prof. dr. m.J.B. taphoorn, beste Martin, ik mocht de afgelopen jaren een beetje deel uit-
maken van jouw onderzoeksgroep waarin kliniek en onderzoek naar neurocognitief func-
tioneren en kwaliteit van leven gecombineerd worden. Mede dankzij jouw vertrouwen 
hebben we onze systematic review aangeboden aan The Lancet Oncology, die het artikel 
gelukkig wilde publiceren. Hopelijk kunnen we de komende jaren nog veel samenwerken 
in het onderzoek.
prof. dr. m. Smits, beste Marion, mede dankzij jou hebben we het eerste artikel over 
de waarde van een centrale radiologie review in primair centraal zenuwstelsel lymfoom 
patiënten kunnen schrijven. Voor de verschillende radiologische projecten binnen mijn 
promotie wist je mensen uit jouw onderzoeksgroep te vinden om mee samen te werken 
en de beelden snel door te laten analyseren. Hopelijk gaat het nog een keer lukken om de 
prognostische waarde van diffusie en perfusie samen op te schrijven.
Samen met prof. Taphoorn en prof. Smits, ook veel dank aan prof. dr. m.C. minnema en 
prof. dr. m. klein, voor jullie bereidheid plaats te nemen in mijn promotiecommissie.
De artikelen heb ik met veel verschillende co-auteurs mogen schrijven. Ik bedank iedereen 
voor de hulp en feedback op de manuscripten. Een aantal wil ik in het bijzonder noemen: 
dr. A.G. dinmohamed, beste Avinash, door jouw enthousiasme hebben we samen maar 




betrokken bij ‘jouw’ population-based studies. Ik heb in korte tijd veel geleerd van de 
epidemiologische analyses op populatieniveau. Hopelijk kunnen we over een paar jaar 
een update schrijven. dr. e.J.J. habets, beste Esther, als dokter wilde ik meteen een soort 
sumscore maken van de cognitieve scores, “dat werkt veel makkelijker”, maar jij hebt me 
uitgelegd dat dat niks zegt en dat de cognitieve tests afzonderlijk gewogen en bekeken 
moeten worden. Dank voor je hulp en uitleg over alle tests en domeinen, tussen jouw 
drukke spreekuren en eigen promotie door. Dr. A.A. Jacobi-Postma, beste Linda, ondanks 
een niet erg behulpzaam programma heb je meer dan 600 MRI’s beoordeeld in het kader 
van onze centrale radiologie review en hebben we het eerste artikel hierover in primair 
centraal zenuwstelsel lymfoom patiënten kunnen schrijven. Dr. Sebastian van der voort 
en dr. hakim Achterberg, dank voor jullie hulp en snelheid waarmee de verzamelde MRI’s 
konden worden geanalyseerd. dr. V.h.J. van der Velden, beste Vincent, dankzij jullie 
analyses konden we het eerste artikel schrijven over de waarde van flowcytometrie op 
hersenbiopten wanneer gedacht wordt aan een centraal zenuwstelsel lymfoom. Dank 
voor de hulp bij het schrijven van dit artikel en het was erg leuk om een ochtend mee te 
lopen op jullie laboratorium.
marit eland en dianne Coule, jullie hebben voor de meer dan 50(!) Erasmus MC patiënten 
die meededen aan de HOVON 105/ ALLG NHL 24 studie de cognitieve tests afgenomen en 
toen ik voorstelde om ook op de langere termijn deze testen te blijven afnemen en dit wel 
zelf wilde doen, gaven jullie aan dit wel te willen voortzetten. Veel dank voor deze enorme 
klus, bovenop jullie volle poli’s en het vele werk dat jullie doen voor de neuro-oncologie 
patiënten.
Het trialbureau van de radiologie, in het bijzonder Laurens Groenendijk en mashiro van 
dal hebben enorm geholpen om een overzicht te maken van welke scans uit welke centra 
aanwezig waren en welke nog miste, waardoor deze laatste konden worden opgevraagd. 
Daarnaast hebben jullie alles ingelezen in Keosys, waardoor Linda Jacobi, Marion Smits en 
ik de beelden konden analyseren. Dank!
Prof. dr. P.A.E. Sillevis Smitt en em. prof. dr. P.J. koudstaal, beste Peter en Peter, in juli 
2012 namen jullie mij aan voor de opleiding tot neuroloog in Rotterdam. Veel dank aan 
jullie en de andere stafleden voor het in mij gestelde vertrouwen om de opleiding bij 
jullie te mogen doen. Ik heb buitengewoon veel geleerd in Rotterdam en een hele mooie 
tijd gehad. Peter (Sillevis Smitt) je bent al die tijd mijn opleider gebleven en tijdens mijn 
neuro-oncologie stages mijn polisupervisor geweest, ik vind het dan ook bijzonder leuk 
dat je in mijn promotiecommissie wilde plaatsnemen, waarvoor dank.
Tijdens de laatste jaren van mijn opleiding heb ik zowel in de Daniël den Hoed als in het 
Erasmus MC (de centrum locatie) een stage neuro-oncologie mogen doen. Veel dank aan 
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dr. walter taal, dr. Joost Jongen en dr. marjolein Geurts voor de mooie tijd en alles wat ik 
van jullie heb geleerd. De ondersteuning die ik als AIOS mocht ondervinden van het secre-
tariaat, van ria, lisette en Hafida was erg prettig en heb me altijd zeer welkom gevoeld.
Alex, Arlette, Carina, Christa, daniëlle, harmke, Joyce, katelijn, Laurike, merel, roos, 
Sonja, yuyi en yvette, jullie hebben mij het gevoel gegeven dat ik onderdeel was van een 
onderzoeksgroep, ik mis de vele koffie- en taartmomenten en het bij jullie (kunnen) bin-
nenlopen op de 22ste.
Tijdens mijn promotie mocht ik twee master studenten begeleiden: merel Snoek en Saad 
Ahmed, dank voor jullie vertrouwen. Ik wens jullie beiden veel succes met jullie carrières 
als respectievelijk plastisch chirurg en reumatoloog.
Mijn tijd in Rotterdam was nooit zo leuk geweest als er niet zo’n bijzonder leuke assisten-
tengroep was geweest. Ook al zijn we allang geen sjaarsjes meer, zoals onze WhatsApp 
groep nog steeds heet; Bob, Christine, harro, Nabil en wan Zheng, het was fantastisch 
om met jullie samen de opleiding te beginnen en te doorlopen en natuurlijk om te bow-
len tijdens de AIOS dagen. En Christine, we hebben samen veel lief en leed gedeeld de 
afgelopen jaren en vind het superleuk dat je 21 april naast me staat. maarten, we hebben 
vele gezamenlijke interesses: eten, wijn, après-ski, fietsen en de neuro-oncologie. Hopelijk 
kunnen we nog veel blijven fietsen en samen naar een volgend congres en daar wél op 
stap. Verder heb ik met veel plezier deel uitgemaakt van de AIOS vertegenwoordiging en 
ik mis de vele borrels bij WP en daarbuiten ;-), de promotiefeestjes en de gezamenlijke 
lunches op vrijdag.
Toen ik begon aan mijn promotie begon ik ook als VAAN-bestuurslid en de laatste twee 
jaar van mijn promotie heb ik ook voorzitter mogen zijn van het VAAN-bestuur. We hebben 
ongelooflijk veel vergaderd, maar ook veel lol gemaakt en pizza gegeten. Dankzij dit avon-
tuur heb ik ook Europees mogen meedenken over de opleiding tot neuroloog en daar een 
artikel over mogen schrijven. Veel dank voor alle mooie momenten en het vertrouwen om 
2 jaar lang de kar te mogen trekken. Deze dank gaat ook uit naar de mede-commissieleden 
van de CWON, de ZeN en het kern Kernconsilium neurologie, waar ik als VAAN-bestuurslid 
deel vanuit heb mogen maken.
Na mijn opleiding mocht ik aan de slag in het Medisch Spectrum Twente, als neuroloog 
met als aandachtsgebied neuro-oncologie. Ik vond het heel spannend om te verhuizen 
naar de andere kant van het land, maar veel dank aan de neurologen: Angelique, ioana, 
iris, Jeroen, Jos, Joyce, Lucille, michel, Paul, renate en ruben, de A(N)IOS en de collega 




Paulien, Astrid en de collega’s hoop ik het mooie neuro-oncologisch centrum verder te 
kunnen uitbouwen de komende tijd.
dr. w.P. mason, dear Warren, thank you for the opportunity to do a fellowship neuro-
oncology in the Princess Margaret Cancer Centre in Toronto starting in July 2021. I am 
really looking forward to have a wonderful time in Canada.
Pap en mam, daniël, Annemarie en irene, van Hattemerbroek naar Utrecht naar Rot-
terdam maakte de fysieke afstand tot jullie alleen maar groter, maar jullie betrokkenheid 
en interesse in mijn onderzoek en werk waren onverminderd aanwezig. Bij elke verhuizing 
stonden jullie klaar om mij te helpen en om meteen te komen kijken als het af was.
Grada, ik ken je al meer dan 16 jaar en we hebben samen heel wat avonturen in binnen- en 
buitenland beleefd en ben blij dat ik altijd bij je terecht kan. Als ik in de buurt van Zwolle 
ben probeer ik altijd bij jullie langs te gaan. Niels, ik ben blij dat je weer in Zwolle zelf 
woont en kom graag regelmatig een avondje langs, wat nu weer een stuk makkelijker gaat.
Heren, Bart, Bart, freek, Niek en timo, dank voor jullie interesse en betrokkenheid de 
afgelopen jaren. We hebben samen regelmatig Utrecht onveilig gemaakt, eindeloos ge-
borreld, gegeten, de Maarsseveense plassen over gezwommen en de hele wereld over 
gereisd: van Groningen naar Boston en van Antwerpen naar San Francisco. Na Corona 
hoop ik dat onze maandelijkse etentjes weer worden opgepakt om elkaar regelmatig te 
blijven zien, ondanks dat we over het land zijn uitgewaaid. Niek, ben blij dat ik heb gezien 
waar jullie in Heidelberg zijn gaan wonen, maar mocht helaas daarna het afgelopen jaar de 
Duitse grens niet meer over. We zijn allebei de neuro-oncologie ingegaan en ben dan ook 
bijzonder blij dat je 21 april naast me staat.
Bart, samen met Niels hebben we in het Sportraad bestuur gezeten, waarin we veel leerde 
(iets met bier en bitterballen). Ik ben blij dat we sindsdien nog vaak zijn blijven afspreken 
in Utrecht, Rotterdam en Enschede om te fietsen, te eten of gewoon het leven te bespre-
ken en om goede wijn te drinken.
De afgelopen jaren heb ik veel mooie reizen mogen maken, waardoor ik nieuwe vrienden 
heb mogen ontmoeten. Het was in Zuid-Afrika en de reünies daarna altijd één groot feest, 
met een bijzonder dank aan edwin, huibert, reinier en Stef. En Stef, hopelijk maken we 
samen, na Corona, nog meer mooie reizen.
De vrienden die ik in Rotterdam heb ontmoet maakte het een mooie tijd en moeilijk om 
weg te gaan. Sid, we hebben veel geborreld op het Smalthof en in Locus Publicus en ik 
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vind het heel leuk dat je al snel in Enschede bent langs geweest. mike, wat begonnen 
is als een cursus in Utrecht is uitgemond in een vriendschap waarbij we samen hebben 
geborreld, gegeten, gesquasht, gefietst en de kleine en de grote problemen bespreken en 
soms lossen we ze ook op. Dat we maar veel mogen blijven afspreken.
Enschede, voorjaar 2021
